erlotinib hydrochloride has been researched along with gefitinib in 1030 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 5,231 | 566 | 2,919 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 316 (30.68) | 29.6817 |
| 2010's | 624 (60.58) | 24.3611 |
| 2020's | 90 (8.74) | 2.80 |
| Authors | Studies |
|---|---|
| Ciardiello, F; Tortora, G | 1 |
| Fry, DW; Slichenmyer, WJ | 1 |
| Tamura, T | 2 |
| Albanell, J; Baselga, J | 2 |
| Sánchez De Cos Escuín, J | 1 |
| Couzin, J | 1 |
| Baselga, J; Hammond, LA | 1 |
| Cohen, RB | 1 |
| Lorusso, PM | 1 |
| Muguruma, H; Sone, S; Yano, S | 2 |
| Bianco, C; De Luca, A; Maiello, MR; Normanno, N; Salomon, DS | 1 |
| Grünwald, V; Hidalgo, M | 1 |
| Gill, S; Goldberg, RM; Thomas, RR | 1 |
| DeGrendele, H | 1 |
| Giaccone, G; Janmaat, ML | 1 |
| Ciardiello, F; De Placido, S; De Vita, F; Orditura, M; Tortora, G | 1 |
| Bunn, PA; Herbst, RS | 1 |
| Gatzemeier, U | 1 |
| Pérez-Soler, R | 3 |
| Averbuch, S; Blackledge, G | 1 |
| Aunoble, B; Bourhis, J; Rolhion, C; Tortochaux, J | 1 |
| Adenis, A; Peyrat, JP | 1 |
| Fayette, J; Le Chevalier, T; Soria, JC | 1 |
| Belani, CP; Ramalingam, S | 1 |
| Langer, CJ | 1 |
| Thomas, M | 1 |
| Caponigro, F | 1 |
| Damjanov, N; Meropol, NJ | 1 |
| Choy, H; Kim, DW | 1 |
| Herbst, RS | 1 |
| Baker, M | 1 |
| El-Rayes, BF; LoRusso, PM | 1 |
| McNeil, C | 1 |
| Cheng, ZW; Gao, JM; Zhang, L | 1 |
| Nishio, K | 1 |
| Armstrong, EA; Benavente, S; Chinnaiyan, P; Harari, PM; Huang, S | 1 |
| Doherty, J; Fulton, L; Heelan, R; Kris, M; Kupfer, D; Mardis, E; Miller, V; Pao, W; Politi, K; Rusch, V; Sarkaria, I; Singh, B; Varmus, H; Wilson, R; Zakowski, M | 1 |
| Vastag, B | 1 |
| Ginsburg, GS; Hortobagyi, GN; Linette, GP; Pietrusko, R; Pusztai, L; Rolfe, M; Ross, JS; Schenkein, DP; Stagliano, NE; Stec, J; Symmans, WF | 1 |
| Adjei, A; Belani, CP | 1 |
| Amador, ML; Ashfaq, R; Baker, SD; Cusati, G; Cusatis, G; Forastiere, A; Hidalgo, M; Iacobuzio-Donahue, C; Maitra, A; Oppenheimer, D; Perea, S; Takimoto, C | 1 |
| Bryant, JA; Charles, AC; Cloughesy, TF; Finn, RS; Slamon, DJ | 1 |
| Harari, PM | 1 |
| Patel, JD | 1 |
| Akita, H | 1 |
| Heelan, RT; Kris, MG; Ladanyi, M; Miller, VA; Pan, Q; Pao, W; Riely, GJ; Varmus, HE; Wang, TY; Zakowski, MF | 1 |
| Twombly, R | 2 |
| Berlin, JD; Lockhart, AC; Lockhart, C | 1 |
| Boggon, TJ; Dayaram, T; Eck, MJ; Halmos, B; Jänne, PA; Johnson, BE; Kobayashi, S; Kocher, O; Meyerson, M; Tenen, DG | 1 |
| Kris, MG; Miller, VA; Pao, W; Politi, KA; Riely, GJ; Somwar, R; Varmus, H; Zakowski, MF | 1 |
| Miller, VA; Pao, W | 1 |
| Hampton, T | 1 |
| Albanell, J; Gascón, P | 1 |
| Lenz, HJ; Vallbohmer, D | 1 |
| Giaccone, G | 1 |
| Ciardiello, F; Di Maio, M; Gridelli, C; Normanno, N; Perrone, F | 1 |
| Bell, DW; Brannigan, BW; Driscoll, DR; Fidias, P; Godin-Heymann, N; Haber, DA; Harris, PL; Isselbacher, KJ; Kwak, EL; Lynch, TJ; McGinnis, JP; Okimoto, RA; Rabindran, SK; Settleman, J; Sharma, SV; Sordella, R; Wissner, A | 1 |
| Magné, N; Milano, G | 1 |
| Gasparini, G; Longo, R; Morabito, A; Torino, F | 1 |
| Blum, HE; Geissler, M; Grimm, CF | 1 |
| Byrne, BJ; Garst, J | 1 |
| Costello, G; Holloway, B; Speake, G | 1 |
| Buter, J; Giaccone, G | 2 |
| Haber, DA; Settleman, J | 1 |
| Masuda, N; Yanase, N; Yokoba, M | 1 |
| Ready, N | 1 |
| Tuma, RS | 1 |
| Engelman, JA; Jänne, PA | 1 |
| Raizer, JJ | 1 |
| Comis, RL | 1 |
| Altundag, K; Altundag, O; Boruban, C; Silay, YS | 1 |
| Branca, MA | 1 |
| Agrawal, A; Gee, JM; Gutteridge, E; Nicholson, RI; Robertson, JF | 1 |
| Harper, P; Spicer, J | 1 |
| Ganti, AK; Potti, A | 1 |
| Govindan, R; Pillot, G; Viswanathan, A | 1 |
| Beijnen, JH; Schellens, JH; Siegel-Lakhai, WS | 1 |
| Alvarez, JV; Bulmer, SE; Chen, TH; Feng, W; Frank, DA; Greulich, H; Hahn, WC; Jänne, PA; Meyerson, M; Sellers, WR; Zappaterra, M | 1 |
| Leighl, NB; Nematollahi, M; Shepherd, FA; Tsao, WS; Zawisza, DL | 1 |
| Endo, K; Fujii, Y; Fukai, I; Haneda, H; Iuchi, K; Kawahara, M; Kobayashi, Y; Konishi, A; Kuwabara, Y; Matsumura, A; Mizuno, K; Okumura, M; Sasaki, H; Sugiura, H; Suzuki, E; Takada, M; Tanaka, H; Yano, M | 1 |
| Kurisu, K; Okamura, T | 1 |
| Elsner, J; Gutzmer, R; Kapp, A; Werfel, T | 1 |
| Garfield, DH | 1 |
| Ohe, Y; Takano, T | 1 |
| Bates, SE; Fojo, T | 1 |
| D'Amico, TA | 1 |
| Ciardiello, F; De Vita, F | 1 |
| Abrey, LE; Chang, S; Cowell, JK; DeAngelis, LM; Gilbert, MR; Grefe, CN; Holland, EC; Kuhn, JG; Lamborn, K; Lassman, AB; Lieberman, FS; Nowak, NJ; Pao, W; Prados, M; Raizer, JJ; Razier, JR; Rossi, MR; Shih, AH; Wen, P; Wilson, R; Yung, WA | 1 |
| Kris, M | 1 |
| Bigner, DD; Friedman, HS | 1 |
| Beroukhim, R; Cavenee, WK; Chute, DJ; Cloughesy, TF; Dia, EQ; Haas-Kogan, DA; Horvath, S; Huang, JH; Lee, JC; Liau, LM; Lu, KV; Mellinghoff, IK; Mischel, PS; Peck, TC; Prados, M; Rao, PN; Riggs, BL; Sawyers, CL; Sellers, WR; Stokoe, D; Vivanco, I; Wang, MY; Yoshimoto, K; Zhu, S | 1 |
| Kabasawa, K; Kawasaki, N; Nakamura, H; Taguchi, M | 1 |
| Pao, W; Riely, GJ | 1 |
| Christoffersen, T; Dajani, O; Guren, TK; Thoresen, GH; Tveit, KM; Wisløff, F | 1 |
| Bunn, PA; Hirsch, FR | 1 |
| Apolone, G; Garattini, S; La Vecchia, C | 1 |
| Altundag, K; Altundag, O; Atik, MA; Baptista, MZ; Turen, S | 1 |
| Reddy, GK | 1 |
| Rivera, MP; Silvestri, GA | 1 |
| Chan, SK; Gullick, WJ; Hill, ME | 2 |
| Harari, PM; Huang, S | 1 |
| Baldwin, PD; Lundberg, AS; Tammaro, KA | 1 |
| Choong, NW; Davies, GC; Dietrich, S; Husain, AN; Lipkowitz, S; Ma, PC; Nallasura, V; Salgia, R; Seiwert, TY; Tretiakova, MS | 1 |
| Lawrence, TS; Nyati, MK | 1 |
| Sun, Y; Wang, Y | 1 |
| Li, Zi; Lu, S; Yu, YF | 1 |
| Ballas, M; Dennis, PA; Egilsson, V; Steinberg, SM; Tsurutani, J | 1 |
| Abrey, LE; Gilbert, MR; Lassman, AB | 1 |
| Gatzemeier, U; Kranich, AL; Reck, M; Steinbach, AK | 1 |
| Kris, MG; Ladanyi, M; Li, AR; Miller, VA; Pao, W; Pham, D; Riely, GJ; Rizvi, N; Venkatraman, ES; Zakowski, MF | 1 |
| Acebo, E; Díaz-Pérez, JL; Lasa, O; Martínez de Lagrán, Z; Ratón, JA | 1 |
| Behnke-Mursch, J; Halatsch, ME; Schmidt, U; Unterberg, A; Wirtz, CR | 1 |
| Gazdar, AF; Girard, L; Lee, W; Minna, JD; Peyton, M; Ramirez, RD; Sato, M; Shames, DS; Shay, JW; Sunaga, N; Vaughan, MB | 1 |
| Bouaroud, N; Brahmer, J; Chan, A; Clark, DP; Forastiere, A; Hidalgo, M; Jimeno, A; Kincaid, E; Kulesza, P | 1 |
| Chuai, S; Kris, MG; Ladanyi, M; McDonough, T; Miller, VA; Pao, W; Pham, D; Riely, GJ; Rusch, VW; Sarkaria, IS; Singh, B; Venkatraman, ES; Wilson, RK | 1 |
| He, YM; Lai, RS; Shen, LS; Xie, L; Zhu, CL | 1 |
| Cerniglia, G; Gupta, A; Jiang, Z; Kao, GD; Maity, A; Pore, N | 1 |
| Iwashige, A; Kagami, S; Tsukada, J; Uramoto, H | 1 |
| Chen, YM; Perng, RP; Tsai, CM; Whang-Peng, J | 1 |
| Khuri, FR; Saba, NF; Shin, DM | 1 |
| Dowell, JE; Minna, JD | 1 |
| Fish-Steagall, A; Searcy, P; Sipples, R | 1 |
| Sipples, R | 1 |
| Garfield, D | 1 |
| Al-Hashem, R; Bronson, RT; Discafani, CM; Eck, M; Glatt, KA; Horner, JW; Ji, H; Jung, BL; Li, D; Maher, E; McNamara, K; Meyerson, M; Mitchell, A; Protopopov, A; Rabindran, SK; Sasaki, H; Shapiro, GI; Shimamura, T; Sun, Y; Thomas, RK; Wong, KK; Xia, H; Yuza, Y; Zhao, X | 1 |
| Goto, K; Kim, YH; Kubota, K; Niho, S; Nishiwaki, Y; Ohmatsu, H; Saijo, N; Yoh, K | 1 |
| Baselga, J | 1 |
| Pérol, M | 1 |
| Le Chevalier, T; Tsuboi, M | 1 |
| Becker, JC; Domschke, W; Muller-Tidow, C; Pohle, T; Serve, H | 1 |
| Blackhall, F; Ranson, M; Thatcher, N | 1 |
| Filov, VA; Gershanovich, ML; Imianitov, EN; Stukov, AN | 1 |
| Levitzki, A; Mishani, E | 1 |
| Cecere, F; Reguart, N; Rosell, R; Santarpia, M; Taron, M | 1 |
| von Eyben, FE | 1 |
| Sandler, AB | 1 |
| Bogeschdorfer, F; Gronau, S; Riechelmann, H | 1 |
| Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Heseltine, D; Meyerhardt, JA; Ogino, S; Ryan, DP; Zhu, AX | 1 |
| Bell, DW; Haber, DA; Halmos, B; Holmes, AJ; Huberman, MS; Jackman, DM; Jänne, PA; Johnson, BE; Joshi, VA; Lindeman, N; Lynch, TJ; Meyerson, M; Rabin, MS; Sequist, LV; Yeap, BY | 1 |
| Arteaga, CL; Carpenter, G; Gazdar, AF; Muthuswamy, SK; Narasanna, A; Perez-Torres, M; Wang, SE; Wu, FY; Xiang, B; Yang, S | 1 |
| Amler, LC; Goddard, AD; Hillan, KJ | 1 |
| Baselga, J; Mendelsohn, J | 1 |
| Morse, L | 1 |
| Blüthner, T; Caca, K; Feisthammel, J; Kamenz, T; Kluge, A; Mössner, J; Tannapfel, A; Wiedmann, M | 1 |
| Curtiss, FR | 1 |
| Agero, AL; Benvenuto-Andrade, C; Busam, KJ; Dusza, SW; Halpern, AC; Myskowski, P | 1 |
| Gaya, A; Khorshid, M; Plowman, PN; Walther, JC | 1 |
| Ahmed, SM; Salgia, R | 1 |
| Kato, T; Nishio, K | 1 |
| Baas, P; Boerrigter, L; Burgers, S; de Jong, D; Mathy, A; Nederlof, P; Ruijter, H; Tielen, I; van Zandwijk, N | 1 |
| Aldanondo Fernández de la Mora, I; Fernández-Guarino, M; García-Millán, C; Garrido López, P; Jaén Olasolo, P; Pérez García, B | 1 |
| Desbois-Mouthon, C; Fartoux, L; Poupon, R; Rosmorduc, O | 1 |
| Balak, MN; Chiang, A; Gong, Y; Kris, MG; Ladanyi, M; Li, AR; Miller, VA; Ouerfelli, O; Pao, W; Riely, GJ; Somwar, R; Yang, G; Zakowski, MF | 1 |
| Pao, W | 1 |
| Cappuzzo, F | 1 |
| Pujol, JL | 1 |
| Golub, T; Halmos, B; Hetherington, CJ; Kobayashi, S; Lowell, AM; Meyerson, M; Monti, S; Shapiro, GI; Shimamura, T; Steidl, U; Tenen, DG | 1 |
| Kuwano, M; Ono, M | 1 |
| Grenier, J; Soria, JC | 1 |
| Chou, LS; Garey, J; Kim, E; Oishi, K | 1 |
| Bréchot, JM | 1 |
| Fidias, P; Haber, DA; Jänne, PA; Johnson, BE; Joshi, VA; Kucherlapati, R; Lynch, TJ; Meyerson, M; Muzikansky, A; Sequist, LV | 1 |
| Bell, DW; Haber, DA; Lynch, TJ; Sequist, LV | 1 |
| Garber, K | 2 |
| Baker, SD; Bates, SE; Brahmer, J; Cusatis, G; Hidalgo, M; Li, J; Robey, RW; Sparreboom, A | 1 |
| van de Vijver, MJ; van Zandwijk, N | 1 |
| Serke, M | 1 |
| Amador, ML; Grunwald, V; Hidalgo, M; Iacobuzio-Donahue, C; Jimeno, A; Maitra, A; Rubio-Viqueira, B | 1 |
| Dutta, PR; Maity, A | 1 |
| Costa, LJ; Drabkin, HA; Gemmill, RM | 1 |
| Evans, WK; Feld, R; Mackay, JA; Shepherd, FA; Sridhar, SS | 1 |
| Davies, A; Fukuoka, M; Garfield, DH; Giaccone, G; Jassem, J; Kris, MG; Quoix, EA; Sandler, AB; Scagliotti, GV; Van Meerbeeck, JP; West, H | 1 |
| Chen, Z; Gonzalez, KD; Gu, D; Hill, KA; Li, K; Saldivar, JS; Scaringe, WA; Sommer, SS | 1 |
| Bergot, E; Richard, N; Zalcman, G | 1 |
| Bekele, BN; Herbst, RS; Liu, DD; Massarelli, E; Ozburn, NC; Tang, X; Varella-Garcia, M; Wistuba, II; Xavier, AC | 1 |
| Dancey, JE | 1 |
| Costa, DB | 1 |
| Aftab, DT; Bentzien, F; Cancilla, B; Chen, J; Chu, F; De Costa, A; Engell, K; Gendreau, SB; Jackman, L; Jaeger, CT; Joly, AH; Keast, P; Laird, AD; Lutman, J; Martini, JF; Meyer, SM; Shi, Y; Ventura, R; Wang, J; Yakes, FM; Yu, P; Zhang, W | 1 |
| Baker, SD; He, P; Hidalgo, M; Li, J; Zhao, M | 1 |
| Bunn, PA | 1 |
| Chang, J; Cho, BC; Choi, HJ; Im, CK; Kim, H; Kim, JH; Kim, SK; Kim, YJ; Park, JP; Park, MS; Shin, SJ; Sohn, JH | 1 |
| Brahmer, J; Juergens, R | 1 |
| Calhoun, R; Gandara, DR; Jablons, D; Wakelee, H | 1 |
| Chang, JW; Cheung, YC; Chou, CL; Hsieh, JJ; Hsu, T; Huang, SF; Wang, HM | 1 |
| Brahmer, JR; Hann, CL | 1 |
| Gyergyay, F | 1 |
| Basti, S; Jampol, LM; Zhang, G | 1 |
| Antoine, M; Cadranel, J; Gounant, V; Lavolé, A; Milleron, B; Wislez, M | 1 |
| Thatcher, N | 1 |
| Colantuoni, G; Del Gaizo, F; Ferrara, C; Galetta, D; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Rossi, A | 1 |
| Akhurst, T; Kris, MG; Miller, VA; Milton, DT; Moore, E; Pao, W; Riely, GJ; Rizvi, NA; Schwartz, LH; Tyson, L; Zhao, B | 1 |
| Andersson, M; Nielsen, DL | 1 |
| Bendell, JC; Clark, JW; Czito, BG; Duda, DG; Jain, RK; Willett, CG | 1 |
| Ashley, S; Barbachano, Y; Norton, A; O'Brien, M; Popat, S | 1 |
| Cadranel, J; Gounant, V; Khalil, A; Lavole, A; Milleron, B; Poulot, V; Wislez, M | 1 |
| Ahmed, F; Ali, S; Gadgeel, SM; Philip, PA; Sarkar, FH; Wozniak, A | 1 |
| Jordis, U; Knesl, P; Röseling, D | 1 |
| Campone, M; Coudert, B; Favier, L; Ferrant, E; Fumoleau, P; Mayer, F | 1 |
| Besse, B; Italiano, A; Planchard, D; Soria, JC | 1 |
| Ng, K; Zhu, AX | 1 |
| Ambudkar, SV; Ashby, CR; Bates, SE; Chen, ZS; Fu, LW; Kim, IW; Peng, XX; Robey, RW; Shen, T; Shi, Z; Shukla, S; Si, QS | 1 |
| Bang, YJ; Han, SW; Kim, TY | 1 |
| Balak, M; Bean, J; Brennan, C; Broderick, S; Chang, WC; Chitale, D; Gazdar, A; Gerald, W; Huang, SF; Ladanyi, M; Miller, V; Motoi, N; Pao, W; Pass, H; Riely, G; Rusch, V; Shih, JY; Szoke, J; Viale, A; Wang, L; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Miller, VA | 1 |
| Costa, DB; Kobayashi, S | 1 |
| Almasi, A; Conte, P; Dominici, M; Eckhardt, S; Jori, B; Kanya, M; Keri, G; Kopper, L; Moldvay, J; Papay, J; Petak, I; Pinter, F; Sapi, Z; Schwab, R; Szabo, E; Szondy, K; Tamasi, A; Varkondi, E | 1 |
| Giordano, S; Petrelli, A | 1 |
| Chang, JW; Chen, YH; Chen, YR; Chen, YT; Chiu, YT; Fang, YF; Hsi, BL; Hsieh, JJ; Hsieh, MH; Hsieh, MS; Hsu, HY; Huang, SF; Liu, HP; Tsai, HY; Tsai, SF | 1 |
| Costa, DB; Kobayashi, S; Schumer, ST; Tenen, DG | 1 |
| Fong, T; Govindan, R; Morgensztern, D | 1 |
| Burgin, S; Heidary, N; Naik, H | 1 |
| Heymann, WR | 1 |
| Fojo, T | 1 |
| Chin, TM; Chuah, KL; Lim, SW; Nga, ME; Seah, SB; Soo, RA; Soong, R; Wong, AS | 1 |
| Ardizzoni, A; Ciardiello, F; De Marinis, F; De Petris, L; Di Maio, M; Gridelli, C; Hanna, N; Heymach, JV; Perrone, F; Rosell, R; Shepherd, FA; Thatcher, N; Vansteenkiste, J | 1 |
| Shih, JY; Wu, SG; Yang, PC; Yu, CJ | 1 |
| Dorfman, JD; Fuchs, BC; Fujii, T; Goodwin, JM; Lanuti, M; Tanabe, KK; Zhu, AX | 1 |
| De Grève, J; Decoster, L; Schallier, D; Teugels, E; Van Meerbeek, J; Vermeij, J | 1 |
| Bartolini, S; Cancellieri, A; Cappuzzo, F; Castaldini, L; Crino, L; Finocchiaro, G; Magrini, E; Metro, G; Tallini, G; Toschi, L; Trisolini, R | 1 |
| Chang, GD; Chen, CS; Hung, JH; Kashida, Y; Kulp, SK; Sargeant, AM; Wang, D; Wang, YC; Yamaguchi, M; Yang, CC | 1 |
| Brannigan, BW; Godin-Heymann, N; Haber, DA; Lamb, J; Maheswaran, S; McDermott, U; Settleman, J; Ulkus, L | 1 |
| Davidson, C; Hardie, WD; Ikegami, M; Korfhagen, TR; Le Cras, TD; Leikauf, GD; Prestridge, A; Whitsett, JA | 1 |
| Adjei, AA; Cassivi, SD; Molina, JR; Schild, SE; Yang, P | 1 |
| Bertalanffy, A; Dieckmann, K; Dietrich, W; Gelpi, E; Hainfellner, JA; Marosi, C; Prayer, D; Preusser, M; Rottenfusser, A; Widhalm, G | 1 |
| Liau, LM; Salgaller, ML | 1 |
| Black, JD; Iyer, RV; Javle, MM; Levea, CM; Maddipatla, S; Nwogu, CE; Pande, AU; Rani, A; Yang, GY | 1 |
| Akita, H; Kinoshita, I | 1 |
| Saijo, N | 2 |
| Colantuoni, G; Del Gaizo, F; Falanga, M; Ferrara, C; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Palazzolo, G; Rossi, A | 1 |
| Riely, GJ | 2 |
| Yang, CH | 1 |
| Jänne, PA | 1 |
| Dunsford, J | 1 |
| Christodoulou, C; Dahabreh, J; Mavri, A; Murray, S; Nikolakopoulou, A; Petraki, K; Skarlos, D | 1 |
| Dahse, R; Kosmehl, H | 1 |
| Herder, GJ; Lind, JS; Smit, EF | 1 |
| Breza, N; Keri, G; Orfi, L; Petak, I; Pinter, F; Robert, K; Schwab, R; Varkondi, E | 1 |
| Crinò, L; Reck, M | 1 |
| Bernhard, JC; Ferrière, JM; Ravaud, A; Robert, G; Wallerand, H | 1 |
| Adès, L; Boehrer, S; de Botton, S; Fenaux, P; Galluzzi, L; Gardin, C; Kroemer, G; Tailler, M; Tajeddine, N | 1 |
| Kim, SW; Lee, DH; Lee, JS; Suh, C; Yi, EJ; Yoon, DH | 1 |
| Bafaloukos, D; Dahabreh, IJ; Kosmidis, P; Linardou, H; Manoloukos, M; Murray, S | 1 |
| Chella, A; Falcone, A; Tibaldi, C; Vasile, E | 1 |
| Agulnik, M; Wang, LX | 1 |
| Agulnik, M; Brockstein, B; Lacouture, M | 1 |
| Bourhis, J; Castadot, P; Chargari, C; Deutsch, E; Ghalibafian, M; Haie-Meder, C; Magné, N; Soria, JC | 1 |
| Bianco, R; Del Vecchio, S; Fonti, R; Iommelli, F; Lettieri, A; Papaccioli, A; Pirozzi, G; Salvatore, M; Sommella, J; Tortora, G; Zannetti, A | 1 |
| Chin, TM; Seto, KY; Soo, RA; Wong, AS | 1 |
| Tamura, K | 1 |
| Loeffler-Ragg, J; Schwentner, I; Sprinzl, GM; Zwierzina, H | 1 |
| Abidoye, O; Salgia, R; Sattler, M | 1 |
| Cho, BC; Costa, DB; Halmos, B; Huberman, MS; Jackman, DM; Jänne, PA; Kim, JH; Kobayashi, S; Nguyen, KS; Pao, W; Riely, GJ; Sequist, LV; Tenen, DG; Yeap, BY | 1 |
| Owonikoko, TK; Ramalingam, S | 1 |
| Balak, M; Bean, J; Ladanyi, M; Marks, JL; Miller, VA; Pao, W; Riely, GJ | 1 |
| Harichand-Herdt, S; Ramalingam, SS | 1 |
| Bang, YJ; Han, SW; Heo, DS; Im, SA; Kim, CS; Kim, DW; Kim, HJ; Kim, TY; Kim, YJ; Lee, SH; Oh, DY; Yi, HG | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Im, SA; Kim, DW; Kim, TY; Kim, YW; Lee, JS; Lee, SH; Oh, DY; Sim, SH | 1 |
| Bajetto, A; Barbieri, F; Capra, MC; Corte, G; Daga, A; Favoni, RE; Florio, T; Gatti, M; Griffero, F; Lo Casto, M; Marubbi, D; Melotti, A; Pattarozzi, A; Porcile, C; Spaziante, R; Zona, G | 1 |
| Carloni, F; Lazzari Agli, L; Santelmo, C; Sartori, S; Tamburini, E; Tassinari, D; Tombesi, P | 1 |
| Choi, Y; Kim, JE; Kim, SW; Lee, DH; Lee, JS; Suh, C; Yoon, DH | 1 |
| Aritakula, A; Ramasamy, A | 1 |
| Beau-Faller, M; Gaub, MP; Guerin, E; Jeung, MY; Legrain, M; Mennecier, B; Molard, A; Neuville, A; Oudet, P; Quoix, E; Ruppert, AM; Voegeli, AC | 1 |
| Armstrong, EA; Benavente, S; Chi, A; Harari, PM; Hsu, KT; Huang, S; Wheeler, DL | 1 |
| Gajjar, A; Wright, KD | 1 |
| Ginsberg, MS; Heelan, R; Hussain, S; Kris, MG; Ladanyi, M; Miller, VA; Pao, W; Rusch, VW; Zakowski, MF | 1 |
| Falcone, A; Tibaldi, C; Vasile, E | 1 |
| Calhau, C; Giovannetti, E; Jansen, G; Kathmann, I; Lemos, C; Peters, GJ | 1 |
| Ali, S; Gadgeel, SM; Philip, PA; Sarkar, FH; Wozniak, A | 1 |
| Dreyer, C; Faivre, S; Raymond, E | 1 |
| Lu, MQ; Wang, J; Wei, Q; Wen, CH; Xu, XH; Zhou, ZT | 1 |
| Lin, CC; Yang, CH | 1 |
| Distel, RJ; Jänne, PA; Kuang, Y; Makrigiorgos, M; Rogers, A; Thiede, S; Vetrand, K; Wang, L; Yeap, BY | 1 |
| Chen, HJ; Chen, ZH; Guo, AL; Mok, TS; Su, J; Wu, YL; Zhang, XC | 1 |
| Filipits, M; Minar, W; Pirker, R | 1 |
| Akslen, LA; Briggs, A; Byers, LA; Cascone, T; Engelman, J; Folkman, J; Halmos, B; Heymach, JV; Jänne, P; Johnson, BE; Kobayashi, S; Lifshits, E; Naumov, GN; Nilsson, MB; Straume, O; Tang, XM; Tenen, D; Wu, HK; Xu, L; Yeap, B | 1 |
| Chang, BW; Saif, MW | 1 |
| Clynes, M; Collins, DM; Crown, J; Devery, A; O'Connor, R; O'Donovan, N; O'Driscoll, L; O'Sullivan, F | 1 |
| Ansari, J; Hussain, SA; Palmer, DH; Rea, DW | 1 |
| Ayabe, E; Endo, M; Igawa, S; Kaira, K; Kaira, R; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shimoyama, R; Shukuya, T; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Abrey, LE; Aldape, K; Chang, SM; Cloughesy, TF; Dancey, J; Deangelis, LM; Fine, HA; Gilbert, MR; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, M; Norden, AD; Prados, MD; Raizer, JJ; Robins, HI; Wen, PY; Yung, WK | 1 |
| Dorans, K | 1 |
| Cohen, EE; Halpern, AB; Kasza, K; Kocherginsky, M; Vokes, EE; Williams, R | 1 |
| Dziadziusko, R; Fennell, D; Gridelli, C; Lacombe, D; Pallis, AG; Serfass, L; van Meerbeeck, JP; Welch, J | 1 |
| Greer, J; Lynch, TJ; Pirl, WF; Sequist, L; Solis, J; Temel, JS | 1 |
| Chen, P; Chen, ZG; Du, Y; Fu, H; Khuri, FR; Li, L; Li, Z; Shin, DM; Sun, SY | 1 |
| Balius, TE; Rizzo, RC | 1 |
| Costa, DB; Kobayashi, S; Nguyen, KS | 1 |
| Aono, N; Isa, S; Kawaguchi, T; Koh, Y; Kubo, A; Kurata, T; Nakao, K; Tachibana, K; Takada, M; Tsujino, K | 1 |
| Anderton, J; Davies, BR; Mark Hickinson, D; Marshall, G; Rukazenkov, Y; Speake, G; Swaisland, A; Wilkinson, RW | 1 |
| Admane, S; Chirieac, LR; Costa, DB; Digumarthy, SR; Heist, RS; Iafrate, AJ; Kobayashi, S; Kwak, EL; Lynch, TJ; Mark, EJ; McDermott, U; Mino-Kenudson, M; Rodig, SJ; Settleman, J; Shaw, AT; Solomon, B; Stubbs, H; Yeap, BY | 1 |
| Cioffredi, LA; Giaccone, G; Jackman, DM; Jänne, PA; Johnson, BE; Miller, VA; Riely, GJ; Ruiz, MG; Sequist, LV; Yeap, BY | 1 |
| Gazdar, AF | 3 |
| Cappuzzo, F; Hirsch, FR; Varella-Garcia, M | 1 |
| Ho, JC; Ip, MS; Lam, B; Lam, WK; Lo, AI; Wong, MK | 1 |
| Murakami, H; Ohashi, Y; Sakurai, M; Shino, M; Suzuki, K; Takahashi, T; Yamamoto, N | 1 |
| Fukui, T; Hatooka, S; Hida, T; Ito, S; Katayama, T; Mitsudomi, T; Onozato, R; Shimizu, J; Suda, K; Sueda, T; Yatabe, Y | 1 |
| Alì, G; Baldini, E; Boldrini, L; Camacci, T; Comin, CE; Fontanini, G; Gisfredi, S; Lucchi, M; Maddau, C; Melfi, F; Mussi, A; Servadio, A; Tibaldi, C; Ursino, S | 1 |
| Gelderblom, H; Guchelaar, HJ; van Erp, NP | 1 |
| Auclair, PL; Battelli, C; Carrier, K; Emery, IF; Hayes, DM | 1 |
| Boggon, TJ; Cappuzzo, F; Clifford, B; Eisenberg, R; Franklin, WA; Fu, P; Halmos, B; Hamdan, A; Hirsch, FR; Jin, C; Leidner, RS; Skokan, M; Varella-Garcia, M | 1 |
| Buttitta, F; Cappuzzo, F; Carlone, D; Ceribelli, A; Cognetti, F; Del Grammastro, M; Felicioni, L; Finocchiaro, G; Gelibter, AJ; Iacobelli, S; Irtelli, L; Malatesta, S; Marchetti, A; Mezzetti, A; Milella, M; Nuzzo, C; Perrucci, B; Sciarrotta, M | 1 |
| Choi, YJ; Kim, CH; Lee, JC; Lee, JK; Lee, SS; Na, II; Rho, JK; Ryoo, BY; Yang, SH; Yoo, YD | 1 |
| House, L; Liu, Y; Ramírez, J; Ratain, MJ | 1 |
| Bronson, RT; Chen, Z; Engelman, JA; Faber, AC; García-Echeverría, C; Li, D; Liang, MC; Lifshits, E; Maira, SM; Song, Y; Wong, KK; Yeap, BY | 1 |
| Banat, GA; Cornitescu, T; Dahal, BK; Dumitrascu, R; Ghofrani, HA; Grimminger, F; Kosanovic, D; Pullamsetti, SS; Schermuly, RT; Seeger, W; Tretyn, A; Voswinckel, R; Weissmann, N | 1 |
| Chahbouni, A; den Burger, JC; Sinjewel, A; Vos, RM; Wilhelm, AJ | 1 |
| Castaldo, V; Ferrara, ML; Gridelli, C; Maione, P; Mazzeo, N; Palazzolo, G; Rossi, A | 1 |
| Chen, JH; Chen, KY; Shih, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Cha, MY; Kim, JW; Kim, MS; Kim, YH; Lee, CG; Lee, GS; Lee, KO; Park, SB; Song, JY | 1 |
| Carter, CA; Giaccone, G; Kelly, RJ | 1 |
| Engelman, JA; Jackman, D; Jänne, PA; Johnson, BE; Kris, MG; Lynch, T; Miller, VA; Pao, W; Riely, GJ | 1 |
| Benlloch, S; Molina, MA; Rosell, R; Taron, M; Viteri, S | 1 |
| Büttner, R; Heukamp, LC | 1 |
| Eck, MJ; Yun, CH | 1 |
| Gutteridge, E; Robertson, JF | 1 |
| Aractingi, S; Nassar, D; Soutou, B | 1 |
| Fukui, T; Hataishi, R; Igawa, S; Jiang, SX; Katagiri, M; Kubota, M; Masuda, N; Mitsufuji, H; Nishii, Y; Otani, S | 1 |
| Chang, J; Cho, BC; Choi, HJ; Kim, JH; Kim, SK; Lee, YJ; Moon, JW; Park, IK | 1 |
| Argiris, A; Burtness, BA; Caprioli, RM; Carbone, DP; Chung, CH; Cohen, EE; Forastiere, AA; Gilbert, J; Grigorieva, J; Murphy, B; Roder, H; Roder, J; Seeley, EH; Tsypin, M | 1 |
| Neal, JW | 1 |
| Aoe, K; Bessho, A; Fujiwara, K; Harita, S; Hotta, K; Kamei, H; Kato, K; Kawai, H; Kiura, K; Kuyama, S; Maeda, T; Moritaka, T; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Umemura, S; Yonei, T; Yoshioka, H | 1 |
| Dirschka, T; Hauschild, A; Kroth, J; Wollenberg, A | 1 |
| Neal, JW; Sequist, LV | 2 |
| Ishida, T; Iwasaku, M; Kunimasa, K; Nishiyama, A; Ubukata, S; Yoshioka, H | 1 |
| Arao, T; Fujita, Y; Fukuoka, M; Ito, H; Nakagawa, K; Nishio, K; Okamoto, I; Takeda, M | 1 |
| Cadranel, J; De Fraipont, F; Faller, MB; Fraboulet, G; Lantuejoul, S; Legendre, A; Milleron, B; Moro-Sibilot, D; Oliveiro, G; Perol, M; Pluquet, E; Quoix, E; Souquet, PJ; Zalcman, G | 1 |
| Bachawal, SV; Sylvester, PW; Wali, VB | 2 |
| Hansen, O; Schytte, T | 1 |
| Fukuoka, M; Nakagawa, K; Okamoto, I; Takeda, M | 1 |
| Chen, J; Liu, H; Xu, Y; Zhou, Q | 1 |
| Miller, VA; Oxnard, GR | 1 |
| Ramalingam, SS; Stinchcombe, TE | 1 |
| Bodio, K; Costa, DB; Huberman, MS; Kobayashi, S; Kris, MG; Lau, MW; Pao, W; Riely, GJ; Tenen, DG; Warner, JL; Yeap, BY; Yeo, WL | 1 |
| Dunn, EF; Harari, PM; Wheeler, DL | 1 |
| Ahn, JS; Ahn, MJ; Choi, YL; Kim, JH; Kim, ST; Lee, J; Park, K; Park, YH; Sun, JM; Won, YW | 1 |
| Wörmann, B | 1 |
| Fujikura, Y; Hizawa, N; Homma, S; Kurishima, K; Morishima, Y; Ota, K; Otsuka, S | 1 |
| Ji, H | 1 |
| Ahn, JS; Ahn, MJ; Kim, JH; Kim, ST; Lee, J; Park, K; Park, YH; Sun, JM; Won, YW; Yun, J | 1 |
| Belsanova, B; Benesova, L; Minarik, M; Pesek, M; Sekerka, P | 1 |
| Döme, B; Ostoros, G; Strausz, J; Tímár, J | 1 |
| Brückl, WM; Ficker, JH; Wiest, GH | 1 |
| Fukuoka, M; Makimura, C; Nakagawa, K; Okamoto, I; Takeda, M | 1 |
| Chang, CY; Chang, SC; Chen, CY; Yu, CJ | 1 |
| Lin, CC; Shao, YY; Yang, CH | 1 |
| Ahn, JS; Ahn, MJ; Ahn, YC; Kim, JA; Lee, J; Lee, S; Park, HC; Park, K; Park, YH; Sun, JM | 1 |
| Cascone, T; Ciardiello, F; D'Aiuto, E; De Palma, R; De Vita, F; Martinelli, E; Morgillo, F; Orditura, M; Troiani, T | 1 |
| Bokemeyer, C; Laack, E; Sauter, G | 1 |
| Ishikawa, H; Kato, T; Naito, T; Nakagaki, S; Ohashi, Y; Onishi, T; Sakurai, M; Shino, M; Suzuki, K; Takahashi, T; Yamamoto, N | 1 |
| Chen, L; Li, C; Liu, X; Tian, Q; Wang, P; Xu, Y; Yang, Z; Zhao, W | 1 |
| Chen, J; Liu, H; Wang, Y | 1 |
| Chan, N; Lim, SW; Soo, RA; Teo, C; Wong, AS; Wong, E | 1 |
| Altorki, N; Camiolo, M; Fenoglio, S; Gao, DC; Johns, C; Kenner, L; Lindsted, T; Mittal, V; Schlederer, M; Sordella, R; Stiles, B; Yao, Z | 1 |
| Lam, KC; Mok, TS | 2 |
| Ahn, HK; Ahn, JS; Ahn, MJ; Chang, MH; Choi, YL; Jung, CK; Lee, J; Park, K; Park, YH | 1 |
| Chopra, A; Ku, GY; Lopes, Gde L | 1 |
| Bafaloukos, D; Dahabreh, IJ; Kosmidis, P; Linardou, H; Murray, S | 1 |
| Cho, EK; Hong, J; Jung, SH; Kyung, SY; Lee, JH; Lee, JI; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB; Sym, SJ | 1 |
| Chang, YC; Chang, YL; Hsu, YC; Shih, JY; Wu, JY; Wu, SG; Yang, CH; Yang, PC | 1 |
| Iqbal, SA; Myerson, JS; O'Brien, ME; Popat, S | 1 |
| Andreuccetti, M; Borghi, F; Caparello, C; Caponi, S; D'Incecco, A; Falcone, A; Ginocchi, L; Lucchesi, M; Tibaldi, C; Vasile, E | 1 |
| Ferris, RL; Ferrone, S; Grandis, JR; Sharafinski, ME | 1 |
| Cheng, G; Li, L; Wu, XN; Zhang, P; Zhang, ZJ | 1 |
| Der, CJ; Roberts, PJ; Socinski, MA; Stinchcombe, TE | 1 |
| Hosomi, Y; Iguchi, M; Miyamoto, S; Ohkuma, Y; Okamura, T; Shibuya, M; Shimokawa, T; Takagi, Y | 1 |
| Basaki, Y; Izumi, H; Kage, M; Kawahara, A; Kohno, K; Kuwano, M; Nakashima, K; Ono, M; Uramoto, H; Yamamoto, C; Yasumoto, K | 1 |
| Benlloch, S; Cardenal, F; Molina, MA; Moran, T; Porta, R; Rosell, R; Taron, M; Viteri, S | 1 |
| Jones, SJ; Milenkova, T | 1 |
| Britt, GJ; Costa, DB; Heon, S; Jackman, DM; Johnson, BE; Rabin, MS; Yeap, BY | 1 |
| Duchnowska, R | 1 |
| Ahn, JS; Ahn, MJ; Chung, MJ; Hwang, HS; Kim, TS; Lee, HY; Lee, JW; Lee, KS; Park, K; Yi, CA | 1 |
| Chen, YM; Chou, KT; Fan, WC; Hsia, TC; Huang, MS; Huang, SF; Lai, CL; Lee, YC; Perng, RP; Tien, YJ; Tsai, CM; Wu, CH; Yu, CJ | 1 |
| Haramoto, M; Horibe, T; Kawakami, K; Kohno, M; Matsuzaki, K; Nakajima, O; Ohara, K; Yano, Y | 1 |
| Abbott, DW; Asara, JM; Tigno-Aranjuez, JT | 1 |
| Bischoff, H; Kindermann, M; Reinmuth, N; Steins, MB; Thomas, M | 1 |
| Baak, JP; Guo, H; Liu, JX; Madebo, T; Xu, L | 1 |
| Azzoli, CG; D'Angelo, SP; Janjigian, YY; Kris, MG; Ladanyi, M; Pao, W; Park, BJ; Shen, R; Zakowski, MF; Zheng, J | 1 |
| Gelderblom, H; Guchelaar, HJ; Pander, J | 1 |
| Lee, P | 1 |
| Cortot, AB | 1 |
| Choi, YJ; Chung, JH; Kim, CH; Kim, HR; Lee, CT; Lee, JC; Lee, JS; Rho, JK; Xu, X; Yoon, HI | 1 |
| Lin, CC; Yang, JC | 1 |
| Heigener, DF; Reck, M | 1 |
| Baba, J; Ichikawa, K; Kagamu, H; Kondo, R; Koshio, J; Miyabayashi, T; Narita, I; Ota, T; Tanaka, H; Tanaka, J; Watanabe, S; Yoshizawa, H | 1 |
| Berardi, F; Colabufo, NA; Contino, M; Leopoldo, M; Niso, M; Perrone, R | 1 |
| Angelo, A; Azzariti, A; Colucci, G; Porcelli, L; Quatrale, AE; Silvestris, N | 1 |
| Azzariti, A; Colucci, G; Fratto, ME; Galluzzo, S; Maiello, E; Santini, D; Silvestris, N; Tommasi, S; Tonini, G; Vincenzi, B; Zoccoli, A | 1 |
| Grazioso Russi, E; Numico, G; Silvestris, N | 1 |
| Longo, M; Merlo, V; Novello, S; Scagliotti, GV | 1 |
| Chen, B; Liu, S; Wang, D; Wang, Y; Wu, J; Zhao, W | 1 |
| Doussau, A; Le Tourneau, C; Ollivier, L; Paoletti, X; Postel-Vinay, S; Servois, V | 1 |
| Boss, DS; Britten, CD; Camidge, DR; Eckhardt, SG; Engelman, JA; Garon, EB; Guo, F; Jänne, PA; Letrent, S; Liang, J; Millham, R; Schellens, JH; Taylor, I; Wong, S | 1 |
| Donev, IS; Li, Q; Matsumoto, K; Nishioka, Y; Sone, S; Takeuchi, S; Wang, W; Yamada, T; Yamori, T; Yano, S | 1 |
| Fan, Y; Huang, ZY; Luo, LH; Yu, HF | 1 |
| Chang, CC; Chang, HJ; Chi, KH; Hsieh, YS; Hsu, PS; Jiang, JS; Kao, SJ; Tsang, YW; Yeh, YW | 1 |
| Duyster, J; Kancha, RK; Peschel, C | 1 |
| Ito, K; Kawano, D; Maehara, Y; Morodomi, Y; Shoji, F; Yano, T | 1 |
| Beck, JF; Kurtze, I; Sonnemann, J | 1 |
| Asami, K; Atagi, S; Kawaguchi, T; Kawahara, M; Okishio, K | 1 |
| Fujitaka, K; Hamada, A; Haruta, Y; Hattori, N; Ishikawa, N; Iwamoto, H; Kanehara, M; Kohno, N; Masuda, T; Murai, H; Ohshimo, S | 1 |
| Camidge, DR; Cappuzzo, F; Varella-Garcia, M | 1 |
| Babu, VC; Harini, VV; Kumar, BS; Nargund, A; Patil Okaly, GV; Rao, R; Rao, S; Sahoo, R; Venkataswamy, E | 1 |
| Chang, DS; Di, YP; Li, HQ; Li, P; Liu, LY; Wang, J; Wang, JD; Wang, X; Wang, YJ; Wu, WZ; Xia, TY | 1 |
| Buhren, BA; Gerber, PA; Homey, B; Kukova, G | 1 |
| Friedrich, MJ | 1 |
| Chen, X; Guo, R; Shu, Y; Sun, J; Wang, T; Zhang, Z | 1 |
| Bergot, E; Creveuil, C; Lechapt, E; Levallet, G; Zalcman, G | 1 |
| Fujita, S; Fukuhara, A; Hatachi, Y; Kim, YH; Masago, K; Mio, T; Mishima, M; Nagai, H; Sakamori, Y; Togashi, Y | 1 |
| De Marinis, F; Karapanagiotou, EM; Oikonomopoulos, G; Saif, MW; Syrigos, KN | 1 |
| Cataldo, VD; Gibbons, DL; Pérez-Soler, R; Quintás-Cardama, A | 1 |
| Castel, M; Despas, F; Mazières, J; Pathak, A | 1 |
| Antoine, M; Cadranel, J; Gounant, V; Lavolé, A; Wislez, M | 1 |
| Akhavanfard, S; Bergethon, K; Christensen, JG; Cosper, AK; Dias-Santagata, D; Digumarthy, S; Engelman, JA; Fidias, P; Gettinger, S; Heist, RS; Iafrate, AJ; Lanuti, M; Lynch, TJ; Mark, EJ; Mino-Kenudson, M; Sequist, LV; Shaw, AT; Temel, J; Turke, AB; Vernovsky, K; Wain, JC; Waltman, BA | 1 |
| Murphy, M; Stordal, B | 1 |
| Döme, B; Fehniger, TE; Laurell, T; Marko-Varga, G; Rezeli, M; Végvári, A | 1 |
| Tuder, RM; Winn, RA | 1 |
| Bae, JH; Chung, JS; Kang, CD; Kim, H; Kim, MJ; Kim, SH; Kim, SJ; Park, SJ | 1 |
| Azuma, J; Fujio, Y; Furukawa, M; Goya, S; Hirata, H; Kawase, I; Kida, H; Kijima, T; Minami, T; Nagatomo, I; Nonen, S; Otani, Y; Shimizu, T; Tachibana, I; Takahashi, R; Takeda, Y | 1 |
| Fujita, S; Hata, A; Hayashi, H; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Kunimasa, K; Morita, S; Nanjo, S; Nishiyama, A; Otsuka, K; Tomii, K; Yoshioka, H | 1 |
| Chang, YC; Shih, JY; Wu, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Anadkat, MJ; Balagula, Y; Lacouture, ME; Wu, PA | 1 |
| Antoine, M; Cadranel, J; Lacave, R; Poulot, V; Ruppert, AM; Wislez, M | 1 |
| Di Gion, P; Doroshyenko, O; Fuhr, U; Scheffler, M; Wolf, J | 1 |
| Crinò, L; Metro, G | 1 |
| Cui, CX; Hao, XZ; Li, JL; Shi, YK; Wang, B; Wang, HY; Wang, Y; Zhang, XR; Zhao, LD | 1 |
| Goya, S; Hirata, H; Kawase, I; Kida, H; Kijima, T; Kuhara, H; Minami, T; Nagatomo, I; Osa, A; Tachibana, I; Takahashi, R; Takeda, Y; Tetsumoto, S | 1 |
| Fujii, M; Maehara, Y; Mitsudomi, T; Murakami, H; Osada, H; Sekido, Y; Suda, K; Tomizawa, K; Yatabe, Y | 1 |
| Azzoli, CG; Ginsberg, MS; Johnson, ML; Kris, MG; Miller, VA; Pao, W; Riely, GJ; Rizvi, NA; Sima, CS | 1 |
| Ma, S; Xu, Y; Zhang, Y | 1 |
| Heneberg, P | 1 |
| Chen, Y; Feng, L; Ge, W; Han, W; Jin, H; Li, J; Lin, X; Pan, H; Sun, J; Wang, X; Wang, Y | 1 |
| Dallas, J; Jantz, MA; Kaye, FJ | 1 |
| Durand, JB; Kim, P; Yusuf, SW | 1 |
| Ahn, JS; Ahn, MJ; Jung, SH; Kim, ST; Kim, SW; Lee, J; Park, K; Park, YH; Sohn, I; Sun, JM; Uhm, JE | 1 |
| Curtit, E; Mansi, L; Viel, E; Vignot, S | 1 |
| Kosaka, T; Kuwano, H; Mogi, A; Yamaki, E | 1 |
| Altavilla, G; Benecchi, S; Magri, I; Pettineo, G; Rosell, R; Salazar, MF; Santarpia, M | 1 |
| Chang, YL; Jan, IS; Luo, SC; Shih, JY; Su, KY; Tsai, TH; Wu, SG; Yang, PC; Yu, CJ; Yu, SL | 1 |
| Han, JY; Kim, HT; Lee, GK; Lee, JS; Lim, KY; Park, SY; Won, YW; Yoon, KA; Yun, T | 1 |
| Amato, KR; Arcila, M; Chmielecki, J; de Stanchina, E; Foo, J; Ginsberg, MS; Hutchinson, K; Inoue, A; Kris, MG; Ladanyi, M; Michor, F; Miller, VA; Ohashi, K; Oxnard, GR; Pao, W; Socci, ND; Somwar, R; Sos, ML; Thomas, RK; Viale, A; Wang, L | 1 |
| Blanchet, B; Dauphin, A; Dusser, D; Faivre, L; Goldwasser, F; Gomo, C; Mir, O; Ropert, S; Schoemann-Thomas, A; Taieb, F; Vidal, M | 1 |
| Berrino, L; Cascone, T; Ciardiello, F; D'Aiuto, E; De Palma, R; Heymach, JV; Martinelli, E; Morgillo, F; Saintigny, P; Troiani, T; Tuccillo, C | 1 |
| Ando, M; Dote, H; Jida, M; Kawasaki, K; Kiura, K; Kobayashi, N; Kubo, T; Miyoshi, S; Ogino, A; Otani, H; Soh, J; Toyooka, S; Ueno, T; Yamamoto, H | 1 |
| Douillard, JY; Lokiec, F | 1 |
| Barlesi, F | 1 |
| Fujita, S; Kim, YH; Masago, K; Mio, T; Mishima, M; Okuda, C; Sakamori, Y; Togashi, Y | 1 |
| Cunningham, D; Yim, KL | 1 |
| Pandiella, A; Sánchez-Martín, M | 1 |
| Arcila, ME; Azzoli, CG; Janjigian, YY; Kass, SL; Kris, MG; Ladanyi, M; Miller, VA; Oxnard, GR; Pao, W; Riely, GJ; Sima, CS | 1 |
| Bellevicine, C; Malapelle, U; Palombini, L; Troncone, G; Zeppa, P | 1 |
| Barberis, M; Catania, C; de Braud, F; De Pas, T; Delmonte, A; Fumagalli, C; Giovannini, M; Manzotti, M; Spaggiari, L; Spitaleri, G; Toffalorio, F | 1 |
| Chaft, JE; Kris, MG; Miller, VA; Oxnard, GR; Riely, GJ; Sima, CS | 1 |
| Gong, Y; Pao, W | 1 |
| Li, L; Liu, JL; Su, H; Xu, CA; Zou, HW | 1 |
| Cavenee, WK; Furnari, F; Gonias, SL; Hu, J; Jo, M; VandenBerg, SR | 1 |
| Chua, KT; Lai, NL; Lee, CH; Liam, CK; Lim, BK; Pang, YK | 1 |
| Abe, T; Hayashi, S; Hirai, M; Hosomi, T; Iwanaga, K; Kimura, S; Komiya, K; Nakamura, T; Sato, A; Sueoka, E; Sueoka-Aragane, N; Ureshino, N | 1 |
| Atherton, PJ; Burger, KN; Jatoi, A; Loprinzi, CL; Miller, RC; Neben Wittich, MA; Sloan, JA | 1 |
| Chen, ZW; Lu, S; Song, ZB; Yu, YF | 1 |
| Bae, JH; Chung, JS; Kang, CD; Kim, MJ; Kim, SH; Kim, SJ; Oh, SO | 1 |
| Grandal, MV; Grøvdal, LM; Holst, MR; Kim, J; Knudsen, SL; van Deurs, B | 1 |
| Guo, ZZ; Huang, JJ; Huang, Y; Lin, TY; Tian, Y; Xu, F; Zhang, LL | 1 |
| Arao, T; Horiike, A; Ikeda, N; Kasahara, K; Kimura, H; Koizumi, F; Matsumoto, K; Nishio, K; Nishio, M; Ohira, T; Saijo, N; Sakai, A; Sakai, K; Sone, T; Yamanaka, T | 1 |
| Belden, CJ; Fadul, CE; Harris, BT; Israel, MA; Pastel, DA; Paulsen, K; Ran, C; Roberts, DW; Valdes, PA | 1 |
| Cho, J; Chowhan, NM; Funke, R; Gadgeel, SM; Lara, PN; Lynch, TJ; Miller, VA; Mitchell, B; Pennell, NA; Pietanza, MC; Vrindavanam, N; Wakelee, HA; Yanagihara, RH | 1 |
| A'Hern, R; Anderson, H; Bliss, J; Dowsett, M; Dunbier, A; Evans, A; Ghazoui, Z; Iskender, A; Johnson, L; Pinhel, I; Robertson, J; Robison, L; Salter, J; Skene, T; Smith, I; Wilcox, M | 1 |
| Higashiyama, M; Kimura, T; Kiura, K; Kondoh, K; Kudoh, S; Minami, Y; Mitsudomi, T; Noguchi, M; Nokihara, H; Oda, M; Ohe, Y; Saito, H; Tachibana, K; Takeuchi, S; Tanaka, H; Uramoto, H; Yamada, T; Yano, S; Yasumoto, K; Yatabe, Y; Yokota, J; Yoshida, J | 1 |
| Murakami, H; Naito, T; Nakamura, Y; Nishio, K; Nokihara, H; Sarashina, A; Seki, Y; Shahidi, M; Takahashi, T; Tamura, T; Yamamoto, N | 1 |
| Brugarolas, A; Evgenyeva, E; Fernández, FJ; Forteza, J; González-Manzano, R; Martínez-Navarro, EM; Rebollo, J; Sureda, M; Valenzuela, B | 1 |
| Beijnen, JH; Lankheet, NA; Malingré, MM; Schaefer-Prokop, CM; Staaks, GH; ter Heine, R; van den Bosch, RT; van den Brand, JJ; van der Westerlaken, MM | 1 |
| Daub, H; Schreiber, TB; Weber, C | 1 |
| Cappuzzo, F; Jänne, PA; Mok, TS; Soria, JC | 1 |
| Chang, YL; Chen, YH; Kuo, YW; Shih, JY; Tsai, MF; Wu, SG; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Bar, J; Onn, A | 1 |
| Boeck, S; Heinemann, V; Kächele, V; Parmar, S; Paul, T; Rüdiger, S; Schumann, C; Seeringer, A; Seufferlein, T; Stingl, JC | 1 |
| Funada, Y; Hatakeyama, Y; Hori, S; Kasai, D; Kobayashi, K; Kondoh, T; Kotani, Y; Nagano, T; Nishimura, H; Nishimura, Y | 1 |
| Goishi, K; Higashiyama, S; Ise, N; Nambara, D; Omi, K | 1 |
| Endo, M; Harada, H; Inomata, M; Kenmotsu, H; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Lee, SH | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Petrelli, F | 1 |
| Agulnik, M | 1 |
| Daw, HA; Peerzada, MM; Spiro, TP | 1 |
| Bardelli, A; Beijersbergen, RL; Bernards, R; Di Nicolantonio, F; Huang, S; Prahallad, A; Salazar, R; Sun, C; Zecchin, D | 1 |
| Amberger-Murphy, V; Clarke, C; Clynes, M; Doolan, P; Farrell, M; Howley, R; Kinsella, P; Madden, SF | 1 |
| Kaira, K; Yamamoto, N | 1 |
| Kondo, T; Murakami, S; Noda, K; Oshita, F; Saito, H; Yamada, K | 1 |
| Ishida, T; Iwasaku, M; Korogi, Y; Kunimasa, K; Masuda, G; Nishiyama, A; Takaiwa, T; Yoshioka, H | 1 |
| Li, Y; Song, L | 1 |
| Chang, S; Ding, J; Ding, K; Geng, M; Liu, Y; Lu, X; Luo, J; Pei, D; Ren, X; Tu, Z; Xu, S; Xu, T; Xu, Y; Zhang, L; Zhang, Z | 1 |
| Barletta, G; Boldrini, L; Brianti, A; Cosso, M; Dal Bello, MG; Defferrari, C; Fontanini, G; Genova, C; Grossi, F; Murolo, C; Pronzato, P; Rijavec, E; Truini, M | 1 |
| Pick, A; Wiese, M | 1 |
| Permsuwan, U; Thongprasert, S; Tinmanee, S | 1 |
| Chen, G; De Grève, J; Kronenberger, P; Teugels, E; Umelo, IA | 1 |
| de Marinis, F; del Signore, E; Fulvi, A; Gori, B; Ricciardi, S | 1 |
| Cadranel, J; Chao, TY; Chen, YM; Cong, XJ; Crino, L; Heo, DS; Hirsh, V; Kim, SW; Lorence, RM; Miller, VA; Park, K; Shahidi, M; Su, WC; Sun, Y; Tan, EH; Wang, M; Yang, JC; Zhou, C | 1 |
| Kawada, A; Nakagawa, K; Oiso, N; Okamoto, I; Takeda, M; Tsurutani, J | 1 |
| Fujiwara, K; Hamada, N; Horita, N; Hotta, K; Kamei, H; Kiura, K; Segawa, Y; Takata, I; Takigawa, N; Tanimoto, M; Tsubouchi, K; Umemura, S; Yamane, H; Yoshioka, H | 1 |
| Burger, JA; Saintigny, P | 1 |
| Ariansen, S; Berg, T; Bremnes, R; Brustugun, OT; Dai, HY; Dønnem, T; Fjellbirkeland, L; Grønberg, BH; Helgeland, L; Helland, Å; Jebsen, P; Kleinberg, L; Mangseth, K; Scott, H; Wahl, SG | 1 |
| Ayoola, A; Barochia, A; Belani, CP; Belani, K | 1 |
| Balu-Iyer, SV; Iyer, V; O'Connor, R; Straubinger, RM; Trummer, BJ | 1 |
| Bertran-Alamillo, J; Costa, C; Giménez-Capitán, A; Mayo, C; Molina-Vila, MÁ; Rosell, R | 1 |
| Gao, H; Guo, W; Li, J; Liu, X; Qin, H; Qu, L; Tang, C; Wang, H; Wang, W; Wei, X | 1 |
| Guo, Z; Li, J | 1 |
| Eastman, BM; Gonias, SL; Jo, M; Takimoto, S; Webb, DL | 1 |
| Harada, H; Mitsuya, K; Mizokami, Y; Nakamura, Y; Nakasu, Y; Nishimura, T; Ono, A; Takahashi, T; Toda, Y; Yamamoto, N | 1 |
| Kim, HT; Kim, KP; Kim, SW; Lee, DH; Lee, JS; Park, SJ; Suh, C | 1 |
| Fukuda, A; Sonoda, T; Takenaka, T; Yamagata, M | 1 |
| Carrión-Salip, D; De Llorens, R; Massaguer, A; Menendez, JA; Oliveras, G; Pandiella, A; Panosa, C; Puig, T | 1 |
| Britt, GJ; Butaney, M; Costa, DB; Heon, S; Jackman, DM; Johnson, BE; Joshi, VA; Lindeman, NI; Rabin, MS; Yeap, BY | 1 |
| Ahn, JS; Ahn, MJ; Cho, SH; Choi, YL; Han, JH; Hwang, DW; Ji, JH; Lee, JY; Park, K; Park, LC; Park, S; Sun, JM | 1 |
| Gu, H; Li, X; Liu, S; Wang, D | 1 |
| Cai, DY; Hong, TT; Hua, D; Wu, XH; Zhang, RX | 1 |
| Fukudo, M; Ikemi, Y; Katsura, T; Kim, YH; Masago, K; Masuda, S; Mishima, M; Mizuno, T; Nagai, H; Sakamori, Y; Togashi, Y | 1 |
| Botteman, MF; Carter, JA; Ganguli, A; Gao, X; Ray, S; Wiegand, P | 1 |
| Abe, H; Arao, T; Azuma, K; Hayashi, K; Kage, M; Kanda, R; Kawahara, A; Kubo, T; Kuwano, M; Murakami, Y; Nishio, K; Ono, M; Rosell, R; Sonoda, K; Tabara, K; Tahira, T; Yoshinaga, A | 1 |
| Gui, T; Shen, K | 1 |
| Abdul Razak, M; Chan, LC; Ong, CK; Tan, WC | 1 |
| Chen, Y; Han, B; Jia, J; Jiang, Y; Ma, X; Tan, C; Wei, X; Zhang, J; Zhu, F | 1 |
| Horn, L; Lovly, CM | 1 |
| Koma, Y; Matsuoka, H; Suzuki, Y; Yoshimatsu, H | 1 |
| Chang, J; Cho, BC; Hong, S; Jung, M; Kang, YA; Kim, DJ; Kim, JH; Kim, SH; Kim, SK; Rha, SY | 1 |
| Shi, YK | 1 |
| An, TT; Bai, H; Duan, JC; Wang, J; Wang, SH; Wang, YY; Wang, ZJ; Wu, MN; Yang, L; Zhao, J; Zhuo, ML | 1 |
| Galvani, E; Giovannetti, E; Peters, GJ | 1 |
| Chen, HM; Kuo, R; Lai, MS; Lin, ZZ; Shao, YY; Shau, WY; Yang, JC | 1 |
| Benešová, L; Bortlíček, Z; Brůha, F; Fiala, O; Fínek, J; Krejčí, J; Minárik, M; Pešek, M | 1 |
| Butaney, M; Capelletti, M; Ercan, D; Garraway, LA; Goetz, EM; Gray, NS; Ivanova, EV; Jänne, PA; Lazzara, MJ; Letai, A; Maertens, O; Monast, CS; Montero, J; Pratilas, CA; Repellin, C; Rogers, A; Rosen, N; Shimamura, T; Sholl, L; Tadi, M; Wong, KK; Xu, C; Yanagita, M | 1 |
| Erdem, L; Giovannetti, E; Honeywell, R; Leon, LG; Peters, GJ | 1 |
| Dziadziuszko, R; Jassem, J | 1 |
| Bobos, M; Christodoulou, C; Fountzilas, G; Karavasilis, V; Kosmidis, P; Murray, S; Papadopoulos, S; Razis, E | 1 |
| Katsura, Y; Ko, R; Koyama, R; Minakata, K; Murakami, A; Muraki, K; Namba, Y; Ohashi, R; Sakuraba, S; Shukuya, T; Takahashi, F; Takahashi, K; Yagishita, S | 1 |
| Chiang, HC; Du, S; Liang, B; Ma, W; Wang, L; Wu, W; Xie, Z; Yao, X; Zhong, Y | 1 |
| Bivona, TG; Blakely, CM | 1 |
| Chen, HJ; Dong, S; Huang, YS; Jiang, BY; Liao, RQ; Nie, Q; Su, J; Wang, BC; Wang, Z; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Zhang, XC; Zhong, WZ; Zhou, Q | 1 |
| Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Mitsuoka, S; Nagata, M; Suzumura, T; Tanaka, H; Umekawa, K; Yoshimura, N | 1 |
| Bouteloup, C; De Botton, S; Fenaux, P; Galluzzi, L; Kroemer, G; Lainey, E; Leroy, C; Scoazec, M; Sébert, M; Thépot, S | 1 |
| Abe, K; Ebina, M; Endo, C; Inoue, A; Kobayashi, M; Kondo, T; Kumamoto, H; Maemondo, M; Miki, Y; Mori, K; Narumi, S; Nukiwa, T; Sasano, H; Sato, I; Suzuki, T; Yamada-Okabe, H | 1 |
| Bortlíček, Z; Coupková, H; Grygárková, Y; Havel, L; Hejduk, K; Hrnčiarik, M; Kolek, V; Košatová, K; Koubková, L; Pešek, M; Roubec, J; Salajka, F; Sixtová, D; Skřičková, J; Spelda, S; Tomíšková, M; Zatloukal, P; Zemanová, M | 1 |
| Alesini, D; Cortesi, E; Passaro, A; Pochesci, A | 1 |
| Basti, S; Borkar, DS; Lacouture, ME | 1 |
| Ahye, N; Azzoli, CG; Chaft, JE; D'Angelo, SP; Dycoco, J; Janjigian, YY; Kris, MG; Ladanyi, M; Riely, GJ; Rusch, V; Shen, R; Sima, CS; Zakowski, MF; Zheng, J | 1 |
| Gemma, A; Saito, Y | 1 |
| Guirgis, HM | 1 |
| Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Matsuura, K; Mitsuoka, S; Nagata, M; Nakai, T; Suzumura, T; Tanaka, H; Umekawa, K; Yoshimura, N | 1 |
| Daga, H; Hirashima, T; Hirata, K; Kawaguchi, T; Kimura, T; Kobayashi, M; Kudoh, S; Mitsuoka, S; Okishio, K; Takeda, K; Yoshimura, N | 1 |
| Fujii, H; Jimmy So, A; Kono, K; Mimura, K; Shabbir, A; Yong, WP | 1 |
| Hirashima, T; Kawase, I; Kitai, K; Morishita, N; Okamoto, N; Otsuka, T; Shiroyama, T; Suzuki, H; Tamiya, M; Yamadori, T | 1 |
| Fujita, S; Hata, A; Imai, Y; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Korogi, Y; Kunimasa, K; Nishiyama, A; Notohara, K; Tachikawa, R; Tomii, K; Yoshioka, H | 1 |
| Bartolotti, M; Brandes, AA; Franceschi, E | 1 |
| Abe, H; Azuma, K; Hattori, S; Hoshino, T; Kage, M; Kawahara, A; Yamada, K; Yamashita, F; Yoshida, T; Zaizen, Y | 1 |
| Brodsky, O; Feng, J; Ferre, R; Gajiwala, KS; Kath, JC; Ryan, K; Stewart, A; Weinrich, S | 1 |
| Beijnen, JH; Harmsen, S; Maas-Bakker, RF; Meijerman, I; Schellens, JH | 1 |
| Hao, XZ; Li, JL; Shi, YK; Wang, B; Wang, Y; Wang, ZP; Zhang, XR | 1 |
| Cai, DY; Hua, D; Wu, XH; Zhang, RX | 1 |
| Hokkoku, K; Igarashi, S; Kitade, H; Mori, M; Nakai, M; Sagawa, M; Shintaku, K; Yamada, T; Yano, S | 1 |
| Corominas-Faja, B; Cufí, S; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Urruticoechea, A; Vazquez-Martin, A | 1 |
| Matsuo, K; Takada, Y | 1 |
| Cadranel, J; Cong, XJ; Fairclough, D; Finnern, HW; Hirsh, V; Lorence, RM; Miller, VA; Palmer, M; Yang, JC | 1 |
| Brooks, MB | 1 |
| Augustin, A; Avila, DW; Duchateau-Nguyen, G; Essioux, L; Golling, S; Hermann, JC; Klughammer, B; Lamerz, J; Langen, H; Meistermann, H; Scheiblich, S; Tzouros, M | 1 |
| Pallis, AG; Syrigos, KN | 1 |
| Fujii, A; Furuyama, K; Giaccone, G; Harada, T; Ijichi, K; Iwama, E; Li, H; Nakanishi, Y; Okamura, K; Ota, K; Shiraishi, Y; Takayama, K; Wang, S | 1 |
| Fujiwara, Y; Horinouchi, H; Kanda, S; Kubota, K; Nakamichi, S; Nokihara, H; Tamura, T; Yamamoto, N | 1 |
| Gwak, HS; Han, JY; Joo, J; Kim, HT; Kim, S; Lee, JS; Lee, SH; Shin, SH; Yoo, H | 1 |
| Gaffney, DC; Simpson, F; Soyer, HP | 1 |
| Huber, RM; Reck, M; Thomas, M | 1 |
| Couraud, S | 1 |
| Arcila, ME; Kris, MG; Ladanyi, M; Miller, VA; Pao, W; Rekhtman, N; Riely, GJ; Sima, CS; Yu, HA; Zakowski, MF | 1 |
| Araya, T; Demura, Y; Kasahara, K; Matsuoka, H; Nishi, K; Nishitsuji, M | 1 |
| Chang, CY; Chang, SC; Liu, YC; Wang, KF; Yang, YH; Yuan, MK | 1 |
| Chen, G; De Grève, J; Kronenberger, P; Noor, A; Teugels, E; Umelo, IA | 1 |
| Beasley, MB; Cagle, PT; Chitale, DA; Dacic, S; Giaccone, G; Jenkins, RB; Kwiatkowski, DJ; Ladanyi, M; Lindeman, NI; Saldivar, JS; Squire, J; Thunnissen, E | 1 |
| Chen, X; Guo, R; Liu, Y; Qian, Y; Røe, OD; Shu, Y; Yin, Y; Zhu, L | 1 |
| Chung, DH; Heo, DS; Jeon, YK; Keam, B; Kim, DW; Kim, JI; Kim, JY; Kim, S; Kim, TM; Koh, Y; Lee, JK; Lee, S; Lee, SH; Min, HS; Park, C; Shin, JY | 1 |
| Furukawa, T; Hamasaki, S; Itakura, S; Miyata, M; Suenaga, M; Tabata, S; Yamamoto, M | 1 |
| Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Matsuura, K; Mitsuoka, S; Nagata, M; Nakai, T; Oka, T; Suzumura, T; Umekawa, K; Yoshimura, N | 1 |
| Fujimoto, D; Fujita, S; Hata, A; Kaji, R; Katakami, N; Kawamura, T; Matsumoto, T; Monden, K; Nagata, K; Nakagawa, A; Otoshi, T; Otsuka, K; Tachikawa, R; Takeshita, J; Tamai, K; Tanaka, K; Tomii, K | 1 |
| Au, JS; Brown, C; Chu, da T; Gebski, V; Gralla, RJ; Hirsh, V; Ho, JC; Inoue, A; Lee, CK; Lee, SM; Osorio Sanchez, JA; Tan, EH; Thongprasert, S; Tsai, CM; Vu, VV; Yang, JC; Zaatar, A | 1 |
| Chen, L; Huang, Y; Liu, J; Ma, Y; Wu, H; Zhao, H; Zhou, N | 1 |
| Hou, YH; Pan, JB; Zhang, GJ | 1 |
| Fujita, Y; Horiike, A; Irwin, DL; Kaburaki, K; Kudo, K; Nishio, K; Nishio, M; Ohyanagi, F; Saito, R; Sakai, K; Sakatani, T; Tanimoto, A; Yanagitani, N | 1 |
| Arpin, D; Bringuier, PP; Couraud, S; Locatelli-Sanchez, M; Riou, R; Souquet, PJ | 1 |
| Bollu, LR; Gao, G; Huang, WC; Hung, MC; Ren, J; Su, F; Weihua, Z; Xu, L | 1 |
| Lin, B; Shao, L; Song, Z; Zhang, Y | 1 |
| Cardarella, S; Hatabu, H; Jackman, DM; Jänne, PA; Johnson, BE; Nishino, M; Rabin, MS; Ramaiya, NH | 1 |
| Adamo, V; David, A; Franchina, T; Gangemi, S; Kennez, I; Minciullo, PL; Profita, M; Zanghì, M | 1 |
| Chung, DH; Heo, DS; Keam, B; Kim, DW; Kim, TM; Lee, E; Lee, SH | 1 |
| Aieta, M; Bulotta, A; Conteduca, V; Gregorc, V; Improta, G; Lazzari, C; Lerose, R; Tartarone, A; Zupa, A | 1 |
| He, AN; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Atagi, S; Ebisawa, R; Goto, K; Hida, T; Horai, T; Ichinose, Y; Inoue, A; Katakami, N; Kiura, K; Koboyashi, K; Nishio, K; Seki, Y; Shahidi, M; Takeda, K; Yamamoto, N | 1 |
| Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Matsuura, K; Mitsuoka, S; Nagata, M; Oka, T; Suzumura, T; Umekawa, K; Yoshimura, N | 1 |
| Chung, DH; Heo, DS; Keam, B; Kim, DW; Kim, TM; Lee, JO; Lee, SH; Park, JH | 1 |
| Stinchcombe, TE; Weiss, JM | 1 |
| Bedi, A; Chang, X; Chatterjee, A; Goodman, SN; Harari, PM; Hidalgo, M; Izumchenko, E; Kim, MS; Ling, S; Monitto, CL; Sidransky, D; Solis, LM; Wistuba, II | 1 |
| Baradia, D; Misra, A; Patil, S; Vhora, I; Yewale, C | 1 |
| Cheng, PS; Lai, FJ | 1 |
| Goto, K; Ishii, G; Matsumoto, S; Nagai, K; Niho, S; Ochiai, A; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Yoshida, T | 1 |
| Fujii, T; Matsumura, S; Okamoto, T; Shinyama, M; Tanaka, H | 1 |
| Atkey, N; Bolton, LM; Cree, IA; Dyson, M; Glaysher, S; Johnson, P; Torrance, C | 1 |
| Chiu, HC; Chiu, HY | 1 |
| Bronte, G; Castiglia, M; Cicero, G; Fiorentino, E; Giovannetti, E; Passiglia, F; Pauwels, P; Rizzo, S; Rolfo, C; Russo, A; Van Meerbeeck, J; Vullo, FL | 1 |
| Shen, W; Turchi, JJ; Xu, J; Zeng, LF; Zhang, ZY | 1 |
| Köhler, J; Schuler, M | 1 |
| Chen, YM; Lee, YC; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J; Wu, WS | 1 |
| Day, RO; Kerridge, IH; Lewis, JR; Lipworth, WL | 1 |
| Ding, JF; Zhong, DF | 1 |
| Döme, B; Fehniger, TE; Jansson, B; Laurell, T; Marko-Varga, G; Rezeli, M; Végvári, Á; Welinder, C | 1 |
| Cass, CE; Damaraju, VL; Kuzma, M; Mowles, D; Ryan, AJ; Sawyer, MB; Scriver, T | 1 |
| Beau-Faller, M; Bièche, I; Blons, H; Bringuier, PP; Cadranel, J; Cayre, A; de Cremoux, P; de Fraipont, F; Denis, MG; Domerg, C; Escande, F; Gajda, D; Legrain, M; Lizard, S; Morin, F; Mosser, J; Nanni-Metellus, I; Olschwang, S; Piard, F; Pignon, JP; Pretet, JL; Richard, N; Rouquette, I; Saulnier, P; Solassol, J; Voegeli, AC; Zalcman, G | 1 |
| Chen, CH; Chen, JY; Chen, WS; Chen, YJ; Chien, PH; Hsia, TC; Huang, WC; Liu, SH; Shih, CY; Tu, CY; Wei, YL; Yeh, MH; Yu, MC; Yu, YL | 1 |
| Koyama, N; Uchida, Y | 1 |
| Azuma, K; Hoshino, T; Itoh, K; Kasama-Kawaguchi, Y; Kim, J; Matsueda, S; Muta, E; Nishio, K; Sasada, T; Sugawara, S; Yamada, T; Yamashita, T; Yamashita, Y; Zhang, GL | 1 |
| Song, Z; Zhang, Y | 1 |
| Lee, VH; Lee, VW; Schwander, B | 1 |
| Gu, QH; Hu, CP; Li, YY; Lu, RL; Wu, L; Yang, HP | 1 |
| Liu, Z; Shi, L; Tang, J; Tong, L | 1 |
| Fu, S; Jiang, L; Lin, YB; Long, H; Shao, JY; Su, XD; Wang, F; Wang, JF; Zhang, SL; Zhang, YG; Zhao, ZR | 1 |
| Choi, CM; Choi, YJ; Kim, HR; Kim, SY; Lee, JC; Park, GM; Rho, JK; So, GS | 1 |
| Arcila, ME; Chaft, JE; Cohen, DW; Costa, DB; Eck, MJ; Hanna, M; Huberman, MS; Ishioka, K; Kobayashi, SS; Lathan, CS; Lucena-Araujo, AR; Meyerson, M; Moran, T; Nakayama, S; Oxnard, GR; Park, E; Riely, GJ; Sequist, LV; Sng, NJ; Soo, RA; Yamaguchi, N; Yasuda, H; Yeo, WL; Yun, CH | 1 |
| Bobilev, D; Peleg, R; Priel, E | 1 |
| An, J; Gao, H; Li, J; Li, X; Liu, X; Liu, Y; Qin, H; Qu, L; Tang, C; Wang, W; Yang, S | 1 |
| Antoine, M; Cadranel, J; Duruisseaux, M; Lacave, R; Lavole, A; Leprieur, EG; Rabbe, N; Rozensztajn, N; Ruppert, AM; Vieira, T; Wislez, M | 1 |
| Fiegl, M; Hilbe, W; Manzl, C; Pircher, A; Pirker, R; Popper, H | 1 |
| Nakagawa, K; Okamoto, I; Takeda, M | 2 |
| Fukihara, J; Hasegawa, Y; Kataoka, K; Kimura, T; Kondoh, Y; Matsuda, T; Taniguchi, H; Watanabe, N; Yokoyama, T | 1 |
| Bogatyreva, L; Braun, JA; Faller, G; Fichter, CD; Geddert, H; Gudernatsch, V; Hauschke, D; Klimstra, D; Lassmann, S; Schöpflin, A; Tang, L; Timme, S; Werner, M | 1 |
| Song, T; Wu, SX; Yu, W | 1 |
| Dinglin, X; Fang, W; Hou, X; Hu, Z; Huang, P; Huang, Y; Liang, W; Ma, Y; Qin, T; Tian, Y; Wu, X; Xue, C; Yan, Y; Yang, Y; Zhang, J; Zhang, L; Zhao, H; Zhao, Y; Zhou, T | 1 |
| Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O | 1 |
| Bae, MK; Cho, BC; Kang, DR; Kim, EY; Kim, HR; Kim, JH; Kim, MH; Lee, CY; Lee, JS | 1 |
| Liu, D; Yang, Y; Zhao, S | 1 |
| Kato, M; Kobayashi, I; Murakami, A; Nurwidya, F; Shimada, N; Shukuya, T; Tajima, K; Takahashi, F; Takahashi, K | 1 |
| Chen, X; Fan, L; Fei, K; Gao, G; He, Y; Li, A; Li, J; Li, S; Li, W; Li, X; Ren, S; Schmid-Bindert, G; Shi, J; Zhao, C; Zhou, C | 1 |
| Ebina, M; Iida, S; Ise, K; Iwabuchi, E; Kondo, T; Maemondo, M; Miki, Y; Mori, K; Narumi, S; Nihira, K; Ono, K; Saito, M; Sasano, H; Sato, I; Yamada-Okabe, H | 1 |
| Horai, T; Horiike, A; Kudo, K; Murakami, H; Naito, T; Nishio, M; Ohyanagi, F; Ono, A; Tanaka, H; Yamamoto, N; Yanagitani, N | 1 |
| Qi, WX; Shen, Z; Sun, YJ; Yao, Y | 1 |
| Ahn, JS; Ahn, MJ; Lee, JY; Lim, SH; Park, K; Sun, JM | 1 |
| Fujiwara, K; Hosokawa, A; Ichiba, Y; Kajiume, S; Kiba, T; Kimoto, S; Nakano, K; Nakashima, T; Ogawa, Y; Okada, Y; Taniguchi, H | 1 |
| Berezo, JÁ; de la Cruz, V; Sanz Rubiales, A; Torres, MÁ | 1 |
| Hong, W; Lin, B; Mao, W; Zhang, B; Zhang, Y | 1 |
| Dziadziuszko, R; Peters, S; Zimmermann, S | 1 |
| Chung, JH; Jheon, S; Jin, Y; Kim, H; Kim, JE; Kim, K; Lee, CT; Sun, PL; Yoo, SB | 1 |
| Wu, YL; Yan, HH; Yang, JJ; Zhang, XC; Zhao, N | 1 |
| de Castro, G; Haaland, B; Lopes, G; Tan, PS | 1 |
| Chun, KS; Hong, YS; Jang, WJ; Jeong, CH | 1 |
| Yano, S | 1 |
| Kuang, K; Yang, K; Yang, X | 1 |
| Asada, H; Imoto, K; Ommori, R; Park, K | 1 |
| Nakanishi, Y | 1 |
| Costa, DB; Gandhi, L; Gerber, DE | 1 |
| Meng, X; Sun, X; Yu, J; Zhang, J | 1 |
| Bianco, C; Giaccone, G; Lee, LC; Luo, J; Mitsudomi, T; Mok, T; Moon, YW; Okamoto, I; Park, KS; Pham, T; Raffeld, M; Rosell, R; Salomon, DS; Subramaniam, D; Wang, Y; Xi, L; Yatabe, Y | 1 |
| Gillissen, A; Nieber, K; Oelkrug, C; Schubert, A; Simasi, J | 2 |
| Hu, G; Liu, D; Long, G; Sun, W; Wang, J | 1 |
| de Marinis, F; Del Signore, E; Di Maio, M; Gori, B; Passaro, A | 1 |
| Aieta, M; Gregorc, V; Lazzari, C; Lerose, R; Tartarone, A | 1 |
| Bolton, LM; Cree, IA; Glaysher, S; Johnson, P; Torrance, C | 1 |
| Deng, Q; He, J; Liu, X; Xu, X; Yang, H; Yang, X; Zhang, Y; Zhao, M | 1 |
| Hayashi, H; Nakagawa, K; Nishio, K; Togashi, Y | 1 |
| Jiao, SC; Peng, L; Song, ZG | 1 |
| Ahn, HK; Cho, EK; Hong, J; Kim, YS; Lee, HY; Lee, JH; Park, I; Park, J; Shin, DB; Sym, SJ; Woo, HS | 1 |
| Geng, Z; Han, X; Hu, L; Li, Z; Qin, X; Wang, Z; Xiao, X; Zeng, C | 1 |
| Luo, J; Shen, L; Zheng, D | 1 |
| Fukuoka, M; Hasegawa, Y; Ozaki, T; Sugiura, T; Suzumura, T; Tsukuda, H; Yonesaka, K | 1 |
| Chai, S; Ke, CQ; Lin, G; Tang, C; To, KK; Wang, YZ; Yao, S; Ye, Y; Yin, C | 1 |
| Cai, W; Cheng, K; Li, T; Shao, T; Zhao, B; Zheng, Y | 1 |
| Bai, C; Chen, S; Ning, X; Sun, Z; Wang, Y; Yang, XD; Ying, H | 1 |
| Fang, W; Hong, S; Hu, Z; Kang, S; Liang, W; Qin, T; Sheng, J; Wu, X; Yan, Y; Zhang, L; Zhang, Y | 1 |
| Fischer, JR; Grohé, C; Gütz, S; Kimmich, M; Laack, E; Märten, A; Schneider, CP; Schuler, M; Thomas, M | 1 |
| Costa, DB; Jorge, SE; Kobayashi, SS | 1 |
| Fu, S; Guo, XM; Qi, WX; Zhang, Q | 1 |
| Hohenforst-Schmidt, W; Huang, H; Kakolyris, S; Kioumis, I; Lampaki, S; Li, Q; Organtzis, J; Papaiwannou, A; Petridis, D; Pitsiou, G; Porpodis, K; Syrigos, K; Tsiouda, T; Turner, JF; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Ali, SA; Burotto, M; O'Sullivan Coyne, G | 1 |
| Chen, XQ; Lin, GN; Liu, DY; Liu, PP; Peng, JW; Xiao, JJ | 1 |
| Gao, HM; Gao, Z; Jia, YF; Tan, W; Tian, YL; Wang, YS; Zhang, MX; Zhang, N; Zhang, RX; Zhao, JQ | 1 |
| Jenks, S | 1 |
| Cavenee, WK; Chen, CC; Furnari, FB; Gomez, GG; Gonias, SL; Hu, J; Mischel, PS; Pizzo, D; Taylor, T; Thorne, AH; VandenBerg, SR; Villa, GR; Wykosky, J | 1 |
| Guo, R; Huang, X; Shu, Y; Wu, H; Xiang, C; Yin, Y; Yu, Q; Yu, S; Zhang, B | 1 |
| Takeuchi, S; Yano, S | 1 |
| Cheng, W; Hu, Y; Peng, P; Qiu, N; Sheng, R; Yuan, Y | 1 |
| Frank, M; Golpon, H; Lange, A; Prenzler, A; von der Schulenburg, JM; Welte, T | 1 |
| Choi, CM; Choi, YJ; Chun, YJ; Kim, CH; Kim, SY; Kim, WS; Lee, JC; Rho, JK; So, KS; Song, JS | 1 |
| Sheng, Z; Zhang, Y | 1 |
| Ahn, MJ; Campbell, AK; Cho, BC; Gernhardt, D; Giri, N; Heo, DS; Kim, DW; Lee, SY; Letrent, SP; O'Connell, J; Park, K; Taylor, I; Zhang, H | 1 |
| Nakamoto, Y; Nakatsura, T; Ofuji, K; Saito, K; Shimomura, M; Tada, Y; Yoshikawa, T; Yoshimura, M | 1 |
| Jonstrup, SP; Lindahl, KH; Loeschke, S; Olsen, KE; Sørensen, FB | 1 |
| Anderson, KS; Apetri, M; Kim, Y; Luo, B; Settleman, JE | 1 |
| Anderson, RA; Sun, Y; Tan, X; Thapa, N | 1 |
| Liao, BC; Lin, CC; Yang, JC | 1 |
| Reguart, N; Remon, J | 1 |
| Chang, CH; Ho, CC; Lee, CH; Wang, JY; Yu, CJ | 1 |
| Chang, FK; Chih-Hsin Yang, J; Chiu, CH; Chuang, CY; Ho, CL; Hsia, TC; Hsiao, SH; Huang, MS; Lai, CL; Lai, RS; Lee, KY; Lin, CB; Lin, YC; Perng, RP; Shih, JY; Su, WC; Tsai, CM; Wang, CC; Wu, MF; Yang, CT; Yu-Wung Yeh, D | 1 |
| Bhattacharya, R; Bovonratwet, P; Liu, L; Mathew, MP; Saeui, CT; Tan, E; Yarema, KJ | 1 |
| Berghmans, T; Grigoriu, B; Meert, AP | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Minarik, M; Pesek, M; Topolcan, O | 1 |
| Bernardo, LA; Borger, DR; Costa, C; Costa, DB; Engelman, JA; Fulton, LE; Garcia, AR; Getz, G; Howe, E; Iafrate, AJ; Jänne, PA; Katayama, R; Lockerman, EL; Mermel, CH; Mino-Kenudson, M; Miyoshi, N; Mohamoud, F; Moran, T; Mulvey, HE; Niederst, MJ; Poirier, JT; Ramaswamy, S; Ross, KN; Rudin, CM; Sequist, LV; Shioda, T; VanderLaan, PA | 1 |
| Baek, IJ; Bivona, TG; Choi, CM; Choi, SH; Choi, YJ; Kim, SY; Kim, WS; Lee, JC; Rho, JK; So, KS | 1 |
| Burotto, M; Fojo, T; Manasanch, EE; Wilkerson, J | 1 |
| Abdel-Rahman, O; Elhalawani, H | 1 |
| Canoll, P; Chen, S; Guo, B; Horner, JW; Klingler, S; Paik, JH; Vaseva, AV; Wang, YA; Yan, H; Yao, J; Ying, H; Zhang, L; Zheng, H | 1 |
| Liang, J; Su, N; Xie, Y | 1 |
| Chinda, J; Fujino, T; Hasebe, N; Kabara, M; Kuroshima, T; Maruyama, K; Nakagawa, N; Ogawa, Y; Ohsaki, Y; Yamamoto, Y | 1 |
| Bidart, JM; Broutin, S; Gil, S; Goffinet, F; Jovelet, C; Mir, O; Paci, A; Seck, A; Simasotchi, C | 1 |
| Kempf, E; Le Chevalier, T; Planchard, D; Soria, JC | 1 |
| Huang, Y; Lee, VH; Ma, L; Wang, DD; Wong, MP; Yan, H | 1 |
| Bonetti, A; Giuliani, J; Martelli, S; Remo, A | 1 |
| Chariot, A; Shostak, K | 1 |
| Chang, YH; Hong, SE; Hong, SI; Hong, YJ; Jin, HO; Kim, B; Kim, CS; Kim, JH; Kim, JY; Lee, JK; Park, IC; Park, JA | 1 |
| Lee, VH; Ma, L; Wang, DD; Wong, MP; Yan, H | 1 |
| Ahn, JS; Ahn, MJ; Jung, HA; Kim, H; Kim, M; Kim, S; Ku, BM; Lee, JY; Lee, MY; Lim, SH; Park, K; Sun, JM | 1 |
| Chasapi, V; Soura, E; Stratigos, AJ | 1 |
| Ai, YQ; He, WJ; Li, RQ; Li, WH; Li, YF; Wang, Y; Xia, YX; Zhang, J; Zhao, PZ | 1 |
| Chicchinelli, N; De Luca, A; Fenizia, F; Forgione, L; Franco, R; Iannaccone, A; Lambiase, M; Morabito, A; Normanno, N; Pasquale, R; Piccirillo, MC; Rocco, G; Rossi, A; Sacco, A | 1 |
| Huang, Z; Liu, P; Qian, J; Shu, Y; Wu, Y; Zhou, X; Zhu, W | 1 |
| Chen, L; Chen, X; Luo, S; Xie, X | 1 |
| Carpentier, O; Jégu, J; Prim, N; Purohit, A; Quoix, E; Selvaggi, L; Velten, M | 1 |
| Chen, HL; Hsiao, FY; Lu, HM; Shen, LJ; Wei, CP | 1 |
| Hata, A; Hattori, Y; Imamura, F; Kaji, R; Kaneda, T; Katakami, N; Mori, M; Morita, S; Negoro, S; Nishino, K; Otsuka, T; Tachihara, M; Uchida, J; Urata, Y; Yano, Y; Yokota, S | 1 |
| Bagust, A; Beale, S; Boland, A; Dickson, R; Dundar, Y; Dwan, K; Greenhalgh, J; Hockenhull, J; Marshall, E; Mullard, A; Proudlove, C; Richardson, M | 1 |
| Bi, Z; Jiang, Y; Li, D; Liu, Y | 1 |
| Chen, Q; Ding, L; Hong, X; Liang, Y; Quan, Q; Wu, H; Zhou, N | 1 |
| Cheong, JG; Choi, J; Jung, JW; Kang, M; Kim, HJ; Kim, TY; Lee, GH; Lee, HY; Lee, JW; Nam, SH; Ryu, J | 1 |
| Azzoli, CG | 1 |
| Cai, L; Hu, J; Liu, C; Liu, W; Meng, QW; Ning, JF; Zhao, YB | 1 |
| Cruz, FM; Del Giglio, A; Normando, SR | 1 |
| Li, E; Li, J; Qiao, H; Ren, K; Shi, H; Zhao, D | 1 |
| Boone, E; Breyne, J; De Laere, E; Dedeurwaerdere, F; Demedts, I; Oyaert, M; Vandorpe, J | 1 |
| Ashinuma, H; Sekine, I | 1 |
| Imai, S; Koyama, S; Matsubara, K; Nakagawa, S; Nakagawa, T; Omura, T; Yano, I; Yonezawa, A | 1 |
| Bora-Singhal, N; Chellappan, S; Nguyen, J; Perumal, D | 1 |
| Adamo, V; Ferraro, G; Franchina, T; Giordano, A; Picone, A; Ricciardi, GR; Russo, A; Toscano, G; Zanghì, M | 1 |
| Goto, K; Kirita, K; Matsumoto, S; Niho, S; Nomura, S; Ohe, Y; Ohmatsu, H; Sugiyama, E; Tsuboi, M; Umemura, S; Yoh, K | 1 |
| Cosmai, L; Gallieni, M; Porta, C | 1 |
| Cao, M; Chen, H; Chu, Q; Han, R; He, Y; Sun, J; Wang, D; Wang, Y; Yao, W | 1 |
| Fujita, S; Hata, A; Kaji, R; Katakami, N; Masago, K; Okuda, C; Otsuka, K; Takeshita, J | 1 |
| Ettinger, DS; Forde, PM | 1 |
| Gilligan, D; Pacey, S; Tan, CS | 1 |
| Ding, X; Li, Y; Mao, W; Meng, X; Tang, H; Wang, X; Xie, S; Yang, H | 1 |
| Cappuzzo, F; D'Incecco, A; Minuti, G | 1 |
| Barber, TA; Engelman, JA; Fleisher, M; Fox, DB; Giri, U; Haber, DA; Heymach, JV; Jänne, PA; Johnson, BE; Kapur, R; Koch, WH; Maher, R; Maheswaran, S; Muzikansky, A; Riely, GJ; Sequist, LV; Stott, SL; Sullivan, JP; Sundaresan, TK; Toner, M; Tran, HT; Walsh, JR; Webb, A; Wei, W; Yu, HA | 1 |
| Cameron, MG; Kersten, C; Laird, B; Mjåland, S | 1 |
| Alharbi, KK; Chakravarthy, S; Goud, I; Khan, IA; Lakshmi M, AM; Matam, K; Prasad, SV; Ravi, V; Shaik, NA; Sridhar, K; Syed, R; Tabassum, SN; Vijayanand, PR | 1 |
| Dickson, JM; Flanagan, JU; McKeage, MJ; Patterson, AV; Silva, S; Smaill, JB; Squire, CJ; Yosaatmadja, Y | 1 |
| Hayashi, H; Hirose, C; Iihara, H; Itoh, Y; Kita, Y; Kitaichi, K; Minatoguchi, S; Ohno, Y; Sugiyama, T; Todoroki, K; Yamada, M; Yanase, K | 1 |
| Hsiue, TR; Hwang, JS; Lai, WW; Lin, CK; Su, WC; Wang, JD; Yang, SC | 1 |
| Cho, KM; Heo, DS; Keam, B; Kim, DW; Kim, TM; Lee, SH | 1 |
| Abdel-Rahman, O; Ahmed, H; ElHalawani, H | 1 |
| Cherpelis, B; Rudnick, EW; Thareja, S | 1 |
| Protsenko, SA; Rudakova, AV | 1 |
| Kim, H; Kim, HS; Kwon, JW; Shin, S; Sohn, HS | 1 |
| Cai, XH; Feng, CJ; Huang, CY; Liu, XK; Lu, Y; Wang, L; Wang, Y; Wang, YS; Xu, Y; Yao, WX; Yu, P; Zhou, J; Zhu, WJ | 1 |
| Bertrán-Alamillo, J; Bosch-Barrera, J; Bria, E; Carcereny, E; Chaib, I; Codony-Servat, C; Codony-Servat, J; Crisetti, E; de Marinis, F; Drozdowskyj, A; Felip, E; Felipe Cardona, A; García-Campelo, R; Gervais, R; Giménez-Capitán, A; González-Cao, M; Karachaliou, N; López-Vivanco, G; Luis Ramírez, J; Majem, M; Massuti, B; Miguel Sánchez, J; Molina-Vila, MA; Morales-Espinosa, D; Morán, T; Pilotto, S; Rosell, R; Sánchez Hernández, JJ; Santarpia, M; Sperduti, I; Teixidó, C; Vergnenegre, A; Verlicchi, A; Viteri, S | 1 |
| Barone, C; Basso, M; Cassano, A; Cerchiaro, E; D'Argento, E; Dadduzio, V; Martini, M; Rossi, S; Strippoli, A | 1 |
| Bennouna, J; Chand, VK; Chen, YM; Chouaid, C; De Marinis, F; Feng, JF; Grossi, F; Kim, DW; Kim, JH; Liu, X; Lu, S; Park, K; Planchard, D; Schuler, M; Strausz, J; Vinnyk, Y; Wang, B; Wiewrodt, R; Yang, JC; Zhou, C | 1 |
| Chen, KL; Cho, YT; Chu, CY; Lin, CC; Sheen, YS; Tsai, HE; Yang, CW | 1 |
| Ahn, JS; Ahn, MJ; Bae, YH; Jung, KS; Kim, HS; Koh, J; Ku, BM; Lee, JY; Lee, SH; Lim, SH; Park, K; Song, HN; Sun, JM; Yoo, KH | 1 |
| Iwakami, S; Katsura, Y; Kido, K; Ko, R; Namba, Y; Sasaki, S; Shukuya, T; Takahashi, K; Tominaga, S; Yoshioka, Y | 1 |
| Ashida, A; Koizumi, T; Ogawa, E; Okuyama, R; Uhara, H | 1 |
| Hasegawa, T; Hirai, S; Kojima, T; Niki, T; Nishikiori, H; Sakuma, Y; Takahashi, H; Watanabe, A; Yamada, G; Yamaguchi, M | 1 |
| Dahlberg, SE; Digumarthy, SR; Fulton, LE; Hatabu, H; Johnson, BE; Nishino, M; Sequist, LV | 1 |
| Hagen, T; Hong, SY; Luo, Y; Yu, FX | 1 |
| Ni, J; Zhang, L | 1 |
| Chou, SH; Han, DX; Hu, P; Ruan, RS; Tzeng, CM; Zheng, LM | 1 |
| Bogdanowicz, BS; Hartranft, ME; Hoch, MA | 1 |
| Goto, K; Matsumoto, S; Niho, S; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Zenke, Y | 1 |
| Broutin, S; Gil, S; Jovelet, C; Mir, O; Paci, A | 1 |
| Ahn, JS; Ahn, MJ; Lee, HY; Lee, JH; Lee, KS; Park, K; Sun, JM | 1 |
| Du, H; Guo, L; He, L; Huang, H; Jiang, J; Li, M; Li, Y; Luan, M; Ma, C; Qin, S; Ruan, Y; Shen, L; Zhang, X | 1 |
| Adamo, V; Alù, M; Bazan, V; Blasi, L; Bronte, G; Celesia, C; De Tursi, M; Franchina, T; Gambale, E; Laudani, A; Natoli, C; Passiglia, F; Picone, A; Rizzo, S; Russo, A; Savio, G; Sortino, G | 1 |
| Huo, LM; Sun, HT; Tian, JH; Xu, JG; Yang, G; Yang, KH; Zhang, P; Zheng, MH | 1 |
| Heo, DS; Keam, B; Kim, DW; Kim, TM; Kim, YW; Lee, SH; Park, S; Suh, B | 1 |
| Daga, H; Fujimoto, D; Goto, I; Ikeda, N; Imamura, F; Iwamoto, Y; Kaji, R; Kanehara, M; Katakami, N; Morita, S; Murakami, H; Nakagawa, K; Nakanishi, Y; Negoro, S; Nogami, N; Oguri, T; Saka, H; Satouchi, M; Seto, T; Sugawara, S; Urata, Y; Yoshioka, H | 1 |
| Carbonnaux, M; Couraud, S; Meert, AP; Peters, M; Scherpereel, A; Souquet, PJ | 1 |
| Sakiyama, S; Takizawa, H; Tangoku, A; Toba, H | 1 |
| Abreu, S; Bernardes, N; Carvalho, FA; Fernandes, F; Fialho, AM; Santos, NC | 1 |
| Amary, F; Barnard, M; Brüderlein, S; Cottone, L; Drewry, DH; Flanagan, AM; Guppy, N; Jorgensen, M; Leite, AP; Leithner, A; Möller, P; Pillay, N; Scheipl, S; Smith, JA; Strauss, SJ; Tirabosco, R; Turlais, F; Ye, H; Zuercher, WJ | 1 |
| Bates, V; Boland, A; Dundar, Y; Dwan, K; Green, JA; Greenhalgh, J; Jain, P; Vecchio, F | 1 |
| David, JM; Dominguez, C; Fernando, RI; Hamilton, DH; McCampbell, KK; Palena, C | 1 |
| Doi, T; Enatsu, S; Kojima, T; Nakamura, T; Ohmatsu, H; Takahashi, H; Turner, K; Uenaka, K; Wacheck, V; Yoh, K; Zenke, Y | 1 |
| Álvarez-Fernández, C; Esteban-González, E | 1 |
| He, X; Hong, S; Huang, Y; Ma, Y; Sheng, J; Yang, Y; Zhang, J; Zhang, L; Zhang, Y; Zhang, Z; Zhao, H; Zhou, T | 1 |
| Hayashi, H; Kudo, K; Nakagawa, K; Takeda, M; Ueda, H | 1 |
| Kowalski, DM; Krzakowski, M; Piórek, A; Szmit, S; Zaborowska-Szmit, M | 1 |
| Chang, TY; Chen, PS; Hsu, HP; Huang, MT; Kuo, KT; Lai, HH; Li, JN; Lyu, YJ; Su, CM; Su, JL | 1 |
| Chen, HJ; Chen, ZH; Su, J; Tu, HY; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Zhang, XC; Zhong, WZ; Zhou, Q | 1 |
| Eigenmann, MJ; Frances, N; Hoffmann, G; Lavé, T; Walz, AC | 1 |
| Beijnen, JH; Rood, JJM; Rosing, H; Schellens, JHM; Sparidans, RW | 1 |
| Nakamura, H; Nishimura, T | 1 |
| Kawahara, K; Maeda, T; Watanabe, S; Yamada, D | 1 |
| Du, Y; Liu, H; Ma, T; Pan, Y; Shen, Y; Zhu, Y | 1 |
| Chen, Z; Jiang, B; Su, J; Wu, YL; Xu, C; Yan, H; Yang, J; Zhang, Q; Zhang, X; Zhou, Q | 1 |
| Hosomi, Y; Kashima, J; Miwa, M; Okuma, Y | 2 |
| Han, B; Jin, B; Lou, Y; Wang, H; Wu, D; Xu, J; Yang, H; Zhang, X; Zhang, Y; Zhong, H | 1 |
| Fujimoto, J; Goshima, N; Higa, A; Hiyama, G; Hoshi, H; Inageda, K; Ishikawa, K; Kawamura, Y; Semba, K; Takagi, M; Takahashi, N; Togashi, T; Wakamatsu, A; Watanabe, S | 1 |
| Asmat, A; Kumarakulasinghe, NB; Loy, EY; Pang, B; Soo, RA; Soon, YY; Syn, N; Zheng, H | 1 |
| Pakkala, S; Ramalingam, SS | 1 |
| Kannan, N; Katiyar, S; Ruan, Z | 1 |
| An, N; Cai, J; Li, Q; Li, Z; Niu, H; Zhang, Y; Zhao, Q | 1 |
| Back, D; Clotet, B; Miranda, C; Moltó, J; Owen, A; Rajoli, R; Siccardi, M; Valle, M | 1 |
| Chen, Z; Deng, W; Ke, E; Niu, F; Su, J; Wu, Y; Xu, C; Yan, H; Yang, J; Zhang, Q; Zhang, X; Zhao, N; Zhou, Q | 1 |
| Song, Z; Wang, W; Zhang, Y | 1 |
| Bray, V; Ding, PN; Gebski, V; Gralla, RJ; Lee, CK; Links, M; Lord, SJ; Yang, JC | 1 |
| Han, L; He, J; Huang, Z; Li, W; Ma, P; Nie, F; Zhang, M | 1 |
| Bai, JP; Chen, X; Li, Y; Liu, LR; Liu, YH; Qu, X; Qu, YC; Zhang, FL; Zhang, HB; Zheng, GJ; Zhu, YJ; Zhu, YZ | 1 |
| Chen, L; Gonzalez, FJ; Gu, J; Hu, CL; Hu, L; Li, L; Li, S; Lin, XM; Liu, JF; Tang, J; Wang, HY; Wang, RY; Wu, MC; Yan, XZ; Zhang, BH; Zhou, WP; Zhu, YJ | 1 |
| Jänne, PA; Saxon, JA; Sholl, LM | 1 |
| Bai, XY; Chen, HJ; Jiang, BY; Su, J; Tu, HY; Wang, BC; Wang, Z; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Zhang, XC; Zhong, WZ; Zhou, Q | 1 |
| Hagiwara, K; Iwai, Y; Kawamura, R; Koyama, N; Koyama, S; Miwa, C; Nagai, Y; Watanabe, Y | 1 |
| Fukui, T; Ichinoe, M; Igawa, S; Katagiri, M; Kubota, M; Masuda, N; Murakumo, Y; Nakahara, Y; Nakashima, H; Otani, S; Ryuge, S; Sasaki, J; Sato, Y; Satoh, Y | 1 |
| Assi, T; El Rassy, E; Ghosn, M; Kattan, J; Moussa, T | 1 |
| Di Maio, M; La Salvia, A; Rossi, A | 1 |
| Urata, Y | 1 |
| Chang, CH; Lee, CH; Wang, JY | 1 |
| Pi, C; Xu, CR; Zhang, YC; Zhou, Q | 1 |
| Fraser, A | 1 |
| Fujii, S; Kashiwabara, K; Semba, H; Tsumura, S | 1 |
| Feng, Q; Fu, X; Hackshaw, A; Mao, C; Tang, J; Yang, Z; Zhang, Y | 1 |
| Biswas, L; Keechilat, P; Melge, AR; Mohan, CG; Panicker, PS | 1 |
| Kaneda, H; Koyama, A; Matsuoka, H; Nakagawa, K; Nishio, K; Sakai, K | 1 |
| Li, J; Ma, J; Wang, Y; Wang, Z; Wu, X | 1 |
| Davies, L; Fukuoka, M; Gebski, V; Gralla, RJ; Inoue, A; Lee, CK; Lord, S; Marschner, I; Mitsudomi, T; Mok, T; Nakagawa, K; Rosell, R; Thongprasert, S; Tu, YK; Wu, YL; Yang, JC; Zhou, C | 1 |
| He, H; He, X; Lan, BH; Li, MX; Li, RQ; Liu, GD; Ruan, ZH; Wang, G; Wu, Y; Xiao, HL; Yang, ZZ; Zhang, ZM; Zhu, B; Zhu, YX | 1 |
| Belli, V; Ciaramella, V; Ciardiello, F; Della Corte, CM; Malapelle, U; Martinelli, E; Morgillo, F; Pepe, F; Troiani, T; Troncone, G; Vigliar, E | 1 |
| Cho, YJ; Chung, JH; Eo, EY; Jung, MH; Kim, CH; Kim, S; Lee, CT; Lee, JH; Lee, SH; Lee, YJ; Park, JS; Park, MY; Yoon, HI | 1 |
| Amin, Z; Jayalie, VF; Rajabto, W | 1 |
| Boeck, S; Heinemann, V; Hichert, V; Kächele, V; Paul, T; Rüdiger, S; Scholl, C; Schumann, C; Seufferlein, T; Steffens, M; Stingl, J | 1 |
| Chen, G; Huang, X; Huang, Y; Kang, S; Miao, S; Wu, M; Zhang, L; Zhang, Y; Zhang, Z; Zhao, H | 1 |
| Cui, S; Jiang, L | 1 |
| Liu, S; Liu, X; Pan, X; Qin, A; Ren, H; Yang, B; Yu, G; Zhang, K | 1 |
| Chen, KL; Cheng, YP; Cho, YT; Chu, CY; Liau, JY; Sheen, YS; Yang, CW | 1 |
| Aderhold, C; Birk, R; Hock, C; Hörmann, K; Kramer, B; Kuhlin, B; Lammert, A; Schultz, JD | 1 |
| Höllhumer, R; Jacob, K; Moloney, G | 1 |
| Hida, T; Horio, Y; Inaba, Y; Kuroda, H; Oya, Y; Sakao, Y; Shimizu, J; Yatabe, Y; Yoshida, T | 1 |
| Dong, Z; Gao, H; Hu, H; Li, X; Liu, B; Liu, X; Liu, Y; Shi, W; Sun, Y; Tang, C; Xu, H; Zhu, G | 1 |
| Chang, CH; Chang, LY; Ko, JC; Lee, CH; Lee, MC; Wang, JY; Yu, CJ | 1 |
| Chen, HJ; Chen, WC; Hsia, TC; Li, CH; Liao, WC; Shen, YC; Tseng, GC; Tu, CY | 1 |
| Corrao, G; Facchinetti, F; Ganzinelli, M; Garassino, MC; Lo Russo, G; Minari, R; Proto, C; Tiseo, M | 1 |
| Beretta, GD; Caprioli, A; Ceresoli, GL; Codignola, C; Fraccon, AP; Meriggi, F; Ogliosi, C; Prochilo, T; Scartozzi, M; Zaniboni, A | 1 |
| Chen, X; Chen, Z; Kong, R; Li, Y; Lu, D; Niu, K; Sun, J; Wang, Y; Xia, L | 1 |
| Groen, HJM; Heideman, DAM; Hiltermann, TJN; Kok, K; Kuiper, JL; Saber, A; Schuuring, E; Smit, EF; Terpstra, MM; Thunnissen, E; Timens, W; van den Berg, A; van der Wekken, AJ; Wei, J | 1 |
| Hu, X; Tam, KY; Yang, Z; Zhang, S; Zhang, W | 1 |
| Hamaguchi, R; Hasegawa, M; Okamoto, T; Sato, M; Wada, H | 1 |
| Chang, S; Choi, BW; Han, K; Hong, YJ; Hur, J; Kim, YJ; Lee, HJ | 1 |
| Camidge, DR; Chand, VK; Fan, J; Freiwald, M; Gettinger, S; Groen, HJM; Horn, L; Janjigian, YY; Miller, VA; Pao, W; Smit, EF; Wang, B | 1 |
| Hayashi, T; Kohsaka, S; Mano, H; Nagano, M; Shimada, N; Suehara, Y; Suzuki, K; Takahashi, F; Takahashi, K; Takamochi, K; Ueno, T | 1 |
| Cheng, Y; Chewaskulyong, B; Cho, BC; Cho, EK; Dechaphunkul, A; Gray, JE; Hodge, R; Imamura, F; Kurata, T; Lee, KH; Lee, SM; Marotti, M; Nogami, N; Ohe, Y; Okamoto, I; Planchard, D; Ramalingam, SS; Reungwetwattana, T; Rukazenkov, Y; Soria, JC; Su, WC; Vansteenkiste, J; Voon, PJ; Zhou, C | 1 |
| Bai, XY; Chen, HJ; Chen, ZH; Dong, ZY; Jiang, BY; Ke, EE; Luo, DL; Mei, P; Su, J; Sun, YL; Tu, HY; Wang, BC; Wang, Z; Wu, SP; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Zhang, XC; Zheng, MY; Zhong, WZ; Zhou, Q | 1 |
| Wu, X | 1 |
| Kastelijn, EA; Peters, BJM; Roepman, P; Schramel, FMNH; Sluga, R; VAN DEN Borne, BEEM | 1 |
| D'Alessandro-Gabazza, CN; Fujimoto, H; Fujiwara, A; Gabazza, EC; Hataji, O; Ito, K; Kobayashi, T; Nakahara, H; Nishihama, K; Taguchi, O; Yasuma, T; Yoshida, M | 1 |
| Oshima, Y; Tanimoto, T; Tojo, A; Yuji, K | 1 |
| Girard, N | 1 |
| Kang, Y; Ma, W; Yang, L; Yang, T; Zhu, M | 1 |
| Chiba, M; Gemma, A; Ishikawa, A; Kobayashi, K; Kubota, K; Kunugi, S; Noro, R; Seike, M; Zou, F | 1 |
| Cappuzzo, F; Cseh, A; Forman, ND; Hilbe, W; Hochmair, M; Jazieh, AR; Lam, KC; Linden, S; Lorence, RM; Schuler, M; Soo, R; Stehle, G; Tsai, CM | 1 |
| Amador, M; Andrade Santiago, JM; Aparisi, F; Arriola, E; Artal, A; Barneto, I; Diz, P; García Gómez, R; Gutierrez, V; Isla, D; Majem, M; Martínez Aguillo, M; Paredes, A; Peralta Muñoz, S; Ponce, S; Provencio, M; Sánchez-Torres, JM; Valdivia, J; Vicente Baz, D | 1 |
| Groen, HJM; Guo, Y; Li, J; Ma, J; Wang, P; Wang, Z; Yang, K; Zhang, C; Zhao, J | 1 |
| Lee, VHF; Yan, H; Zou, B | 1 |
| Borics, A; Dömötör, O; Enyedy, ÉA; Keppler, BK; Kowol, CR; Pelivan, K | 1 |
| Li, Y; Liu, Y; Ou, Q; Shao, YW; Wang, X; Wu, X; Ying, J | 1 |
| Boespflug, A; Kaya, A; Kaya, G; Saurat, JH; Saxer-Sekulic, N; Sorg, O; Thomas, L | 1 |
| Arimoto, T; Chihara, Y; Date, K; Imabayashi, T; Iwasaki, Y; Kaneko, Y; Morimoto, Y; Seko, Y; Takayama, K; Takemura, Y; Tanimura, K; Ueda, M | 1 |
| Ahn, JS; Ahn, MJ; Cho, BC; Choi, MK; Kim, JH; Kim, SW; Kim, YC; Lee, JS; Oh, IJ; Park, K | 1 |
| Peng, J; Wei, Y; Xu, J; Yu, D; Zhang, W | 2 |
| Chen, KY; Chen, TT; Chuang, HC; Feng, PH; Han, CL; Huang, YC; Kuo, CH; Lee, CN; Lee, KY; Lee, WH; Lin, CF; Luo, CS; Wu, SM; Yeh, CT | 1 |
| Fukui, T; Harada, S; Igawa, S; Kasajima, M; Katagiri, M; Kubota, M; Kusuhara, S; Mitsufuji, H; Naoki, K; Nishinarita, N; Okuma, Y; Ozawa, T; Sasaki, J; Sugita, K; Yokoba, M | 1 |
| Chang, CL; Chang, JH; Chang, YC; Chow, JM; Hsu, HL; Lin, WC; Wu, ATH; Wu, SY; Yen, YC; Yuan, KS | 1 |
| Li, L; Liu, W; Meng, L; Wang, Y; Wang, Z; Yan, H; Zhang, H | 1 |
| Ghaedi, K; Mojtabavi Naeini, M; Tavassoli, M | 1 |
| Aguiar, PN; de Lima Lopes, G; Del Giglio, A; Haaland, B; Park, W; San Tan, P | 1 |
| Ahn, JS; Ahn, MJ; Kim, Y; Lee, SH; Park, K; Sun, JM | 1 |
| Fujita, S; Fukushima, S; Imamichi, F; Irie, K; Katakami, N; Masago, K; Okada, Y; Yatabe, Y | 1 |
| Aigner, P; Barbacid, M; Brcic, L; Casanova, E; Dezso, K; Dome, B; Eferl, R; Grabner, B; Győrffy, B; Hidalgo, M; Hruschka, N; Laszlo, V; Lopez-Casas, PP; Mohrherr, J; Moldvay, J; Moll, HP; Moriggl, R; Musteanu, M; Penninger, J; Popper, H; Pranz, K; Schramek, D; Sibilia, M; Stiedl, P; Stoiber, D | 1 |
| Bin, L; Guo-Qiang, LI; Liang, S; Yu-Hua, Z | 1 |
| Hase, T; Hasegawa, Y; Matsui, A; Morise, M; Omote, N; Sato, M; Shimoyama, Y; Suzuki, K; Tanaka, I | 1 |
| Ding, K; Hu, X; Li, QY; Li, YL; Lin, NM; Tan, BQ; Wang, F; Zhang, B; Zhang, C | 1 |
| Hanada, S; Kishi, K; Miyamoto, A; Mochizuki, S; Moriguchi, S; Morokawa, N; Murase, K; Ogawa, K; Takahashi, Y; Takaya, H; Uruga, H | 1 |
| Kenzaka, T; Miyoshi, K; Nakaji, H | 1 |
| Gu, P; Hu, F; Hu, P; Li, C; Nie, W; Shen, Y; Wang, H; Wang, S; Xu, J; Zhang, B; Zhang, X; Zhang, Y | 1 |
| Li, XF; Liu, GF; Miao, YY; Yu, SN; Zhang, SH | 1 |
| Aguiar-Bujanda, D; Blanco-Sanchez, MJ; Bohn-Sarmiento, U; Dueñas-Comino, A; Galvan-Ruiz, S; Hernandez-Sosa, M; Lorenzo-Barreto, JE; Mori-De Santiago, M; Ros-Sanjuan, L; Saura-Grau, S; Vargas-Prado, AM | 1 |
| Cao, L; Huang, J; Jiang, Y; Li, N; Xu, B; Zhang, J; Zhao, M | 1 |
| Liu, H; Wang, J; Wang, X; Wei, N; Zhang, F; Zhang, X | 1 |
| Chen, JS; Chen, KY; Ho, CC; Hsu, CL; Lee, JH; Liao, WY; Lin, YT; Lin, ZZ; Shih, JY; Yang, CY; Yang, JC; Yu, CJ | 1 |
| Jiang, Y; Li, Z; Wan, S; Wu, X; Yan, R; Zhang, J | 1 |
| Agazzi, GM; Berruti, A; Bettoni, V; Borghesi, A; Caprioli, A; Farina, D; Ganeshan, B; Maroldi, R; Ravanelli, M; Roca, E; Tononcelli, E | 1 |
| Fiore, J; Gadgeel, SM; Papadimitrakopoulou, VA; Patnaik, A; Raftopoulos, H; Saraf, S; Sequist, LV; Su, WC; Wu, CL; Yang, JC | 1 |
| Chen, JY; Ting, CH | 1 |
| Choi, EY; Cullen, KJ; Dan, H; Lapidus, RG; Li, Z; Liao, J; Liu, X; Yang, Z | 1 |
| Cai, H; Chen, S; Li, N; Liu, MB; Weng, L; Yang, J; Zhang, L; Zheng, B | 1 |
| Chu, YB; Gu, X; Kuo, D; Su, B; Wu, B; Zhang, Q; Zhang, YJ; Zhao, YY | 1 |
| Agarwal, V; Nayar, RC; Rao, V; Subash, A | 1 |
| Fujii, K; Ichiyasu, H; Ikeda, T; Imamura, K; Kashiwabara, K; Komatu, T; Maruyama, H; Saeki, S; Sakagami, T; Saruwatari, K; Shingu, N; Tomita, Y; Ushijima, S | 1 |
| An, X; Diao, XY; Feng, YF; Shao, Q; Wang, F; Wang, HY; Zhang, X | 1 |
| Baretta, Z; Basso, M; Bernardi, D; Bonanno, L; Bonetti, A; Bortolami, A; Calvetti, L; Conte, P; Corte, DD; Favaretto, A; Frega, S; Gatti, C; Giovanis, P; Gori, S; Guarneri, V; Menis, J; Oliani, C; Oniga, F; Palazzolo, G; Pasello, G; Redelotti, R; Rosetti, F; Santo, A; Toso, S; Vicario, G; Zustovich, F | 1 |
| Endo, M; Gon, Y; Harada, H; Kawamura, T; Kenmotsu, H; Kobayashi, H; Mamesaya, N; Mitsuya, K; Miyawaki, E; Mori, K; Murakami, H; Naito, T; Nakashima, K; Nakasu, Y; Omori, S; Ono, A; Takahashi, T; Wakuda, K | 1 |
| Ding, JY; Gao, J; Jiang, JH; Jin, C; Li, HR | 1 |
| Hsu, JC; Wei, CF; Yang, SC | 1 |
| Ahn, JS; Ahn, MJ; Choi, YL; Jung, HA; Kim, Y; Lee, K; Lee, SH; Park, K; Sun, JM | 1 |
| Han, B; Qiao, R; Wang, S; Xu, J; Zhang, B; Zhang, L; Zhang, Y; Zhao, Y | 1 |
| Ju, Q; Shao, H; Shi, H; Xu, R; Zhu, J | 1 |
| Al-Shahrour, F; Barbacid, M; Blasco, MT; Bousquet-Mur, E; Cabras, L; Castellano, E; Djurec, M; Drosten, M; Dusetti, N; Esteban-Burgos, L; Graña-Castro, O; Guerra, C; Hidalgo, M; Iovanna, J; Jacob, HKC; Khiabanian, H; Lechuga, CG; Li, J; Martín-Díaz, L; Martín-Serrano, G; Morales-Cacho, L; Mulero, F; Musteanu, M; Navas, C; Ortega, S; Perales-Patón, J; Rabadán, R; Sainz, B; Sánchez-Bueno, F | 1 |
| Chen, X; Duan, Y; Liao, XY; Sun, J; Wang, Y; Xu, Z; Yang, Q; Zheng, L; Zhu, B; Zhu, G | 1 |
| Batra, U; Lau, SCM; Loong, HH; Mok, TSK | 1 |
| Horn, L; Jie, F; Kelly, RJ; Krivoshik, A; Shepherd, FA | 1 |
| Baba, K; Hasegawa, Y; Ishioka, Y; Itoga, M; Nakagawa, H; Okudera, K; Sakamoto, H; Shiratori, T; Taima, K; Takanashi, S; Tanaka, H; Tasaka, S; Tsuchiya, J; Yasugahira, H | 1 |
| Chooback, N; Ho, C; Lau, SC; Melosky, B | 1 |
| Hamamoto, J; Ikemura, S; Kawada, I; Kobayashi, K; Manabe, T; Masuzawa, K; Naoki, K; Oashi, A; Soejima, K; Tani, T; Terai, H; Yasuda, H | 1 |
| Kim, HS; Kim, JY; Yoon, S | 1 |
| Atagi, S; Hirashima, T; Imamura, F; Inoue, T; Kimura, M; Kuhara, H; Kumagai, T; Kunimasa, K; Moriizumi, K; Nakahama, K; Nishino, K; Suzuki, H; Tamiya, A; Tamiya, M; Taniguchi, Y | 1 |
| Costa, DB; Jänne, PA; Kobayashi, SS; Lau, CJ; Mushajiang, M; Oxnard, GR; Paweletz, CP; Rangachari, D; Shpilsky, JE; To, C; VanderLaan, PA | 1 |
| Chang, LC; Chang, LY; Chen, KY; Lim, CK; Shih, JY; Yu, CJ | 1 |
| Pan-Pan, L; Qing, L; Yang, F; Ye, H; Yue-Yun, C; Zhen-Yu, D | 1 |
| Hanafi, A; Jayusman, M; Sutandyo, N | 1 |
| George, C; Joshua, JM; Pavithran, K; Thomas, P; Vijayan, M; Vincent, B | 1 |
| Bonanno, L; Buoro, V; Calabrese, F; Cecere, FL; Conte, P; Dal Maso, A; Del Conte, A; Frega, S; Indraccolo, S; Lorenzi, M; Macerelli, M; Monteverdi, S; Nardo, G; Pasello, G; Pilotto, S; Polo, V; Roca, E; Scattolin, D; Urso, L; Zulato, E | 1 |
| Chen, CY; Chen, YF; Chen, YH; Shih, JY; Yu, CJ | 1 |
| DerSarkissian, M; Duh, MS; Fernandes, AW; Laliberté, F; Pavilack, M; Subramanian, J | 1 |
| Chella, A; Crucitta, S; Danesi, R; Del Re, M; Garassino, MC; Gianfilippo, G; Mazzoni, F; Miccoli, M; Petrini, I; Pozzessere, D; Restante, G; Rofi, E; Valleggi, S | 1 |
| Cheema, P; Cheng, Y; Chewaskulyong, B; Cho, BC; Cobo, M; Gray, JE; Hodge, R; Imamura, F; John, T; Kurata, T; Lee, KH; Lin, MC; Ohe, Y; Planchard, D; Ramalingam, SS; Reungwetwattana, T; Rukazenkov, Y; Saggese, M; Shah, R; Soria, JC; Tiseo, M; Todd, A; Vansteenkiste, J; Zhou, C | 1 |
| Cho, BC; Gray, JE; Hovey, T; Karaseva, N; Leighl, NB; Nakagawa, K; Novello, S; Rydén, A; Walding, A | 1 |
| Chen, YH; Chien, LN; Fang, WT; Hsieh, YY; Lo, YW | 1 |
| Chen, J; Li, X; Liu, H; Liu, M; Zhang, H | 1 |
| Dekker, H; Frampton, AE; Giovannetti, E; Honeywell, RJ; Kathmann, I; Keller, K; Liu, DSK; Musters, RJP; Pauwels, P; Peters, GJ; Porcelli, L; Rolfo, C; Ruijtenbeek, R; Van Der Steen, N; Van Meerloo, J | 1 |
| Guan, R; Hu, D; Jiang, W; Li, K; Li, Y; Liao, D; Liu, L; Mansfield, AS; Wang, J; Xia, C; Xiao, L; Xiong, Y; Yang, H; Yang, N; Zeng, L; Zhang, Y; Zhou, C | 1 |
| Edeline, J; Frenel, JS; Gilabert, M; Raoul, JL; Senellart, H | 1 |
| Fukui, T; Igawa, S; Katagiri, M; Kubota, M; Kurahayashi, S; Kusuhara, S; Mitsufuji, H; Naoki, K; Okuma, Y; Ono, T; Ozawa, T; Sasaki, J; Sugimoto, A; Yokoba, M | 1 |
| Chen, H; Huang, J; Luo, Z; Meng, L; Sun, S; Yang, B | 1 |
| Bach, DH; Hu, R; Kim, D; Lee, SK; Luu, TT; Park, HJ | 1 |
| Hsu, JC; Lai, WW; Su, WC; Wang, JD; Yang, SC | 1 |
| Deng, Q; He, D; Wang, F; Xie, Z; Yang, H | 1 |
| Austin-Muttitt, K; Goh, EJH; Lau, AJ; Mullins, JGL; Saburulla, NF; Sivanandam, P; Tan, ARY; Tan, WK; Yap, ZP | 1 |
| Chen, KH; Tseng, LC; Wang, CL; Weng, LC | 1 |
| Gota, V; Gurjar, M; Joshi, A; Kannan, S; Nookala, M; Noronha, V; Patil, A; Patil, D; Patil, V; Prabhash, K; Shriyan, B | 1 |
| Aderhold, C; Birk, R; Huber, L; Kramer, B; Mueller, CE; Rotter, N; Schell, A | 1 |
| Damhuis, RAM; Gijtenbeek, RGP; Groen, HJM; van der Wekken, AJ; van Geffen, WH | 1 |
| Abe, T; Asada, K; Hataji, O; Hayai, S; Hida, T; Imaizumi, K; Inui, N; Ito, K; Karayama, M; Kimura, T; Kubo, A; Kunii, E; Morikawa, S; Murotani, K; Okuno, M; Oya, Y; Shindoh, J; Suda, T; Takahashi, K; Taniguchi, H; Tsuda, T; Yamagichi, T; Yoshida, T | 1 |
| Brat, K; Jakubíková, L; Šťastná, N | 1 |
| Lei, HM; Lv, QM; Ma, CS; Shen, Y; Tang, YB; Zhang, KR; Zhang, YF; Zhu, L | 1 |
| Al-Shahrour, F; Alandes, S; Alcácer, J; Aliena-Valero, A; Aparisi, S; Becker, JH; Benet, M; Borgia, JA; Carretero, J; Chuliá-Peris, L; Dalheim, AV; Fernández-Coronado, JA; García-Cañaveras, JC; Juan, O; Kaja, S; Lahoz, A; López, A; Nishimura, MI; Ollosi, S; Pulido, I; Qiu, W; Rodríguez, ML; Salom, JB; Shimamura, T; Soucheray, M; Tamayo-Torres, E | 1 |
| Arrieta, O; Barrón, F; Catalán, R; de la Garza, J; Flores-Estrada, D; Guzmán-Vazquez, S; Lara-Mejía, L; Ramos-Ramírez, M; Soto-Molina, H | 1 |
| Chang, YL; Chen, YM; Chou, YC; He, CH; Hsu, CC; Huang, TY; Su, VY; Yang, KY; Yen, JC | 1 |
| Ariyasu, R; Fujita, N; Katayama, R; Kitazono, S; Nishio, M; Tadokoro, K; Uchibori, K; Yamaguchi, T; Yanagitani, N | 1 |
| Bleilevens, A; Denecke, B; Denzinger, S; Ecke, T; Eltze, E; Eyll, M; Gaisa, NT; Geelvink, M; Gereitzig, M; Grimm, T; Herrmann, E; Horst, D; Knuechel, R; Maurer, A; Maurer, J; Rose, M; Rüchel, N; Toma, M; Vögeli, TA; Waldmann, T; Wenz, M; Wirtz, J | 1 |
| Aderhold, C; Birk, R; Huber, L; Jungbauer, F; Knuettel, M; Kramer, B; Lammert, A; Rotter, N; Scherl, C | 1 |
| Endo, T; Funayama, Y; Furukawa, K; Hayashi, S; Hayashihara, K; Hizawa, N; Ichimura, H; Iguchi, K; Inagaki, M; Inage, Y; Ishikawa, H; Kaburagi, T; Kamiyama, K; Kikuchi, N; Kiyoshima, M; Kodama, T; Kurishima, K; Miyazaki, K; Nakamura, H; Nakamura, R; Nomura, A; Okubo, H; Saito, K; Saito, T; Sakai, M; Sato, Y; Satoh, H; Sekine, I; Shiozawa, T; Suzuki, H; Tamura, T; Yamada, H; Yamada, Y; Yamamoto, Y; Yamashita, T | 1 |
| Landmesser, ME; Lehman, HL; Raup-Konsavage, WM; Stairs, DB | 1 |
| Mohty, R; Tfayli, A | 1 |
| Huang, L; Jiang, T; Sun, Y; Wang, L; Wang, X; Wen, M; Xia, J; Yang, S; Zhang, Y; Zhang, Z | 1 |
| Li, G; Lin, Z; Mei, J; Xu, X | 1 |
| Fujitaka, K; Hamai, K; Hongoh, M; Hotta, T; Ishihara, N; Ishikawa, N; Isobe, T; Kobayashi, M; Kubota, T; Nakamura, A; Nishimura, N; Sugisaka, J; Tanino, A; Tsubata, Y; Yamasaki, M | 1 |
| Akdeniz, N; Akinci, MB; Aktas, BY; Alan, O; Avci, O; Ayhan, M; Basoglu, T; Bilgin, B; Celik, E; Cinkir, HY; Dede, DS; Demir, A; Demirkazık, A; Deniz, GI; Dogan, I; Erol, C; Gulmez, A; Gurbuz, M; Hizal, M; Ilhan, A; Karaagac, M; Karatas, F; Kilickap, S; Koca, S; Kut, E; Menevse, S; Oksuzoglu, B; Ozyukseler, DT; Paydas, S; Sakalar, T; Sen, E; Sendur, MAN; Taskaynatan, H; Tatli, AM; Yalcin, B; Yucel, S; Yumuk, F | 1 |
| Aiken, T; Broude, EV; Hennes, C; Lim, CU; McDermott, MSJ; Philavong, KP; Roninson, IB; Sharko, AC; Tatarskiy, VV | 1 |
| Beijnen, JH; Huitema, ADR; Janssen, JM; Muller, M; Schellens, JHM; Steeghs, N; van den Broek, D; van den Heuvel, MM; van Duijl, TT; Verheijen, RB; Vessies, D | 1 |
| Gupta, A; Momi, G; Vaid, AK | 1 |
| Chai, J; Cui, JW; Li, LY; Li, WQ | 1 |
| Au, JS; Au, KH; Cho, WCS; Kwan, CK; Li, YC; Ming, WK; You, JHS | 1 |
| Bates, V; Boland, A; Chaplin, M; Dundar, Y; Green, JA; Greenhalgh, J; Vecchio, F | 1 |
| Chen, HH; Fearon, D; Horton, S; Kim, YJ; McFarlane, T; Oremus, M | 1 |
| Arora, S; Bhat, ZR; Biswas, S; Joshi, G; Kumar, M; Kumar, R; Sharma, N; Singh, S; Singh, T; Tikoo, K | 1 |
| Choi, H; Kho, BG; Kim, MS; Kim, YC; Lee, JK; Oh, HJ; Oh, IJ; Park, CK | 1 |
| Fujita, A; Hatsuyama, T; Inotsume, N; Mukai, Y; Sato, H; Toda, T; Wakamoto, A; Yoshida, T | 1 |
| Dong, Y; Li, D; Li, Q; Miao, Q | 1 |
| Akrour, Y; Duchemann, B; Gaudry, S; Gibelin, A; Gonzalez, F; Jaubert, P; Moreau, AS; Oppenheimer, A; Stoclin, A; Tandjaoui-Lambiotte, Y | 1 |
| Chang, GC; Chen, JJW; Chen, KC; Chin, CS; Hsu, KH; Huang, YH; Su, KY; Tseng, JS; Yang, TY; Yu, SL | 1 |
| Aguilar-Serra, J; Cortijo, J; Gimeno-Ballester, V; Milara, J; Pastor-Clerigues, A; Trigo-Vicente, C | 1 |
| Chang, HC; Chang, YP; Huang, KT; Lai, CH; Lin, MC; Tseng, CC; Wang, CC | 1 |
| Endo, M; Harada, H; Kenmotsu, H; Ko, R; Kobayashi, H; Kodama, H; Mamesaya, N; Miyawaki, E; Miyawaki, T; Mori, K; Murakami, H; Naito, T; Nishioka, N; Omori, S; Ono, A; Takahashi, K; Takahashi, T; Wakuda, K | 1 |
| Dai, JG; Gao, DC; Hou, B; Liu, QX; Lu, X; Zheng, H; Zhou, D | 1 |
| Aronis, C; Chaniotis, D; Degn, SE; Frantzi, T; Kalofonos, HP; Koutras, A; Makatsoris, T; Papanastasiou, AD; Sirinian, C | 1 |
| Hager, S; Messeha, SS; Nezami, MA; Soliman, KFA | 1 |
| Du, X; Liu, W; Wang, Z; Xiong, X; Yang, L; Yang, P; Zhang, Y; Zhou, C | 1 |
| Imoto, S; Miyano, S; Park, H; Yamaguchi, R | 1 |
| Bajan, S; Boonyaratanakornkit, V; Hutvagner, G; Kaewjanthong, P; McGowan, E; Sasano, H; Sooksai, S | 1 |
| Akangunduz, B; Akdeniz, N; Aksoy, A; Akyol, M; Alan, Ö; Arak, H; Atci, MM; Balli, S; Bayram, E; Bekmez, ET; Bilgin, B; Bilici, A; Cavdar, E; Celik, E; Demirci, NS; Demirkazik, A; Ellez, Hİ; Erdem, D; Erdoğan, AP; Goker, E; Gursoy, P; Hedem, E; Katgi, N; Kilickap, S; Kut, E; Menekse, S; Nart, D; Oyan, B; Ozturk, A; Pilanci, KN; Sakalar, T; Sakin, A; Selçukbiricik, F; Tatli, AM; Telli, TA; Topcu, A; Turhal, S; Turkoz, FP; Yapar, B; Yildirim, HÇ; Yumuk, PF | 1 |
| Chang, JS; Hsieh, KP; Huang, YB; Lee, CH; Shen, MC; Tsai, MJ; Yang, YH | 1 |
| Babu, TD; C M, P; Joshy, G; K P, SH; Mathew, D; Thayyil, MS | 1 |
| An, L; Chu, C; Duan, S; Li, L; Liu, C; Liu, Q; Wang, Z; Wu, G | 1 |
| Ho, JCM; Ip, MSM; Kwok, WC; Lam, DCL; Tam, TCC | 1 |
| Chauhan, SJ; Sahu, RP; Thyagarajan, A | 1 |
| Choowongkomon, K; Mahalapbutr, P; Poo-Arporn, RP; Rungrotmongkol, T; Todsaporn, D | 1 |
| Al-Zubaidi, Y; Bourget, K; Murray, M; Rahman, MK; Tam, S; Zhou, F | 1 |
| Dong, W; Gong, Y; Hu, S; Li, M; Wang, C; Xie, C; Zhao, K | 1 |
| Lucia, F; Nicolas, E | 1 |
| Aerts, JGJV; Dingemans, AC; Hurkmans, DP; Mathijssen, RHJ; Oomen-de Hoop, E; Paats, MS; van der Leest, CH; van Leeuwen, RW; van Thiel, ERE; Veerman, GDM | 1 |
| Chen, H; Fang, S; Hu, Z; Li, N; Liu, K; Pan, Q; Wei, Y; Xu, G; Xu, S; Zhu, L; Zhu, Y | 1 |
| Acconcia, F | 1 |
| Donald, BR; Feichtner, A; Guerin, N; Kaserer, T; Stefan, E | 1 |
| Li, S; Li, Z; Liu, S; Wang, Z; Zhao, F | 1 |
| Tan, J; Xu, M; Zhong, Z | 1 |
| Guo, YW; Li, SW; Li, XW; Luo, C; Wang, H; Wu, Q; Xu, H; Yao, LG; Zhang, H | 1 |
| Abbie, E; Boyne, DJ; Brenner, DR; Cheung, WY; Eaton, K; Elia-Pacitti, J; Ewara, EM; Gogna, P; Hu, LXY; Jarada, TN; O'Sullivan, DE; Pabani, A; Rose, JB; Yusuf, A | 1 |
| Boily, G; Boulanger, J; Golo, KT; Guédon, AC; Lehuédé, C; Qureshi, S; Roussafi, F; Strumpf, E; Truchon, C | 1 |
| Daga, H; Fujisaka, Y; Hattori, Y; Ikeda, N; Iwamoto, Y; Katakami, N; Kozuki, T; Morita, S; Nakagawa, K; Nishino, K; Oguri, T; Okamoto, T; Oki, M; Sato, Y; Sugawara, S; Takahashi, T; Urata, Y; Yamamoto, N; Yokoyama, T | 1 |
| Chang, CF; Chang, JW; Fang, YF; Hsu, PC; Huang, CY; Kuo, CS; Wu, CE; Yang, CT | 1 |
| Chen, PC; Guo, CH; Hsia, S; Lee, SY; Li, WC; Peng, CL | 1 |
| Harada, H; Katagiri, H; Miyagi, M; Mori, K; Murakami, H; Murata, H; Takahashi, M; Takahashi, T; Wasa, J | 1 |
| Ahn, JS; Ahn, MJ; Jung, HA; Lee, SH; Park, S; Sun, JM | 1 |
| Chen, CH; Hour, MJ; Hsieh, HH; Kuo, YH; Wu, TY | 1 |
| Chen, KY; Ho, CC; Hsu, CL; Huang, CT; Liao, WY; Lin, CA; Su, TJ; Tsai, TH; Yang, CY; Yu, CJ | 1 |
| Chen, GY; Chen, KY; Liang, SK; Wei, YF; Weng, TI | 1 |
| Boily, G; Boulanger, J; Pagé, É; Qureshi, S; Strumpf, E | 1 |
| Chen, M; Li, D; Li, H; Li, M; Shi, P; Yang, T | 1 |
| Akazawa, Y; Igawa, S; Kaizuka, N; Kasajima, M; Kubota, M; Manaka, H; Mitsufuji, H; Nakahara, Y; Naoki, K; Sasaki, J; Sato, T; Yagami, Y; Yamada, K; Yamamoto, H; Yokoba, M | 1 |
| Chang, HC; Chang, YP; Chen, YC; Chen, YM; Chuang, HY; Huang, KT; Lai, CH; Tseng, CC; Wang, CC | 1 |
| Chang, HC; Chang, YP; Chen, YM; Chuang, HY; Fang, WF; Huang, KT; Lai, CH; Lin, MC; Tseng, CC; Wang, CC | 1 |
| Chiu, TH; Chung, FT; Fang, YF; Guo, YK; Hsu, PC; Huang, AC; Huang, CH; Ju, JS; Ko, HW; Kuo, CS; Tung, PH; Wang, CC; Yang, CT | 1 |
318 review(s) available for erlotinib hydrochloride and gefitinib
| Article | Year |
|---|---|
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Quinazolines; Xenograft Model Antitumor Assays | 2001 |
Anticancer therapy targeting the erbB family of receptor tyrosine kinases.
Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2001 |
[Molecular target-based cancer therapy: epidermal growth factor receptor inhibitors].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2002 |
Targeting epidermal growth factor receptor in lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2002 |
[New therapeutic targets and strategies in lung cancer].
Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Benzodiazepines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Endothelial Growth Factors; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Lymphokines; Metalloendopeptidases; Multicenter Studies as Topic; Piperazines; Polyisoprenyl Phosphates; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Quinolones; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Sesquiterpenes; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
HER-targeted tyrosine-kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Morpholines; Ovarian Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2 | 2002 |
Epithelial growth factor receptor interacting agents.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Drug Design; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunization, Passive; Irinotecan; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms; Quinazolines; Recombinant Fusion Proteins; Xenograft Model Antitumor Assays | 2002 |
[Molecular-targeted therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Endothelial Growth Factors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Lymphokines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Epidermal growth factor receptor as a therapeutic target in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Panitumumab; Quinazolines | 2003 |
Phase I studies of ZD1839 in patients with common solid tumors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Morpholines; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
[Molecular targetting therapy for non-small-cell lung neoplasms with EGF-R inhibitors].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Small Cell; Cetuximab; Clinical Trials as Topic; Depression, Chemical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Quinazolines | 2003 |
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Design; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Ligands; Neoplasms; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2003 |
Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
Topics: Aminoquinolines; Aniline Compounds; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Design; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Morpholines; Neoplasms; Organic Chemicals; Panitumumab; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Structure-Activity Relationship | 2003 |
[Non-small cell lung cancer: 1) Molecular-target therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2003 |
New targeted therapies in gastrointestinal cancers.
Topics: Adult; Aged; Antibodies, Monoclonal; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Gastrointestinal Neoplasms; Gefitinib; Humans; Immunotherapy; Male; Middle Aged; Neoplasm Staging; Panitumumab; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome | 2003 |
Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Treatment Outcome | 2003 |
Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Cell Differentiation; Cell Movement; Cell Survival; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; History, Modern 1601-; Humans; Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Quinazolines | 2003 |
Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2003 |
Targeting the HER1/EGFR receptor to improve outcomes in non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prognosis; Quinazolines; Treatment Outcome | 2003 |
Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Quinazolines; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2003 |
HER1/EGFR targeting: refining the strategy.
Topics: Antineoplastic Agents; Drug Delivery Systems; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Ligands; Neoplasms; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Signal Transduction | 2004 |
Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
[Targeting of epidermal growth factor receptor and applications in ORL cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Morpholines; Neoplasm Proteins; Otorhinolaryngologic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines | 2003 |
[Inhibitors of epidermal growth factor receptor and colorectal cancer].
Topics: Antineoplastic Agents; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasm Proteins; Protein-Tyrosine Kinases; Quinazolines | 2003 |
[Therapeutic implications of epidermal growth factor receptor in lung cancer].
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cisplatin; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Proteins; Quinazolines | 2004 |
Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Rationale and clinical validation of epidermal growth factor receptor as a target in the treatment of head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Quinazolines | 2004 |
Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Radiation-Sensitizing Agents | 2004 |
Review of epidermal growth factor receptor biology.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Morpholines; Neoplasm Proteins; Panitumumab; Quinazolines; Radiation Tolerance; Receptor, ErbB-2 | 2004 |
Targeting the epidermal growth factor receptor.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
[New advance of the molecular targeting agents in advanced non-small cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
[Resistance to target-based therapy and its circumvention].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Cetuximab; Drug Delivery Systems; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Quinazolines; Rituximab; Trastuzumab | 2004 |
Targeted therapies for cancer 2004.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Bevacizumab; Breast Neoplasms; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Gemtuzumab; Humans; Neoplasms; Pharmacogenetics; Quinazolines; Rituximab; Trastuzumab | 2004 |
Epidermal growth factor receptor inhibition strategies in oncology.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of bronchoalveolar carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
[Second-line treatment for advanced non-small-cell lung cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2005 |
The epidermal growth factor receptor as a target for colorectal cancer therapy.
Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Transformation, Neoplastic; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Organic Chemicals; Panitumumab; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction | 2005 |
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2005 |
Small molecules with EGFR-TK inhibitor activity.
Topics: Aminoquinolines; Aniline Compounds; Animals; Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Mutation; Neoplasms; Organic Chemicals; Quinazolines; Signal Transduction | 2005 |
Epidermal growth factor receptor as a target for chemotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Panitumumab; Quinazolines | 2005 |
Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2005 |
Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Metaphor; Mutation; Protein Kinase Inhibitors; Quinazolines | 2005 |
[Targeted therapies: last focus on EGF receptor inhibitors in breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Prognosis; Quinazolines; Receptor, ErbB-2; Receptors, Estradiol; Taxoids; Trastuzumab | 2004 |
Therapy of breast cancer with molecular targeting agents.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclooxygenase 2; Docetaxel; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Paclitaxel; Prenylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2005 |
[Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, abl; Humans; Imatinib Mesylate; Neoplasms; Patient Selection; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Trastuzumab; Vascular Endothelial Growth Factor A | 2005 |
Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2005 |
Recent developments related to the EGFR as a target for cancer chemotherapy.
Topics: Aminoquinolines; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Structure; Organic Chemicals; Protein Kinase Inhibitors; Quinazolines | 2005 |
Medical treatment of non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
[New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Furans; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Oxonic Acid; Pemetrexed; Pyrazines; Pyridines; Quinazolines; Tegafur; Vinblastine; Vinorelbine | 2005 |
Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Factors predicting response to EGFR tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Patient Selection; Quinazolines | 2005 |
HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
Topics: Animals; Brain Neoplasms; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioblastoma; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2005 |
The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2005 |
Overview of tyrosine kinase inhibitors in clinical breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2005 |
Targeted therapies for non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Therapy; Humans; Lung Neoplasms; Mutation; Oligonucleotides, Antisense; Protein Kinase Inhibitors; Quinazolines | 2005 |
Epidermal growth factor inhibition in solid tumours.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; Drug Delivery Systems; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic | 2005 |
Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Forecasting; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2005 |
[Molecular targeted therapy for malignant brain tumors].
Topics: Antineoplastic Agents; Benzamides; Brain Neoplasms; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Piperidines; Protein Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2005 |
Adjuvant chemotherapy for non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Oncogene Proteins; Protein Kinase Inhibitors; Quinazolines | 2005 |
Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Quinazolines | 2005 |
Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Survival Analysis | 2006 |
[Antineoplastic agents targeting tyrosine kinases].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gastrointestinal Stromal Tumors; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Trastuzumab | 2005 |
Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Genes, erbB-1; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Patient Selection; Prognosis; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Genetic Therapy; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Radiation combined with EGFR signal inhibitors: head and neck cancer focus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
EGFR inhibitors in lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Controlled Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Patient Selection; Quinazolines; Treatment Failure | 2005 |
[EGFR/HER1 inhibition: an example of new targeted therapies in non-small cell lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Quinazolines; Survival Rate | 2005 |
Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.
Topics: Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines | 2006 |
[Chemotherapy for lung cancer patients].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Etoposide; Evidence-Based Medicine; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2006 |
Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Mice; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Clinical experience with anti-EGFR therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Safety; Survival Rate; Treatment Outcome | 2006 |
Common side effects of anti-EGFR therapy: acneform rash.
Topics: Acneiform Eruptions; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diarrhea; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Nurse's Role; Oncology Nursing; Patient Education as Topic; Quinazolines; Severity of Illness Index | 2006 |
Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Stomach Neoplasms; Trastuzumab | 2006 |
Where next for gefitinib in patients with lung cancer?
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2006 |
[Problems in the current target therapy of malignancies].
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Azathioprine; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Phthalazines; Piperazines; Pyridines; Pyrimidines; Quinazolines; Quinolones; Rituximab; Sesquiterpenes; Sesquiterpenes, Guaiane; Trastuzumab | 2005 |
Tyrphostins and other tyrosine kinase inhibitors.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzamides; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Graft Occlusion, Vascular; Humans; Imatinib Mesylate; Janus Kinase 2; Janus Kinase 3; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Tyrphostins | 2006 |
Predicting the outcome of chemotherapy for lung cancer.
Topics: 14-3-3 Proteins; Antineoplastic Agents; Cell Transformation, Neoplastic; Clinical Trials as Topic; DNA Repair Enzymes; DNA-Binding Proteins; Drug Resistance, Neoplasm; Epigenesis, Genetic; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mesoderm; Mutation; Nuclear Proteins; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Smoking; Thioredoxins; Treatment Outcome; Y-Box-Binding Protein 1 | 2006 |
Epidermal growth factor receptor inhibition and non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Denmark; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Structure, Tertiary; Quinazolines; Signal Transduction | 2006 |
Advanced non-small-cell lung cancer: new data, therapy choices, and challenging decisions.
Topics: Antineoplastic Agents; Biological Products; Biomedical Research; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Medical Oncology; Protein Kinase Inhibitors; Quinazolines | 2006 |
[New substances in the therapy of head and neck cancer].
Topics: Administration, Oral; Aminoquinolines; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Controlled Clinical Trials as Topic; Double-Blind Method; Erlotinib Hydrochloride; Fibroblast Growth Factor 7; Gefitinib; Head and Neck Neoplasms; Humans; Imiquimod; Infusions, Intravenous; Iodine Radioisotopes; Lung Neoplasms; Lymphatic Metastasis; Lymphoma, Non-Hodgkin; Ointments; Protein Kinase Inhibitors; Quinazolines; Radioimmunotherapy; Randomized Controlled Trials as Topic; Skin Neoplasms; Time Factors; United States; United States Food and Drug Administration | 2006 |
Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Genes, ras; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Smoking | 2005 |
Epidermal growth factor receptor targeting in cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2006 |
Clinical breakthroughs in EGFR inhibition: applying the science to your clinical practice.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Communication; Cetuximab; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Forecasting; Gefitinib; Humans; Neoplasms; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Care Planning; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2006 |
The role of the epidermal growth factor receptor in breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Prognosis; Quinazolines; Receptor, ErbB-2 | 2006 |
Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Drug Eruptions; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Quinazolines | 2006 |
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.
Topics: Antineoplastic Agents; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Deletion; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
[Anti-EGFR therapy: towards a "à la carte" targeting of hepatocellular carcinoma].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cetuximab; Clinical Trials, Phase II as Topic; Disease Models, Animal; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Ligands; Liver Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Rats; Signal Transduction; Transforming Growth Factor alpha | 2006 |
Defining clinically relevant molecular subsets of lung cancer.
Topics: Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2006 |
[Is it possible to treat bronchial carcinoma without chemotherapy?].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meta-Analysis as Topic; Neoadjuvant Therapy; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Risk Factors; Sex Factors; Smoking | 2006 |
Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Duplication; Genes, ras; Humans; Models, Biological; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Quinazolines; Signal Transduction | 2006 |
[Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2007 |
Managing dermatologic toxicities of epidermal growth factor receptor inhibitors.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2006 |
Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2006 |
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Amplification; Gene Expression Profiling; Genetic Testing; Humans; Lung Neoplasms; Male; Mutation; Patient Selection; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome | 2007 |
Cellular responses to EGFR inhibitors and their relevance to cancer therapy.
Topics: Antineoplastic Agents; Cell Movement; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Morphogenesis; Neoplasm Invasiveness; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2007 |
Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2006 |
[New biological treatments for lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biopsy; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Forecasting; Gefitinib; Humans; Lung; Lung Neoplasms; Male; Mutation; Patient Selection; Polymerase Chain Reaction; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
Epidermal growth factor receptor inhibitors in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Analysis | 2007 |
Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2007 |
"Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?".
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Medical Oncology; Mutation; Quinazolines; ras Proteins; Smoking | 2007 |
[Therapeutic management of extensive bronchiolo-alveolar adenocarcinoma: chemotherapy or inhibitors of epidermal growth factor receptor tyrosine kinase?].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2007 |
The place of targeted therapy in the patient management of non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2007 |
[Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Trastuzumab | 2007 |
Targeted therapy in rectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Drug Delivery Systems; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Irinotecan; Neoadjuvant Therapy; Quinazolines; Rectal Neoplasms; Vascular Endothelial Growth Factor A | 2007 |
[Targeting ErbB receptors in breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2007 |
[Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Proteins; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2007 |
Targeting the epidermal growth factor receptor in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Mutation; Neoplasm Metastasis; Panitumumab; Quinazolines | 2008 |
Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives.
Topics: Antineoplastic Agents; Asian People; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Humans; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines | 2007 |
EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2008 |
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab | 2008 |
EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2008 |
Chemotherapeutic agents and the skin: An update.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids | 2008 |
Commentary: Novel therapies for cancer: why dirty might be better.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microtubules; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Purinergic P2 | 2008 |
[Targeted therapies in the treatment of non-small cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-1 | 2008 |
Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Quinazolines; Trastuzumab; Treatment Outcome | 2006 |
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Diet; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Lymph Node Excision; Neoplasm Staging; Pharmacogenetics; Quinazolines; Radiotherapy Dosage; Risk Factors; Smoking; Survival Analysis; Survivors; Tobacco Smoke Pollution; Treatment Outcome | 2008 |
Current status of clinical trials for glioblastoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Biocompatible Materials; Brain Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Decanoic Acids; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Glioblastoma; Humans; Imatinib Mesylate; Immunotoxins; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Piperazines; Polyesters; Protein Kinase Inhibitors; Proteins; Pyrimidines; Quinazolines; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases; Transcription Factors | 2006 |
Epidermal growth factor receptor-directed therapy in esophageal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Gefitinib; Humans; Incidence; Lung Neoplasms; Quinazolines; Survival Analysis | 2007 |
[Non-small-cell lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2008 |
Advances in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2008 |
New insights in drug development for the non-small cell lung cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future.
Topics: Antineoplastic Agents; Asia, Eastern; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2008 |
Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.
Topics: Alleles; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Quinazolines | 2008 |
Nursing management of epidermal growth factor receptor inhibitor-induced toxicities.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diarrhea; Drug Eruptions; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Nursing Assessment; Oncology Nursing; Panitumumab; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Severity of Illness Index | 2008 |
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Prognosis; Quinazolines; Quinolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
[New therapies for the treatment of advanced non-small cell lung cancer: inhibitors of the epidermal growth factor receptor and angiogenesis].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neovascularization, Pathologic; Quinazolines | 2008 |
Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Medical Oncology; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
[Targeted therapy for locally advanced and/or metastatic bladder cancer].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Disease Progression; Erlotinib Hydrochloride; Gefitinib; Genetic Therapy; Humans; Immunosuppressive Agents; Mutation; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Targeted Gene Repair; Trastuzumab; Urinary Bladder Neoplasms | 2008 |
The role of inhibitors of the epidermal growth factor in management of head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Panitumumab; Protein Kinase Inhibitors; Quinazolines | 2008 |
The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2008 |
[Targeted therapies for lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erlotinib Hydrochloride; Evidence-Based Medicine; Gefitinib; Gene Targeting; Humans; Lung Neoplasms; Patient Selection; Protein-Tyrosine Kinases; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
EGFR inhibition as a therapy for head and neck squamous cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Head and Neck Neoplasms; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2008 |
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Quinazolines | 2008 |
Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Treatment Outcome | 2008 |
Second line treatments in advanced platinum-resistant non small cell lung cancer. A critical review of literature.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2009 |
[Targeted therapies and their indications in solid neoplasias].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer.
Topics: Age Factors; Aging; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2009 |
Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Panitumumab; Platinum Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2008 |
Combining epidermal growth factor receptor inhibitors and radiation therapy in pancreatic cancer: small step or giant leap?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Quinazolines | 2010 |
Targeted therapies in the treatment of advanced/metastatic NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Quinazolinones | 2009 |
Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Databases, Factual; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; ROC Curve; Survival Rate | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Humans; Quinazolines; Randomized Controlled Trials as Topic | 2009 |
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptors, Growth Factor; Sequence Deletion; Treatment Outcome | 2009 |
Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Gene Expression; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2009 |
Clinical pharmacokinetics of tyrosine kinase inhibitors.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Benzenesulfonates; Biological Availability; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Intestinal Absorption; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Tissue Distribution | 2009 |
Treatment of advanced non-small-cell lung cancer in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cardiovascular Diseases; Cisplatin; Clinical Trials as Topic; Comorbidity; Contraindications; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Vascular Endothelial Growth Factor A | 2009 |
Small-molecule inhibitors of the human epidermal receptor family.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Delivery Systems; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Models, Biological; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2010 |
[Molecular diagnostics in lung carcinoma for therapy stratification].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Molecular Diagnostic Techniques; Neoplasm Staging; Prognosis; Protein-Tyrosine Kinases; Quinazolines | 2010 |
Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer.
Topics: Animals; Catalytic Domain; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Small Cell Lung Carcinoma; Structure-Activity Relationship | 2010 |
[Cutaneous side effects of EGFR inhibitors--appearance and management].
Topics: Acneiform Eruptions; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hair Diseases; Humans; Ichthyosis; Mucositis; Neoplasms; Panitumumab; Paronychia; Protein Kinase Inhibitors; Quinazolines | 2010 |
First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2010 |
Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib.
Topics: Adenocarcinoma; Animals; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2010 |
Use of erlotinib or gefitinib as initial therapy in advanced NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2010 |
Understanding resistance to EGFR inhibitors-impact on future treatment strategies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2010 |
[Oncology 2010].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2010 |
Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation-targeted lung cancer therapy.
Topics: Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2010 |
[Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Pemetrexed; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2010 |
[Current status of erlotinib and gefitinib in palliative therapy for NSCLC--does the EGF-R mutation state have any significance?].
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Long-Term Care; Lung Neoplasms; Palliative Care; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2010 |
Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2010 |
Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Discovery; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2010 |
[The predictive value of EGFR status in non-small cell lung cancer patients treated with EGFR-TKIs].
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
Targeted therapy: an evolving world of lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2011 |
EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Genetic Markers; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Odds Ratio; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; White People | 2011 |
Second-line treatment for non-small-cell lung cancer: one size does not fit all.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Prognosis; Quinazolines; Taxoids | 2010 |
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Quinazolines | 2010 |
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cetuximab; Cisplatin; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Paclitaxel; Patient Selection; Precision Medicine; Predictive Value of Tests; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases; Signal Transduction; Survival Analysis; Translocation, Genetic | 2010 |
[Consolidation therapy in advanced non-small cell lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Lung Neoplasms; Medical Oncology; Neoplasm Staging; Prognosis; Quinazolines; Risk Assessment | 2010 |
Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2010 |
Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Neoplasm Proteins; Pharmacogenetics; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines | 2010 |
[EGFR inhibitors in non-small cell lung cancer: more than yesterday (but less than tomorrow)].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Controlled Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Staging; Quinazolines; Survival Rate | 2010 |
Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
EGFR tyrosine kinase inhibitors and multidrug resistance: perspectives.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2011 |
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.
Topics: Antineoplastic Agents; Apoptosis; Cell Division; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2011 |
Targeting EGFR in bilio-pancreatic and liver carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Biliary Tract Neoplasms; Carcinoma; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liver Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib | 2011 |
Advances in EGFR-directed therapy in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Hypersensitivity; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Head and Neck Neoplasms; Humans; Lung Diseases, Interstitial; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis | 2011 |
EGFR pathway in advanced non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2011 |
The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2011 |
[Dose finding methods for targeted agents: new perspectives].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Survival; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Erlotinib Hydrochloride; Gefitinib; Humans; Maximum Tolerated Dose; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2010 |
[Prognostic and predictive biomarkers in non-small cell lung cancers. From conditioned registrations to routine molecular mapping of lung cancers: Methodological issues].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Mutational Analysis; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2011 |
The need for third-line treatment in non-small cell lung cancer: an overview of new options.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Quinazolines; Salvage Therapy | 2011 |
Treatment of non-small-cell lung cancer with erlotinib or gefitinib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2011 |
[Adverse effects of new biological therapies for non-small-cell bronchial cancer].
Topics: Angiogenesis Inhibitors; Biological Products; Carcinoma, Non-Small-Cell Lung; Cooperative Behavior; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Interdisciplinary Communication; Lung Neoplasms; Neoplasm Staging; Patient Care Team; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2011 |
[Bronchiolar-alveolar carcinoma: From concept to innovative therapeutic strategies].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Pneumonectomy; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2011 |
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Gene Expression; Humans; Lung Neoplasms; Mutation; Ovarian Neoplasms; Platinum; Protein Kinase Inhibitors; Quinazolines; Recurrence; Survival Rate; Treatment Outcome | 2011 |
Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Molecular Targeted Therapy; Panitumumab; Protein Kinase Inhibitors; Quinazolines | 2011 |
[A simple view on lung cancer biology: The EGFR pathway].
Topics: Adenocarcinoma; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.
Topics: Animals; Antineoplastic Agents; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Pharmacogenetics; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution | 2011 |
EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Quinazolines; Radiation Tolerance | 2011 |
[Indication of EGFR kinase inhibitors should be refined].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2011 |
[EGFR/HER1: a target life].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Cetuximab; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Neoplasm Proteins; Neoplasms; Panitumumab; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; Quinazolines; ras Proteins | 2012 |
Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Receptors, Growth Factor | 2011 |
Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Patient Selection; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2011 |
Problems involved in the clinical trials for non-small cell lung carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Mutation; Patient Selection; Pemetrexed; Platinum; Quinazolines | 2012 |
Targeted drug therapies and cancer.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Drug Delivery Systems; Erlotinib Hydrochloride; Gastrointestinal Neoplasms; Gefitinib; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Neoplasm Metastasis; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2011 |
Genetics of glioblastoma: a window into its imaging and histopathologic variability.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell Survival; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neovascularization, Pathologic; Phosphorylcholine; Protein Kinase Inhibitors; Quinazolines | 2011 |
Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Myocardial Infarction; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
Long-term outcome after multidisciplinary approach for leptomeningeal carcinomatosis in a non-small cell lung cancer patient with poor performance status.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Quinazolines; Radiotherapy, Adjuvant; Time Factors; Treatment Outcome; Ventriculoperitoneal Shunt | 2011 |
Role of chemotherapy on brain metastasis.
Topics: Brain Neoplasms; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines | 2012 |
Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arterial Occlusive Diseases; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Incidence; Neoplasms; Panitumumab; Quinazolines; Randomized Controlled Trials as Topic; Risk; Venous Thromboembolism | 2012 |
New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Quinazolines; Squamous Cell Carcinoma of Head and Neck | 2012 |
Pulmonary toxicities of tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Benzamides; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Lung Diseases, Interstitial; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines | 2011 |
[Research progress on resistance mechanisms of epidermal growth factor receptor
tyrosine kinase inhibitors in non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Quinazolines | 2012 |
Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2012 |
Recent advances in non-small cell lung cancer biology and clinical management.
Topics: Animals; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Quinazolines; Vascular Endothelial Growth Factor A | 2012 |
Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2012 |
Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications.
Topics: Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Pharmacogenetics; Protein Kinase Inhibitors; Quinazolines | 2012 |
The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Gefitinib; Health Status; Humans; Lung Neoplasms; Practice Guidelines as Topic; Quality of Life; Quinazolines; Sickness Impact Profile; Taxoids; Time Factors; Treatment Outcome | 2013 |
The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cetuximab; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Molecular Targeted Therapy; Mutation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Panitumumab; Protein-Tyrosine Kinases; Quinazolines | 2012 |
Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review.
Topics: Adenocarcinoma; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Germ-Line Mutation; Humans; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Germ-Line Mutation; Humans; Indoles; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2014 |
Potential therapeutic significance of HER-family in esophageal squamous cell carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Drug Delivery Systems; Erlotinib Hydrochloride; Esophageal Neoplasms; Gefitinib; Genes, erbB-1; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Trastuzumab | 2012 |
EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2012 |
Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Molecular Targeted Therapy; Panitumumab; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Skin Neoplasms | 2014 |
Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemoradiotherapy; Clinical Trials as Topic; Combined Modality Therapy; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Gefitinib; Humans; Immunotherapy; Lung Neoplasms; Pyrazoles; Pyridines; Quinazolines | 2013 |
Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2013 |
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2013 |
Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases | 2013 |
Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors | 2013 |
Second-Line Therapy for Advanced NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Mutation; Oncogene Proteins, Fusion; Pemetrexed; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids | 2013 |
Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Proliferation; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2013 |
Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Polymorphism, Single Nucleotide; Quinazolines | 2013 |
[Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
Topics: Antineoplastic Agents; Crown Ethers; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Glucuronosyltransferase; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2013 |
Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Incidence; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines; Risk; Survival Analysis | 2014 |
Subsequent treatment choices for patients with acquired resistance to EGFR-TKIs in non-small cell lung cancer: restore after a drug holiday or switch to another EGFR-TKI?
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Drug Substitution; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Retreatment | 2014 |
Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Crown Ethers; Data Collection; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Markov Chains; Mutation; Probability; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; PTEN Phosphohydrolase; Quinazolines; Signal Transduction | 2014 |
Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Factors | 2015 |
Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Incidence; Lung Neoplasms; Molecular Targeted Therapy; Prognosis; Quinazolines; Radiosurgery; Treatment Outcome | 2014 |
Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2014 |
[Programs for continuing medical education: B session; 4. Progress in lung cancer therapy].
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Crizotinib; Drug Discovery; Education, Medical, Continuing; Erlotinib Hydrochloride; Etoposide; Gefitinib; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Small Cell Lung Carcinoma | 2014 |
The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2014 |
Management and future directions in non-small cell lung cancer with known activating mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Mutation Rate; Neoplasms, Squamous Cell; Oncogenes; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2014 |
Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Predictive value of a serum-based proteomic test in non-small-cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors: a meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Predictive Value of Tests; Proteomics; Quinazolines | 2014 |
Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence.
Topics: Asian People; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Maximum Tolerated Dose; Protein Kinase Inhibitors; Quinazolines | 2014 |
Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Area Under Curve; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines; ROC Curve | 2014 |
Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Proportional Hazards Models; Quinazolines | 2014 |
Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2014 |
Anti-epidermal-growth-factor-receptor agents and complete responses in the treatment of advanced non-small-cell lung cancer: a meta-analysis of 17 phase III randomized controlled trials.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2015 |
Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Models, Biological; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2015 |
Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Membrane Proteins; Molecular Targeted Therapy; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Small Cell Lung Carcinoma | 2014 |
A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC).
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines | 2014 |
EGFR-TKIs combined with chemotherapy versus EGFR-TKIs single agent as first-line treatment for molecularly selected patients with non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2015 |
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2015 |
Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors.
Topics: Afatinib; Base Sequence; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Signal Transduction; Survival Rate | 2015 |
Management of EGFR mutated nonsmall cell lung carcinoma patients.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2015 |
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2015 |
Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Publication Bias; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk | 2015 |
EGFR and NF-κB: partners in cancer.
Topics: Animals; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hyaluronoglucosaminidase; Neoplasms; NF-kappa B; Protein Kinase Inhibitors; Proteins; Quinazolines; Signal Transduction | 2015 |
Pharmacologic treatment options for advanced epithelial skin cancer.
Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Molecular Targeted Therapy; Pyridines; Quality of Life; Quinazolines; Skin Neoplasms; Treatment Outcome | 2015 |
EGFR mutations in lung cancer: from tissue testing to liquid biopsy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genotyping Techniques; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured | 2015 |
Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Docetaxel; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Sirolimus; Taxoids; TOR Serine-Threonine Kinases | 2015 |
Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2015 |
Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic | 2015 |
[Radiotherapy concomitant with first-generation epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of brain metastases from non small cell lung cancer: a meta-analysis].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2015 |
Practical Value of Molecular Pathology in Stage I-III Lung Cancer: Implications for the Clinical Surgeon.
Topics: Afatinib; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases | 2015 |
Cumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines | 2015 |
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Medical Oncology; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2015 |
Renal toxicity of anticancer agents targeting HER2 and EGFR.
Topics: Acute Kidney Injury; Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Maytansine; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Renal Dialysis; Renal Insufficiency, Chronic; Trastuzumab | 2015 |
Managing acquired resistance in EGFR-mutated non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2015 |
Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2015 |
Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2015 |
Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis.
Topics: Afatinib; Alanine Transaminase; Antineoplastic Agents; Aspartate Aminotransferases; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2016 |
Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies.
Topics: Administration, Oral; Anilides; Antineoplastic Agents; Biphenyl Compounds; Capecitabine; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Hedgehog Proteins; Molecular Targeted Therapy; Phthalazines; Podophyllotoxin; Pyridines; Quinazolines; Receptor, IGF Type 1; Retinoids; Skin Neoplasms; Tumor Burden | 2016 |
Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Smoking | 2015 |
Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Crown Ethers; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
[Tyrosine kinase inhibitors and pregnancy: A risk to the fetus?].
Topics: Abnormalities, Drug-Induced; Adult; Antineoplastic Agents; Dasatinib; Erlotinib Hydrochloride; Female; Fetus; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Maternal Age; Placenta; Pregnancy; Pregnancy Complications, Neoplastic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Risk | 2016 |
Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Quinazolines | 2016 |
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2016 |
[Current status of EGFR/ErbB inhibitors in non-small cell lung carcinoma].
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-2; Genetic Markers; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2016 |
EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Platinum Compounds; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer: A Changing Treatment Paradigm.
Topics: Acrylamides; Adenocarcinoma; Afatinib; Amino Acid Substitution; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2017 |
EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Survival Analysis; Taxoids | 2016 |
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Survival Rate | 2017 |
Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prospective Studies; Quinazolines | 2017 |
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Humans; Lung Neoplasms; Mutation; Outcome Assessment, Health Care; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2017 |
Prognostic value of early response assessment using (18F)FDG-PET in patients with advanced non-small cell lung cancer treated with tyrosine-kinase inhibitors.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Reproducibility of Results; Treatment Outcome | 2017 |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Retreatment; Sequence Deletion | 2017 |
Recent Management of Patients with Advanced Epidermal Growth Factor Receptor Mutation Non-small Cell Lung Cancer: Role of Afatinib and Lesson Learned for Developing Countries.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Developing Countries; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Indonesia; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2017 |
Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Crown Ethers; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Network Meta-Analysis; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Randomized Controlled Trials as Topic; Survival Rate | 2017 |
Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Quinazolines | 2017 |
Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2017 |
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking | 2017 |
Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2018 |
Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Comparative Effectiveness Research; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2018 |
Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non-small cell lung cancer: a meta-analysis.
Topics: Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Progression-Free Survival | 2018 |
Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Network Meta-Analysis; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Randomized Controlled Trials as Topic | 2019 |
Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer.
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Class I Phosphatidylinositol 3-Kinases; Disease Progression; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunotherapy; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-met; Quinazolinones; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1; Signal Transduction | 2019 |
Combination strategies based on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for cancer patients: Pooled analysis and subgroup analysis of efficacy and safety.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Disease-Free Survival; Drug Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Radiotherapy; Randomized Controlled Trials as Topic | 2019 |
Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quality of Life; Quinazolinones | 2019 |
[Proton pump inhibitors and cancers: A hazardous association?]
Topics: Antineoplastic Agents; Bacterial Infections; Capecitabine; Contraindications, Drug; Drug Interactions; Dysbiosis; Erlotinib Hydrochloride; Fractures, Bone; Gastrointestinal Absorption; Gastrointestinal Neoplasms; Gefitinib; Humans; Indazoles; Kidney; Neoplasms; Prognosis; Protein-Tyrosine Kinases; Proton Pump Inhibitors; Pyrimidines; Sulfonamides | 2020 |
Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review).
Topics: Acrylamides; Administration, Oral; Afatinib; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolinones; Randomized Controlled Trials as Topic | 2021 |
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Topics: Afatinib; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bias; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Pemetrexed; Progression-Free Survival; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2021 |
Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review.
Topics: Biopsy; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Drug Resistance, Neoplasm; Drug Substitution; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Progression-Free Survival; Radiotherapy, Intensity-Modulated; Response Evaluation Criteria in Solid Tumors; Salvage Therapy | 2021 |
REPORT- Clinical outcomes of using second - versus first-Generation EGFR-tkis for the First-Line treatment of advanced NSCLC patients with EGFR mutations: A meta-analysis.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Treatment Outcome | 2021 |
Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
[Radiation therapy and targeted therapies: Risks and opportunities].
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Agents; Cetuximab; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Panitumumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Radiotherapy; Receptor Protein-Tyrosine Kinases; Trastuzumab | 2022 |
The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta-Analysis.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Network Meta-Analysis; Prospective Studies; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2023 |
Survival outcomes of east Asian patients with advanced non-small cell lung cancer treated with first-line EGFR tyrosine kinase inhibitors: A network meta-analysis of real-world evidence.
Topics: Adult; Afatinib; Carcinoma, Non-Small-Cell Lung; East Asian People; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Network Meta-Analysis; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors | 2023 |
Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta-analysis of real-world survival outcomes of East Asian patients with advanced non-small cell lung cancer treated with first-line EGFR-TKIs.
Topics: Afatinib; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; East Asian People; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Network Meta-Analysis; Protein Kinase Inhibitors; Treatment Outcome; Tyrosine Kinase Inhibitors | 2023 |
62 trial(s) available for erlotinib hydrochloride and gefitinib
| Article | Year |
|---|---|
A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cost of Illness; ErbB Receptors; Erlotinib Hydrochloride; Fees, Pharmaceutical; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Compliance; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2006 |
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.
Topics: Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Clinical Trials as Topic; Cluster Analysis; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Gene Deletion; Gene Expression Regulation, Neoplastic; Genome; Glioma; Humans; Lung Neoplasms; Models, Biological; Mutation; Nucleic Acid Hybridization; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Time Factors | 2005 |
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2006 |
A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Fatigue; Female; Gefitinib; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Salvage Therapy; Survival Rate; Tegafur | 2006 |
Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2007 |
Second-line treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2008 |
Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study.
Topics: Adult; Aged; Brain Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Secondary Prevention | 2008 |
Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy | 2008 |
Erlotinib in advanced non-small-cell lung cancer after gefitinib failure.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Failure; Treatment Outcome | 2009 |
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Tomography, X-Ray Computed | 2010 |
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.
Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Treatment Outcome | 2009 |
Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Treatment Failure | 2010 |
Response to gefitinib and erlotinib in Non-small cell lung cancer: a restrospective study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; STAT3 Transcription Factor | 2009 |
Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2010 |
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Heptanoic Acids; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Protein-Tyrosine Kinases; Pyrazoles; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-4; Signal Transduction; Treatment Outcome | 2011 |
[Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pemetrexed; Platinum; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Salvage Therapy; Taxoids; Treatment Failure | 2010 |
Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Heart Neoplasms; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Thiazoles; Treatment Outcome | 2011 |
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Quinazolines | 2012 |
XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Azabicyclo Compounds; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2012 |
Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2012 |
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
[Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Stomatitis; Treatment Outcome | 2012 |
Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Point Mutation; Quinazolines; Sequence Deletion; Treatment Outcome | 2012 |
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Chromatography, High Pressure Liquid; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Quinazolines; Tandem Mass Spectrometry; Treatment Outcome | 2012 |
Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatigue; Female; Gefitinib; Glutamates; Guanine; Humans; Infections; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2013 |
Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).
Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cough; Double-Blind Method; Dyspnea; Erlotinib Hydrochloride; Fatigue; Female; Follow-Up Studies; Gefitinib; Humans; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pain; Prognosis; Quality of Life; Quinazolines; Salvage Therapy | 2013 |
LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2013 |
Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome | 2014 |
[Prospective study of biotin treatment in patients with erythema due to gefitinib or erlotinib].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biotin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Erythema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2014 |
[Association between GNAS1 T393C polymorphism and therapeutic efficacy of tyrosine kinase inhibitor in pretreated advanced non-small cell lung cancer with unknown EGFR mutation status].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chromogranins; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; GTP-Binding Protein alpha Subunits, Gs; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Asia, Southeastern; Carcinoma, Non-Small-Cell Lung; Cooking; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Inhalation Exposure; Life Style; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Surveys and Questionnaires | 2014 |
Prospective assessment of pemetrexed or pemetrexed plus platinum in combination with gefitinib or erlotinib in patients with acquired resistance to gefitinib or erlotinib: a phase II exploratory and preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome | 2015 |
Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins; Republic of Korea; Treatment Outcome | 2014 |
[Gefitinib versus Erlotinib as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2015 |
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Biopsy; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Male; Middle Aged; Mutation; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines | 2016 |
Epidermal growth factor receptor-inhibition (EGFR-I) in the treatment of neuropathic pain.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Antibodies, Monoclonal; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Neuralgia; Pain Measurement; Panitumumab; Prospective Studies; Quinazolines; Recurrence; Young Adult | 2015 |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2016 |
A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib.
Topics: Adult; Afatinib; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents | 2016 |
Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Case-Control Studies; Contrast Media; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate; Tomography, Spiral Computed; Tumor Burden; Young Adult | 2016 |
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Proto-Oncogene Proteins c-met; Quinazolines; Treatment Outcome | 2016 |
Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cluster Analysis; Disease-Free Survival; DNA; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2016 |
Study of efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced non-small cell lung cancer patients with secondary drug resistance: A single center, single arm, phase II clinical trial.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Prognosis; Quinazolines; Treatment Outcome | 2016 |
Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2016 |
A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Survival Analysis; Treatment Outcome | 2017 |
Circulating Tumor Cells Predict Prognosis Following Tyrosine Kinase Inhibitor Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Patients.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2017 |
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cohort Studies; Diarrhea; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2017 |
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2018 |
Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Gefitinib; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2018 |
Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Mutation; Prognosis; United States | 2018 |
Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Survival Rate | 2019 |
Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Dose Fractionation, Radiation; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Gefitinib; Glucocorticoids; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pneumonia; Progression-Free Survival; Protein Kinase Inhibitors; Radiation Injuries | 2019 |
A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Survival Rate | 2019 |
Overall Survival with Osimertinib in Untreated,
Topics: Acrylamides; Aged; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors | 2020 |
Clinical study of apatinib combined with EGFR-TKI in the treatment of chronic progression after EGFR-TKI treatment in non-small cell lung cancer (ChiCTR1800019185).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Prospective Studies; Pyridines; Quinazolines; Research Design; Young Adult | 2020 |
Treatment of Patients With Non-small-cell Lung Cancer With Uncommon
Topics: Acrylamides; Adult; Afatinib; Aged; Aged, 80 and over; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors | 2020 |
Influence of esomeprazole on the bioavailability of afatinib: A pharmacokinetic cross-over study in patients with non-small cell lung cancer.
Topics: Afatinib; Biological Availability; Carcinoma, Non-Small-Cell Lung; Cross-Over Studies; ErbB Receptors; Erlotinib Hydrochloride; Esomeprazole; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proton Pump Inhibitors | 2022 |
Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS).
Topics: Adenocarcinoma of Lung; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2023 |
650 other study(ies) available for erlotinib hydrochloride and gefitinib
| Article | Year |
|---|---|
Cancer drugs. Smart weapons prove tough to design.
Topics: Advisory Committees; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; Drug Industry; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasms; Patient Selection; Piperazines; Pyrimidines; Quinazolines; United States; United States Food and Drug Administration | 2002 |
Lung cancer: looking ahead in 2004.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
EGFR inhibitors square off at ASCO.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Industry; Economic Competition; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Panitumumab; Quinazolines | 2004 |
Early-stage lung cancer findings end a debate, put focus on next steps.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Canada; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemotherapy, Adjuvant; Cisplatin; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Patient Selection; Quinazolines; Randomized Controlled Trials as Topic; Selection Bias; Survival Analysis; Treatment Outcome; United States; Vinblastine; Vinorelbine | 2004 |
Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mitogen-Activated Protein Kinases; Phosphorylation; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
Topics: Adenocarcinoma; Amino Acid Sequence; Base Sequence; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Quinazolines | 2004 |
Research unveils the 'who' and 'why' of gefitinib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Mutation; Piperazines; Pyrimidines; Quinazolines; Trastuzumab | 2004 |
Combining targeted agents in lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sirolimus | 2004 |
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Dinucleotide Repeats; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Silencing; Genes, erbB-1; Genetic Predisposition to Disease; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Introns; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; RNA, Small Interfering; Skin | 2004 |
EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells.
Topics: Adenosine Triphosphate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Calcium; Calcium Signaling; Carcinoma, Squamous Cell; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Protein Kinase Inhibitors; Quinazolines; Receptors, Purinergic; Tumor Cells, Cultured | 2004 |
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Decision Making; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2005 |
Failing survival advantage in crucial trial, future of Iressa is in jeopardy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Survival Analysis; Treatment Failure; United States; United States Food and Drug Administration | 2005 |
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
Topics: Aged; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Models, Structural; Molecular Structure; Neoplasm Recurrence, Local; Point Mutation; Quinazolines; RNA, Neoplasm; Sequence Analysis, DNA; Sequence Analysis, RNA | 2005 |
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Point Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2005 |
FDA Oncology Committee debates Iressa's status following negative trial results.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Treatment Failure; United States; United States Food and Drug Administration | 2005 |
Will lung cancer targeting hit its mark?
Topics: Antineoplastic Agents; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.
Topics: Aminoquinolines; Aniline Compounds; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplasm Recurrence, Local; Organic Chemicals; Phosphorylation; Quinazolines; Quinolines; Receptor, ErbB-2; Sequence Analysis, DNA; Signal Transduction; Tumor Cells, Cultured | 2005 |
Overcoming acquired resistance to Iressa/Tarceva with inhibitors of a different class.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catalysis; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering | 2005 |
New studies look beyond EGFR mutations for clues to sensitivity to erlotinib.
Topics: Animals; Canada; Cell Cycle Proteins; Clinical Trials as Topic; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Multicenter Studies as Topic; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Retrospective Studies | 2005 |
Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Dinoprostone; Disease Progression; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Taxoids; Treatment Outcome | 2005 |
BiDil raises questions about race as a marker.
Topics: Biomarkers; Black People; Clinical Trials as Topic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Drug Approval; Drug Combinations; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Heart Failure; Humans; Hydralazine; Isosorbide; Middle Aged; Mutation; National Institutes of Health (U.S.); Polymorphism, Genetic; Quinazolines; Risk Factors; Socioeconomic Factors; Treatment Outcome; United States; Uracil; White People | 2005 |
Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2005 |
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Genetic Therapy; Humans; Mice; Mice, Nude; Mutation; Neoplasms, Experimental; NIH 3T3 Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Shc Signaling Adaptor Proteins; Src Homology 2 Domain-Containing, Transforming Protein 1; STAT3 Transcription Factor; Transfection; Tumor Stem Cell Assay | 2005 |
Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines; Sensitivity and Specificity; Stomach Neoplasms | 2005 |
[Cutaneous side effects of EGF-receptor inhibition and their management].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Statistics as Topic | 2006 |
Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy | 2005 |
Erlotinib in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2005 |
Epidermal growth factor receptor inhibitors: a moving target?
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mutation; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
New approaches in the management of lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins; Quinazolines | 2005 |
Glioblastoma multiforme and the epidermal growth factor receptor.
Topics: Amino Acid Sequence; Base Sequence; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Deletion; Gene Expression; Glioblastoma; Humans; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines | 2005 |
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Amplification; Gene Deletion; Gene Expression; Genes, erbB-1; Genes, erbB-2; Glioblastoma; Humans; Male; Middle Aged; Mutation; Oligodendroglioma; Polymerase Chain Reaction; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Sequence Analysis, DNA; Signal Transduction | 2005 |
Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important?
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Pancreatic Neoplasms; Quinazolines | 2005 |
Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Quinazolines | 2005 |
Targeted kinase inhibitors in lung cancer: from EGFR to patients.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2006 |
Re: Cetuximab therapy and symptomatic hypomagnesemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Magnesium; Magnesium Deficiency; Protein-Tyrosine Kinases; Quinazolines | 2005 |
Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2005 |
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Meningeal Neoplasms; Mutation; Quinazolines; Ribs; Treatment Failure | 2006 |
Hitting the target: measuring EGFR response to tyrosine kinase inhibitors.
Topics: Colon; Colorectal Neoplasms; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Image Processing, Computer-Assisted; Immunoblotting; Immunohistochemistry; Protein Kinase Inhibitors; Quinazolines | 2005 |
[Current status and prospect of neoplasm targeted therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Drug Delivery Systems; Drug Design; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Immunologic Factors; Neoplasms; Palliative Care; Piperazines; Pyrimidines; Quinazolines; Signal Transduction | 2005 |
[Advances in the molecular target therapy in lung cancer].
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Pyrimidines; Quinazolines | 2005 |
Gefitinib for refractory advanced non-small-cell lung cancer.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Smoking | 2006 |
Response of glioblastomas to EGFR kinase inhibitors.
Topics: ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Deletion; Glioblastoma; Humans; Phosphorylation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Signal Transduction | 2006 |
[Acneiform eruption from epidermal growth factor receptor inhibitors].
Topics: Acneiform Eruptions; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Quinazolines | 2005 |
Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.
Topics: Aged; Bronchi; Cell Adhesion; Cell Growth Processes; Cell Transformation, Neoplastic; Dual Specificity Phosphatase 6; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Genes, p16; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Oncogenes; Phosphorylation; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; STAT3 Transcription Factor; Telomerase; Transfection; Up-Regulation | 2006 |
C-fos assessment as a marker of anti-epidermal growth factor receptor effect.
Topics: Animals; Biomarkers, Tumor; Cell Growth Processes; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, fos; Humans; Mice; Mice, Nude; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fos; Quinazolines; RNA, Messenger; Xenograft Model Antitumor Assays | 2006 |
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.
Topics: Adenocarcinoma; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genes, erbB-1; Humans; Incidence; Lung Neoplasms; Male; Molecular Biology; Mutation; Protein Kinase Inhibitors; Quinazolines; ROC Curve; Smoking | 2006 |
[Mutations in the epidermal growth factor receptor and targeted therapy of non-small-cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2005 |
EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms.
Topics: Binding Sites; Carcinoma, Squamous Cell; Cell Line, Tumor; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines; Sp1 Transcription Factor; Vascular Endothelial Growth Factor A | 2006 |
EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2006 |
Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2006 |
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Line; Cyclin-Dependent Kinase Inhibitor p16; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Knockout; Mutation; Protein Isoforms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Tumor Suppressor Protein p14ARF | 2006 |
Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Protein Kinase Inhibitors; Quinazolines; Radiography, Thoracic; Tomography, X-Ray Computed; X-Ray Film | 2006 |
Is there a role for the irreversible epidermal growth factor receptor inhibitor EKB-569 in the treatment of cancer? A mutation-driven question.
Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Neoplasms; Organic Chemicals; Protein Kinase Inhibitors; Quinazolines | 2006 |
[From ASCO and WCLC 2005 to the clinical practice: targeted therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Forecasting; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Patient Selection; Placebos; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Sex Factors; Smoking; Time Factors; Vascular Endothelial Growth Factor A | 2006 |
Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Incidence; Japan; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines; Risk Factors | 2006 |
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Point Mutation; Quinazolines; Retrospective Studies; Sequence Deletion; Survival Rate; Treatment Outcome | 2006 |
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mice; Mice, Nude; Models, Biological; Morpholines; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Transforming Growth Factor alpha; Trastuzumab; Xenograft Model Antitumor Assays | 2006 |
Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
Topics: Animals; Antineoplastic Agents; Biliary Tract Neoplasms; Cell Division; Cell Line, Tumor; Cholangiocarcinoma; DNA, Complementary; DNA, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoblotting; Immunohistochemistry; In Situ Hybridization, Fluorescence; Mice; Mice, Nude; Purines; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
Cross-over response to erlotinib of brain metastatic disease from bronchial adenocarcinoma after gefitinib failure, and an unusual rash.
Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Bronchial Neoplasms; Drug Hypersensitivity; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Middle Aged; Quinazolines; Skin Diseases, Vesiculobullous | 2006 |
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2007 |
[Treatment of acneiform rash by epidermal growth factor inhibitors with oral tetracyclines].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents; Doxycycline; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2006 |
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
Topics: Adenocarcinoma; Amino Acid Sequence; Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Humans; In Situ Hybridization; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Should every lung cancer patient be tested for EGFR mutation?
Topics: Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Patient Selection; Pharmacogenetics; Quinazolines | 2006 |
Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclin D; Cyclin-Dependent Kinases; Cyclins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flavonoids; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutant Proteins; Mutation, Missense; Oligonucleotide Array Sequence Analysis; Piperidines; Quinazolines; Signal Transduction; Transcription, Genetic; Transfection | 2006 |
[Associations of tyrosine kinase inhibitors with chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2007 |
Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2007 |
New insights into oncogene addiction found.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Benzamides; Cyclin D1; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, bcl-1; Humans; Imatinib Mesylate; Mutation; Neoplasms; Oncogenes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Signal Transduction; Trastuzumab | 2007 |
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.
Topics: Adult; Amino Acid Substitution; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Neoplasm Proteins; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Clairvoyance or reliable prediction of the future?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Patient Selection; Prognosis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Treatment Outcome | 2007 |
Lung cancer: not just for smokers. People who never smoked may have a different form of the disease that responds better to a new generation of targeted medications.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Pyrimidines; Quinazolines; Tobacco Smoke Pollution | 2007 |
[Lung cancer: targeted therapy].
Topics: Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Therapy; Humans; Lung Neoplasms; Models, Biological; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biliary Tract Neoplasms; Biomarkers, Tumor; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2007 |
Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells.
Topics: Antibiotics, Antineoplastic; Benzamides; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinases; Carcinoma, Renal Cell; Cell Cycle; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Kidney Neoplasms; Mitogen-Activated Protein Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2007 |
Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2006 |
Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature.
Topics: Adult; Aged; Base Sequence; Cluster Analysis; Databases, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutagenesis, Insertional; Neoplasms; Protein Kinase Inhibitors; Protein Structure, Secondary; Quinazolines; Sequence Deletion; Smoking | 2007 |
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2007 |
To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azabicyclo Compounds; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Mice, SCID; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2007 |
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.
Topics: Anesthetics, Intravenous; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Gefitinib; Humans; Microsomes, Liver; Midazolam; Protein Kinase Inhibitors; Quinazolines; Recombinant Proteins | 2007 |
Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Adjuvant chemotherapy of stage I non-small cell lung cancer in North America.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Quinazolines | 2007 |
Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer.
Topics: Adult; Amino Acid Sequence; Base Sequence; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Tomography, X-Ray Computed | 2007 |
[Role of targeted therapy in the treatment of squamous cell head and neck cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant | 2007 |
Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature.
Topics: Acneiform Eruptions; Adenocarcinoma, Bronchiolo-Alveolar; Aged, 80 and over; Antineoplastic Agents; Blepharitis; Carcinoma, Small Cell; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Gefitinib; Humans; Hypertrichosis; Lung Neoplasms; Middle Aged; Quinazolines; Retrospective Studies | 2007 |
Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2007 |
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Tomography, X-Ray Computed | 2007 |
Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer.
Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2007 |
Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Division; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Prostaglandins E; Pyrazoles; Quinazolines; Sulfonamides; Tumor Cells, Cultured | 2007 |
Improved synthesis of substituted 6,7-dihydroxy-4-quinazolineamines: tandutinib, erlotinib and gefitinib.
Topics: Chromatography, High Pressure Liquid; Erlotinib Hydrochloride; Gefitinib; Magnetic Resonance Spectroscopy; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2006 |
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Estradiol; Gefitinib; Humans; Methotrexate; Mitoxantrone; Neoplasm Proteins; Neoplasms; Paclitaxel; Protein Binding; Quinazolines | 2007 |
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Chromosomes, Human, Pair 7; Cohort Studies; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Quinazolines | 2007 |
Response of intracranial metastases to epidermal growth factor receptor tyrosine kinase inhibitors: it may all depend on EGFR mutations.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Sequence Deletion | 2008 |
Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Genotype; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Quinazolines; Treatment Outcome | 2008 |
Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Genes, erbB-1; Genes, ras; Humans; In Situ Hybridization; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2008 |
Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
Epidermal growth factor receptor inhibitors and hair.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hair; Humans; Neoplasms; Quinazolines | 2008 |
Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2008 |
Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.
Topics: Adenocarcinoma; Aged; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Tomography Scanners, X-Ray Computed; Treatment Failure | 2008 |
Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cetuximab; Enzyme Activation; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Insulin-Like Growth Factor II; Liver Neoplasms; Mesoderm; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, IGF Type 1; STAT3 Transcription Factor; Vimentin | 2008 |
Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors.
Topics: Actins; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Endoplasmic Reticulum; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazoles; Quinazolines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides | 2008 |
The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cells, Cultured; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Mice; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Quinolines | 2008 |
EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-alpha-induced pulmonary fibrosis.
Topics: Animals; Bronchoalveolar Lavage Fluid; Doxycycline; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; Mice; Pulmonary Fibrosis; Quinazolines; RNA, Messenger; Transforming Growth Factor alpha | 2008 |
Response of malignant thymoma to erlotinib.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Epidermal Growth Factor; Erlotinib Hydrochloride; Fatal Outcome; Gefitinib; Humans; Immunohistochemistry; Protein Kinase Inhibitors; Quinazolines; Thymoma | 2008 |
Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma.
Topics: Aged; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; DNA, Neoplasm; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Parotid Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Biochemical assay-based selectivity profiling of clinically relevant kinase inhibitors on mutant forms of EGF receptor.
Topics: Aminoquinolines; Aniline Compounds; Biological Assay; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Inhibitory Concentration 50; Morpholines; Mutant Proteins; Protein Kinase Inhibitors; Quinazolines; Substrate Specificity; Tyrphostins | 2008 |
Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Cell Differentiation; Cell Line, Tumor; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines | 2008 |
Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database.
Topics: Carcinoma, Non-Small-Cell Lung; Databases, Factual; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2008 |
Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Promising newer molecular-targeted therapies in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Models, Biological; Niacinamide; Panitumumab; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2008 |
Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3.
Topics: Aged; Animals; Apoptosis; bcl-X Protein; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunoprecipitation; Inositol 1,4,5-Trisphosphate Receptors; Lung Neoplasms; Male; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Middle Aged; Mitochondria; Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Radiopharmaceuticals; Signal Transduction; Technetium Tc 99m Sestamibi | 2008 |
Lung cancer response to gefitinib, then erlotinib, then gefitinib again.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiography; Treatment Outcome | 2008 |
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
The role of targeted agents in the treatment of elderly patients with non-small cell lung cancer (NSCLC).
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2008 |
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Afatinib; Aged; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Protein Kinase Inhibitors; Protein Structure, Quaternary; Quinazolines; Sequence Alignment | 2008 |
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2009 |
Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Risk Factors; Smoking | 2009 |
Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors.
Topics: Aged; Animals; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Glioma; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Microfilament Proteins; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplastic Stem Cells; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Tensins; Time Factors; Tumor Cells, Cultured | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptor Protein-Tyrosine Kinases; Remission Induction; Smoking | 2009 |
Drosophila-based in vivo assay for the validation of inhibitors of the epidermal growth factor receptor/Ras pathway.
Topics: Animals; Antineoplastic Agents; Biological Assay; Catalytic Domain; Computer Simulation; Drosophila melanogaster; ErbB Receptors; Erlotinib Hydrochloride; Eye; Gefitinib; Gene Expression Regulation; Models, Molecular; Protein Conformation; Protein Structure, Tertiary; Quinazolines; ras Proteins; Wings, Animal | 2008 |
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Quinazolines; Recurrence; Treatment Outcome | 2009 |
Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Mice; Mice, Nude; Models, Biological; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Radiation Dosage; Tumor Cells, Cultured | 2009 |
New chemotherapy strategies and biological agents in the treatment of childhood ependymoma.
Topics: Adolescent; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Child; Child, Preschool; Ependymoma; Erlotinib Hydrochloride; Gefitinib; Humans; Infant; Quinazolines; Treatment Outcome; Young Adult | 2009 |
Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Quinazolines; Retrospective Studies; Treatment Outcome | 2009 |
Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Salvage Therapy | 2009 |
Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Folic Acid; Gefitinib; Genotype; Humans; Neoplasm Proteins; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines | 2009 |
Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Dinoprostone; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genistein; Humans; Lung Neoplasms; NF-kappa B; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines | 2009 |
Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2009 |
Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; China; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Survival Analysis | 2009 |
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; NIH 3T3 Cells; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Transfection; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2009 |
Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.
Topics: Adenosine Triphosphatases; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Multiple; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2010 |
Role of tyrosine kinase inhibitors in lung cancer.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2009 |
Outpacing cancer.
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Mutation; Piperazines; Pyrimidines; Quinazolines | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors and depression.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Depression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2009 |
Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells.
Topics: Antineoplastic Agents; Biosensing Techniques; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2009 |
Quantitative prediction of fold resistance for inhibitors of EGFR.
Topics: Animals; Cell Line, Tumor; Computer Simulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Models, Molecular; Quinazolines | 2009 |
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Genotype; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor Protein-Tyrosine Kinases; Sex Factors; Treatment Outcome | 2009 |
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Databases, Factual; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Online Systems; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Registries | 2009 |
Personalized medicine and inhibition of EGFR signaling in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2009 |
[Comparative evaluation of adverse reactions between gefitinib and erlotinib treatments in the same patients].
Topics: Aged; Anorexia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Spinal Cord Neoplasms; Treatment Outcome | 2009 |
Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sex Factors; Smoking | 2009 |
Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Black or African American; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Genetic Predisposition to Disease; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Staging; Probability; Quinazolines; ras Proteins; Risk Assessment; White People | 2009 |
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Base Sequence; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2009 |
The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2009 |
Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.
Topics: Adolescent; Adult; Aged; Area Under Curve; Bilirubin; Binding, Competitive; Biocatalysis; Cell Line; Child; Drug Interactions; Erlotinib Hydrochloride; Female; Gefitinib; Glucuronic Acid; Glucuronosyltransferase; Humans; Hymecromone; Imipramine; Indinavir; Isoenzymes; Kinetics; Male; Microsomes, Liver; Middle Aged; Models, Biological; Protein Kinase Inhibitors; Quinazolines; Recombinant Proteins; Young Adult | 2010 |
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Imidazoles; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Quinolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2009 |
Role of epidermal growth factor inhibition in experimental pulmonary hypertension.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; Hypertension, Pulmonary; Lapatinib; Male; Mice; Muscle, Smooth, Vascular; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pulmonary Wedge Pressure; Quinazolines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Vascular Resistance | 2010 |
Simultaneous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry.
Topics: Analytic Sample Preparation Methods; Benzamides; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Microchemistry; Piperazines; Pyrimidines; Quinazolines; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2009 |
Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2010 |
Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Molecular Conformation; Neoplasm Transplantation; Pyrrolidines; Quinazolines; Rats; Receptor, ErbB-2; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous | 2009 |
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Guidelines as Topic; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2010 |
Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors.
Topics: Animals; Breast Neoplasms; Drug Discovery; Drug Industry; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Technology, Pharmaceutical | 2009 |
[Cutaneous side effects of EGF receptor inhibitors].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Folliculitis; Gefitinib; Humans; Nail Diseases; Panitumumab; Quinazolines; Skin | 2009 |
Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease.
Topics: Adenocarcinoma; Adult; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Incidence; Korea; Male; Protein Kinase Inhibitors; Quinazolines | 2010 |
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mass Spectrometry; Mutation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2010 |
Histology matters: individualizing treatment in non-small cell lung cancer.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; SEER Program | 2010 |
Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Incidence; Japan; Logistic Models; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Factors | 2010 |
Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Mutation; Quinazolines; Treatment Outcome | 2010 |
[Two cases of non-small cell lung cancer which developed central nervous system metastases during gefitinib treatment, improving after changing to erlotinib treatment].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2010 |
De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate | 2010 |
Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Osteoblasts; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromans; Culture Media, Serum-Free; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Mammary Neoplasms, Animal; Mice; Quinazolines; Signal Transduction; Trastuzumab; Vitamin E | 2010 |
Combined gamma-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Proliferation; Chromans; Erlotinib Hydrochloride; Female; Gefitinib; Mammary Neoplasms, Animal; Mice; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT Transcription Factors; Vitamin E | 2010 |
[Maintenance treatment of non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2010 |
Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Quinazolines | 2010 |
Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2010 |
Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2010 |
The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy | 2011 |
[Satisfactory outcome with erlotinib after failure with gefitinib in a patient with meningeal carcinomatosis secondary to non-small cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2010 |
Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Recurrence; Retreatment; Retrospective Studies; Treatment Failure | 2010 |
Denaturing capillary electrophoresis for automated detection of L858R mutation in exon 21 of the epidermal growth factor receptor gene in prediction of the outcome of lung cancer therapy.
Topics: Adenocarcinoma; Automation; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Electrophoresis, Capillary; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Nucleic Acid Denaturation; Pharmacogenetics; Point Mutation; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Treatment Outcome | 2010 |
Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Quinazolines; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Quinazolines; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases.
Topics: Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2011 |
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2011 |
[Safety analysis of eight patients treated with erlotinib after severe gefitinib-induced liver injury].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Enzyme Inhibitors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Structure; Quinazolines | 2010 |
[Application of epidermal growth factor receptor tyrosine kinase inhibitor as the first-line therapy in patients with advanced non-small cell lung cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Quinazolines; Retrospective Studies; Young Adult | 2010 |
Targeted therapy at the end of life for patients with lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Delivery Systems; Drug Utilization; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Patient Selection; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Singapore; Sirolimus; Terminal Care; Time Factors; Treatment Outcome | 2010 |
TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer.
Topics: Animals; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Lung Neoplasms; Mesoderm; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transforming Growth Factor beta | 2010 |
Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; EGF Family of Proteins; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2011 |
Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity.
Topics: Aged, 80 and over; Aspartate Aminotransferases; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Gefitinib; Green Fluorescent Proteins; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Monitoring, Physiologic; Neoplasm Metastasis; Quinazolines; Recurrence | 2010 |
Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Survival Analysis | 2011 |
Supersensitive mutation: two case reports of non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2010 |
[Feasibility of erlotinib after gefitinib failure in patients with advanced pulmonary adenocarcinoma previously responding to gefitinib].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Tolerance; Erlotinib Hydrochloride; Feasibility Studies; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Treatment Outcome | 2010 |
[Re-treatment with epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)for lung adenocarcinoma].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2010 |
Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Nucleus; Cell Proliferation; Drug Resistance, Neoplasm; Early Growth Response Protein 1; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; PTEN Phosphohydrolase; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured | 2010 |
Predictive biomarkers in the management of EGFR mutant lung cancer.
Topics: Adenocarcinoma; Aged; Apoptosis; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genetic Therapy; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; White People | 2010 |
ILD during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Prognosis; Quinazolines | 2010 |
Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2010 |
New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Research Design; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Different efficacies of erlotinib and gefitinib in taiwanese patients with advanced non-small cell lung cancer: a retrospective multicenter study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Taiwan | 2011 |
A novel hybrid peptide targeting EGFR-expressing cancers.
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mice; Mutant Chimeric Proteins; Neoplasm Transplantation; Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Transplantation, Heterologous | 2011 |
Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine responses.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; Cells, Cultured; Cytokines; Enzyme Activation; Erlotinib Hydrochloride; Gefitinib; Gene Knockout Techniques; HEK293 Cells; HT29 Cells; Humans; Mice; Nod2 Signaling Adaptor Protein; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor-Interacting Protein Serine-Threonine Kinase 2; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination | 2010 |
Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Drugs, Chinese Herbal; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Medicine, Chinese Traditional; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Organoplatinum Compounds; Outpatients; Paclitaxel; Platinum Compounds; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Lung cancer: recent advances.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Global Health; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma | 2010 |
Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Acinar Cell; Cell Line, Tumor; Cell Movement; Cell Shape; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Gene Expression Profiling; Humans; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Quinazolines; Sequence Deletion | 2011 |
Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retreatment; Retrospective Studies; Treatment Outcome | 2011 |
Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Topics: Animals; Apoptosis; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Furans; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, SCID; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2011 |
The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors.
Topics: Animals; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Kidney; Mice; Mutation; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Quinazolines | 2011 |
Effectiveness of erlotinib against recurrent pulmonary adenocarcinoma unresponsive to gefitinib: report of a case.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Quinazolines | 2011 |
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lapatinib; Lung Neoplasms; Membrane Potential, Mitochondrial; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Tumor Cells, Cultured; Vorinostat | 2011 |
Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Proportional Hazards Models; Quinazolines; Retrospective Studies; Time Factors; Treatment Failure | 2011 |
Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Drug Substitution; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Quinazolines | 2011 |
Is FISH floating or still swimming in the lung cancer ocean?
Topics: Antineoplastic Agents; Biomarkers, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Meta-Analysis as Topic; Molecular Diagnostic Techniques; Mutation; Quinazolines; Small Cell Lung Carcinoma; Treatment Outcome | 2011 |
Screening for EGFR mutations in lung cancer, a report from India.
Topics: Age Factors; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; India; Lung Neoplasms; Middle Aged; Mutation, Missense; Polymorphism, Single Nucleotide; Prevalence; Quinazolines; Sequence Deletion; Sex Factors | 2011 |
Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Quinazolines; Radiation Injuries; Radiotherapy Dosage; Tumor Burden | 2011 |
Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors.
Topics: Adult; Aged; Animals; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Male; Middle Aged; Mite Infestations; Mites; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Rosacea; Skin | 2011 |
NSCLC drug targets acquire new visibility.
Topics: Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Tetrahydronaphthalenes; Treatment Outcome | 2011 |
Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2011 |
Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Dosage Calculations; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Liver Function Tests; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Population Groups; Quinazolines; Retrospective Studies; Skin Diseases; Treatment Failure | 2011 |
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines | 2011 |
Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry | 2011 |
"Un-slugging" resistance to epidermal growth factor receptor inhibition. A positive outlook for the future of lung cancer therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Snail Family Transcription Factors; Transcription Factors | 2011 |
EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells.
Topics: Cell Line, Tumor; Cytotoxicity, Immunologic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Intercellular Signaling Peptides and Proteins; Intracellular Signaling Peptides and Proteins; Killer Cells, Natural; Lung Neoplasms; Protein Kinase C; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Transcription Factor AP-2 | 2011 |
Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Liver; Lung Neoplasms; Mutation; Quinazolines; Transaminases; Treatment Outcome | 2011 |
Tyrosine kinase inhibitors and epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer: to test or not to test?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Genetic Testing; Humans; Lung Neoplasms; Mutation; Pharmacogenetics; Protein-Tyrosine Kinases; Quinazolines; Taiwan; Treatment Outcome | 2011 |
Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Genes, erbB-1; Humans; Insurance Benefits; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Patient Selection; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Failure | 2011 |
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion | 2011 |
[Factors affecting the sensitivity of EGFR-TKI treatment in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking | 2011 |
Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib.
Topics: Blood-Brain Barrier; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Quinazolines | 2012 |
Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
Topics: Adenocarcinoma; Biomarkers, Tumor; Blotting, Western; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Proliferation; DNA, Neoplasm; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mutation; Oligonucleotide Array Sequence Analysis; Protein Array Analysis; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Tumor Cells, Cultured | 2011 |
EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.
Topics: Autophagy; Autophagy-Related Protein 5; Autophagy-Related Protein 7; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Lysosomes; Microscopy, Confocal; Microscopy, Electron; Microtubule-Associated Proteins; Phagosomes; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Ribosomal Protein S6 Kinases, 70-kDa; RNA Interference; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Ubiquitin-Activating Enzymes | 2011 |
Erlotinib or gefitinib for non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Erlotinib or gefitinib for non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Myocardial Ischemia; Protein Kinase Inhibitors; Quinazolines; Stroke | 2011 |
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Quinazolines; RNA | 2012 |
Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Treatment Outcome | 2011 |
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Evolution, Molecular; Female; Gefitinib; Genes, erbB-1; Humans; Mice; Mice, Nude; Models, Theoretical; Mutation; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines | 2011 |
A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Spectrophotometry, Ultraviolet | 2011 |
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Xenograft Model Antitumor Assays | 2011 |
The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mutation; Quinazolines; Xenograft Model Antitumor Assays | 2012 |
[Inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase: similarity and differences].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Odds Ratio; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2011 |
[Management of patients with resistance to EGFR-TKI].
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Survival Analysis; Treatment Outcome | 2011 |
Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Quinazolines | 2012 |
Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications.
Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Morpholines; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Recurrence | 2011 |
Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Review Literature as Topic; Treatment Outcome | 2011 |
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Time Factors; Withholding Treatment | 2011 |
EGFR mutant lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Quinolines | 2012 |
[Value of serum carcinoembryonic antigen in prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor].
Topics: Aged; Antineoplastic Agents; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate | 2011 |
Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
Topics: Animals; Antibiotics, Antineoplastic; Brain; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioblastoma; Humans; Immunoblotting; Mice; Mice, Nude; Mice, SCID; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor Cross-Talk; Receptors, Urokinase Plasminogen Activator; RNA Interference; STAT5 Transcription Factor; Transplantation, Heterologous; Tyrosine | 2011 |
Successful pregnancy with epidermal growth factor receptor tyrosine kinase inhibitor treatment of metastatic lung adenocarcinoma presenting with respiratory failure.
Topics: Adenocarcinoma; Adult; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Lymphangitis; Lymphatic Metastasis; Neoplasm Staging; Pleural Effusion, Malignant; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, Third; Quinazolines; Remission Induction; Respiratory Insufficiency; Sequence Deletion; Term Birth | 2011 |
A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Case-Control Studies; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2011 |
Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993).
Topics: Algorithms; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Male; Middle Aged; Mometasone Furoate; Neoplasms; Pregnadienediols; Protein Kinase Inhibitors; Protein Synthesis Inhibitors; Quinazolines; Radiodermatitis; Randomized Controlled Trials as Topic; Severity of Illness Index; Sunscreening Agents; Surveys and Questionnaires; Terminology as Topic; Tetracycline | 2012 |
Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction.
Topics: Blotting, Western; Chromatin Immunoprecipitation; Colonic Neoplasms; Cytotoxicity, Immunologic; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; GPI-Linked Proteins; Humans; Intracellular Signaling Peptides and Proteins; Killer Cells, Natural; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Up-Regulation | 2012 |
EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
Topics: Breast Neoplasms; Butadienes; Cell Line, Tumor; Chromones; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression; Gene Expression Profiling; Humans; Imidazoles; MAP Kinase Kinase 1; Morpholines; Nitriles; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; RNA, Messenger; Signal Transduction; Tyrphostins; Up-Regulation | 2012 |
EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis.
Topics: Adenoviridae; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Therapy; Genetic Vectors; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Recombinant Proteins; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Heparitin Sulfate; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Failure | 2011 |
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ki-67 Antigen; Lapatinib; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoadjuvant Therapy; Nitriles; Predictive Value of Tests; Preoperative Period; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Hepatocyte Growth Factor; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2011 |
Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2011 |
Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Mass Spectrometry; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Proteomics; Quinazolines; Signal Transduction | 2012 |
EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Cell Cycle Proteins; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Microtubule-Associated Proteins; Middle Aged; Multivariate Analysis; Mutation Rate; Oncogene Proteins, Fusion; Pleural Effusion, Malignant; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases; Smoking; Translocation, Genetic | 2012 |
Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2012 |
Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genetic Association Studies; Haplotypes; Humans; Male; Middle Aged; Neoplasms; Panitumumab; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines | 2013 |
Overexpressed HER2 in NSCLC is a possible therapeutic target of EGFR inhibitors.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Mice; Mutation; Neoplasm Transplantation; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2011 |
Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer.
Topics: Adult; Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Treatment Outcome | 2011 |
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Feedback, Physiological; Female; Gefitinib; HEK293 Cells; Humans; Indoles; Melanoma; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; RNA Interference; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays | 2012 |
Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Brain Neoplasms; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression; Glioma; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Survival Rate; Tumor Cells, Cultured; Young Adult | 2012 |
Erlotinib after failure of gefitinib treatment of more than 6 months in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines | 2012 |
Effectiveness of erlotinib in advanced non-small cell lung cancer in cases of gefitinib resistance after treatment of more than 6 months.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
Successful treatment of non-small cell lung cancer with gefitinib after severe erlotinib-related hepatotoxicity.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Methionine; Mice; Mice, Nude; Mice, SCID; Molecular Conformation; Mutation; Neoplasm Transplantation; Pyrimidines; Quinazolines; Structure-Activity Relationship; Threonine; Transplantation, Heterologous | 2012 |
Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Benzimidazoles; Cell Line; Cetuximab; Chromones; Dose-Response Relationship, Drug; Drug Resistance, Multiple; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Morpholines; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Signal Transduction; Tyrphostins | 2012 |
Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Budgets; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Models, Economic; Pemetrexed; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Thailand; Treatment Outcome | 2012 |
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cetuximab; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Phenotype; Protein Kinase Inhibitors; Quinazolines; RNA Interference; RNA, Small Interfering; Transfection | 2012 |
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome | 2012 |
Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2012 |
[Mutation testing for non-small-cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Point Mutation; Polymerase Chain Reaction; Precision Medicine; Protein Kinase Inhibitors; Quinazolines | 2012 |
Physicochemical properties of epidermal growth factor receptor inhibitors and development of a nanoliposomal formulation of gefitinib.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liposomes; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Rats; Spectrometry, Fluorescence | 2012 |
[Selected arterial infusion chemotherapy combined with target drugs for non-small cell lung cancer with multiple brain metastase].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Infusions, Intra-Arterial; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nimustine; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Skin Diseases; Survival Analysis; Treatment Outcome | 2012 |
A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen.
Topics: Animals; Breast Neoplasms; Erlotinib Hydrochloride; Estrogen Receptor alpha; Estrogens; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Humans; Mice; Mice, SCID; Protein Kinase Inhibitors; Quinazolines; Receptors, Urokinase Plasminogen Activator; Signal Transduction; Tumor Cells, Cultured | 2012 |
[Multidisciplinary treatment of leptomeningeal metastasis in patients with lung adenocarcinoma: the triple modality combination of EGFR-TKI, VP shunt and irradiation].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Combined Modality Therapy; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Ventriculoperitoneal Shunt | 2012 |
Long-term survival of a patient with carcinomatous meningitis due to non-small cell lung cancer treated with erlotinib following gefitinib.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Spinal Puncture | 2011 |
Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
Topics: Androgens; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Betacellulin; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Intercellular Signaling Peptides and Proteins; Male; Neuregulin-1; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; RNA, Messenger | 2012 |
The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Recurrence; Risk Factors | 2012 |
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Retrospective Studies | 2012 |
Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Linear Models; Lung Neoplasms; Multivariate Analysis; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
[Comparison of the efficacy of second line EGFR TKIs followed by third line pemetrexed or the reverse sequence in the treatment of advanced lung adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Survival Rate | 2012 |
Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells.
Topics: Alleles; Cell Line, Tumor; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Polymorphism, Single-Stranded Conformational; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2012 |
Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management.
Topics: Adenocarcinoma; Adult; Disease Progression; Drug Eruptions; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Support Vector Machine | 2012 |
Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Keratin-19; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Sex Factors | 2012 |
[Current status and perspectives of individualized therapy for non-small cell lung cancer based on molecular targeting].
Topics: Animals; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Crizotinib; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoglobulins, Intravenous; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Precision Medicine; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quality Control; Quinazolines | 2012 |
[Correlation between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors and EGFR mutations in advanced squamous cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Quinazolines; Salvage Therapy | 2013 |
[EGFR mutations in patients with advanced NSCLC].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2012 |
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.
Topics: Acrylamides; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase 1; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, ErbB-2 | 2012 |
Epidermal growth factor receptor (EGFR) inhibitors and derived treatments.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Quinazolines; Quinolines; Translational Research, Biomedical; Treatment Outcome | 2012 |
Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Rate; Treatment Outcome | 2012 |
[Efficacy of erlotinib after gefitinib administration in patients with non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Retrospective Studies | 2012 |
Epidermal growth factor receptor is a preferred target for treating amyloid-β-induced memory loss.
Topics: Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Blotting, Western; Chlorocebus aethiops; COS Cells; Drosophila; Drosophila Proteins; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Maze Learning; Memantine; Memory; Memory Disorders; Mice; Mice, Transgenic; Molecular Structure; Peptide Fragments; Protein Kinase Inhibitors; Quinazolines | 2012 |
Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance.
Topics: Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2012 |
Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins c-met; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Failure; Tumor Burden | 2013 |
Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cytochrome P-450 CYP2D6; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Erlotinib antagonizes ABC transporters in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Down-Regulation; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplastic Stem Cells; Quinazolines | 2012 |
Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Biomarkers, Tumor; Carcinoembryonic Antigen; Cell Adhesion; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
[The TULUNG clinical registry].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Czech Republic; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Registries | 2012 |
Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Chicago; ErbB Receptors; Erlotinib Hydrochloride; Eye Diseases; Female; Follow-Up Studies; Gefitinib; Humans; Male; Medical Audit; Neoplasms; Panitumumab; Quinazolines; Retrospective Studies | 2013 |
Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Retrospective Studies; Survival Rate; Young Adult | 2012 |
[Lung injury].
Topics: Antineoplastic Agents; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Lung Diseases; Quinazolines; Sirolimus | 2012 |
Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Health Care Costs; Humans; Lung Neoplasms; Pemetrexed; Quinazolines | 2012 |
Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2D6; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genetic Predisposition to Disease; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Polymorphism, Single Nucleotide; Quinazolines; Real-Time Polymerase Chain Reaction | 2012 |
The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2013 |
How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?
Topics: Aged; Aged, 80 and over; Base Sequence; Carcinoma, Squamous Cell; Confidence Intervals; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion | 2013 |
Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Retrospective Studies | 2013 |
Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catalytic Domain; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Models, Molecular; Mutation, Missense; Phosphorylation; Protein Binding; Protein Processing, Post-Translational; Protein Stability; Protein Structure, Secondary; Quinazolines; Quinazolinones; Sf9 Cells; Spodoptera | 2013 |
PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Humans; Niacinamide; Phenylurea Compounds; Piperidines; Pregnane X Receptor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptors, Steroid; Sorafenib | 2013 |
[Efficacy of erlotinib after the failure of gefitinib in patients with metastasis of non-small cell lung cancer with unknown EGFR mutation status].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate | 2012 |
[Efficacy and safety of docetaxol, pemetrexed and EGFR-TKIs as second-line treatment for patients with advanced non-small-cell lung cancer].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Taxoids | 2012 |
[Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 12; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Humans; Lapatinib; Mice; Mice, Nude; Molecular Targeted Therapy; Oligonucleotide Array Sequence Analysis; Phenotype; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; RNA Interference; Small Ubiquitin-Related Modifier Proteins; Time Factors; Transfection; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Gefitinib, but not erlotinib, is a possible inducer of Fra-1-mediated interstitial lung disease.
Topics: Animals; Antineoplastic Agents; Chemokine CCL2; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation; Lipopolysaccharides; Lung Diseases, Interstitial; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Primary Cell Culture; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fos; Quinazolines; RNA, Messenger; Tumor Necrosis Factor-alpha | 2012 |
Erlotinib and gefitinib, epidermal growth factor receptor kinase inhibitors, may treat non-cancer-related tumor necrosis factor-α mediated inflammatory diseases.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Inflammation; Quinazolines; Tumor Necrosis Factor-alpha | 2013 |
Quantitative chemical proteomics profiling differentiates erlotinib from gefitinib in EGFR wild-type non-small cell lung carcinoma cell lines.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphate; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; LIM Domain Proteins; Lung Neoplasms; Membrane Proteins; Microfilament Proteins; Molecular Conformation; Molecular Docking Simulation; Protein Binding; Protein Serine-Threonine Kinases; Proteomics; Quinazolines; Signal Transduction | 2013 |
Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.
Topics: Afatinib; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; MCF-7 Cells; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Treatment Outcome | 2013 |
Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease.
Topics: Adenocarcinoma; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2013 |
Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cranial Nerve Diseases; Cytarabine; Erlotinib Hydrochloride; Female; Gefitinib; Headache; Humans; Hydrocortisone; Infusions, Intraventricular; Intracranial Pressure; Karnofsky Performance Status; Lung Neoplasms; Male; Meningeal Carcinomatosis; Mental Disorders; Methotrexate; Middle Aged; Nausea; Palliative Care; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Vomiting | 2013 |
[About new treatments in thoracic oncology].
Topics: Afatinib; Antineoplastic Agents; Crizotinib; DNA Mutational Analysis; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Oncogene Proteins, Fusion; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines | 2013 |
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biopsy; CD56 Antigen; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Ki-67 Antigen; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2 | 2013 |
Successful treatment with erlotinib of severe neutropenia induced by gefitinib in a patient with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Mutation; Neutropenia; Protein Kinase Inhibitors; Quinazolines | 2013 |
Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2013 |
Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.
Topics: Afatinib; Analysis of Variance; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Fluorometry; Gefitinib; Humans; Indoles; Microscopy, Fluorescence; Piperazines; Proto-Oncogene Proteins c-met; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Signal Transduction; Spectrophotometry; Sulfonamides | 2013 |
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Patho
Topics: Adenocarcinoma; Anaplastic Lymphoma Kinase; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Molecular Targeted Therapy; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Systematic Reviews as Topic | 2013 |
Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis Regulatory Proteins; Base Sequence; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cell Transdifferentiation; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Sequence Analysis, DNA; Sequence Deletion | 2013 |
Influence of gefitinib and erlotinib on apoptosis and c-MYC expression in H23 lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2013 |
Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemokine CCL5; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Inflammation; Interleukin-10; Interleukin-8; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Treatment Outcome | 2013 |
Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Keratin-19; Luminescent Measurements; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
[The cost-effectiveness analysis of gefitinib or erlotinib in the treatment of advanced EGFR mutant non-small cell lung cancer patients].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cost-Benefit Analysis; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Insurance, Health; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Outcome Assessment; Protein Kinase Inhibitors; Quinazolines | 2013 |
Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: Adult; Aged; Alleles; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity | 2013 |
Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exons; Feasibility Studies; Female; France; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Analysis, DNA; Survival Rate; Treatment Outcome | 2013 |
EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors.
Topics: Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Male; Phosphorylation; Prostate; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Quinazolines; Sodium-Glucose Transporter 1 | 2013 |
Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Adenosquamous; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Treatment Outcome | 2013 |
RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Statistics, Nonparametric; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
IL-33/IL-31 axis: a new pathological mechanisms for EGFR tyrosine kinase inhibitors-associated skin toxicity.
Topics: Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Interleukin-33; Interleukins; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Skin | 2013 |
Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.
Topics: Adult; Aged; Blood-Brain Barrier; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2013 |
Reaction of plasma adiponectin level in non-small cell lung cancer patients treated with EGFR-TKIs.
Topics: Adiponectin; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Insulin; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2013 |
Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2014 |
The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors.
Topics: Adaptor Proteins, Signal Transducing; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunoblotting; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Mice; Middle Aged; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; Signal Transduction; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2013 |
"Arrow" sign: a rapid microscopic diagnosis of hair change associated with epidermal growth factor receptor inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Hair; Humans; Male; Microscopy; Middle Aged; Quinazolines; Scalp Dermatoses | 2013 |
Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Treatment Outcome | 2013 |
[A case of lung adenocarcinoma wtih exon19 and T790M mutations in EGFR having good response to erlotinib after gefitinib treatment failure].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Salvage Therapy | 2013 |
Targeting EGFR and PI3K pathways in ovarian cancer.
Topics: Antibiotics, Antineoplastic; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Triazines; Tumor Cells, Cultured | 2013 |
Scalp pustules in a patient receiving chemotherapy.
Topics: Acneiform Eruptions; Aged; Aged, 80 and over; Biopsy; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Scalp | 2013 |
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Quinazolines; Xenograft Model Antitumor Assays | 2013 |
The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cause of Death; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies | 2013 |
The economic evaluation of personalised oncology medicines: ethical challenges.
Topics: Antineoplastic Agents; Australia; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Precision Medicine; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Experimental models to study drug distributions in tissue using MALDI mass spectrometry imaging.
Topics: Adenocarcinoma; Animals; Biological Transport; Cholinergic Antagonists; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Microtomy; Neoplasms, Experimental; Protein Kinase Inhibitors; Quinazolines; Scopolamine Derivatives; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tiotropium Bromide; Tissue Culture Techniques; Tumor Microenvironment | 2013 |
Erlotinib, gefitinib, and vandetanib inhibit human nucleoside transporters and protect cancer cells from gemcitabine cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Inhibitory Concentration 50; Nucleoside Transport Proteins; Piperidines; Quinazolines; Saccharomyces cerevisiae; Uridine | 2014 |
A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platform
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; False Positive Reactions; Gefitinib; Genotype; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Nucleic Acid Amplification Techniques; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sequence Analysis, DNA | 2014 |
Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; I-kappa B Kinase; Lapatinib; Mice, SCID; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Pyrazines; Quinazolines; Receptor, ErbB-2; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation.
Topics: Aged; Amino Acid Sequence; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Epitopes, T-Lymphocyte; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; HLA-A2 Antigen; Humans; Immunotherapy; Leukocytes, Mononuclear; Lung Neoplasms; Lymphocyte Activation; Male; Middle Aged; Molecular Sequence Data; Mutation; Peptides; Protein Kinase Inhibitors; Quinazolines | 2013 |
Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Treatment Failure | 2014 |
Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Young Adult | 2014 |
Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Regression Analysis; Retrospective Studies; Treatment Outcome | 2014 |
Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 3; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2013 |
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
Topics: Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crystallography, X-Ray; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Models, Molecular; Molecular Sequence Data; Mutagenesis, Insertional; Mutation; Protein Conformation; Protein Kinase Inhibitors; Quinazolines; Structural Homology, Protein; Translational Research, Biomedical | 2013 |
Topoisomerase I as a target of erlotinib and gefitinib: efficacy of combined treatments with camptothecin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Erlotinib Hydrochloride; Female; Gefitinib; Humans; MCF-7 Cells; Molecular Targeted Therapy; Protein Processing, Post-Translational; Quinazolines | 2014 |
Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retreatment; Retrospective Studies; Smoking; Treatment Outcome | 2014 |
Factors associated with early progression of non-small-cell lung cancer treated by epidermal growth factor receptor tyrosine-kinase inhibitors.
Topics: Aged; Aged, 80 and over; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2014 |
Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Vinblastine; Vinorelbine | 2014 |
Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2014 |
Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation, Missense; Proportional Hazards Models; Quinazolines; Retrospective Studies; Treatment Outcome | 2014 |
EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Fluorescent Antibody Technique; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Tumor Cells, Cultured | 2014 |
[Development and biochemical characterization of EGFR/c-Met dual inhibitors].
Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines | 2013 |
Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation, Missense; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion; Smoking; Treatment Outcome | 2014 |
Autophagy facilitates the EGFR-TKI acquired resistance of non-small-cell lung cancer cells.
Topics: Antineoplastic Agents; Autophagy; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2014 |
T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines | 2014 |
An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2014 |
Erlotinib or gefitinib as first-choice therapy for bronchorrhea in bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Bronchi; Bronchial Diseases; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Radiography, Thoracic | 2014 |
Cytoplasmic YAP expression is associated with prolonged survival in patients with lung adenocarcinomas and epidermal growth factor receptor tyrosine kinase inhibitor treatment.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Cytoplasm; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphoproteins; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Response Evaluation Criteria in Solid Tumors; Survival Rate; Transcription Factors; YAP-Signaling Proteins; Young Adult | 2014 |
Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2014 |
Epidermal growth factor receptor inhibitors selectively inhibit the expressions of human β-defensins induced by Staphylococcus epidermidis.
Topics: beta-Defensins; Cells, Cultured; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Host-Pathogen Interactions; Humans; Immunity, Innate; Keratinocytes; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Staphylococcus aureus; Staphylococcus epidermidis; Time Factors | 2014 |
Ten lessons from EGFR.
Topics: Afatinib; Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quinazolines | 2014 |
CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; GPI-Linked Proteins; Homeodomain Proteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Nude; MicroRNAs; Mutation; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Transcription Factors; Xenograft Model Antitumor Assays; Zinc Finger E-box-Binding Homeobox 1 | 2014 |
Comparison is beyond IPASS and OPTIMAL.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Primary and secondary resistance to tyrosine kinase inhibitors in lung cancer.
Topics: Apoptosis; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured | 2014 |
management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis.
Topics: Afatinib; Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Feeding Behavior; Gefitinib; Humans; Incidence; Lung Neoplasms; Mucositis; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Withholding Treatment | 2014 |
Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model.
Topics: Breast; Cell Line; Cell Survival; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triazines | 2014 |
Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromatography, Liquid; Cisplatin; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Pemetrexed; Quinazolines; Retrospective Studies; Tandem Mass Spectrometry | 2015 |
Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2014 |
Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Design, synthesis and biological evaluation of quinoxalin-2(1H)-one derivatives as EGFR tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Quinazolines; Quinoxalines | 2015 |
Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Drug Substitution; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Polyoxypregnane steroids from the stems of Marsdenia tenacissima.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Glycosides; Humans; Marsdenia; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Pregnanes; Quinazolines | 2014 |
Recombinant expression of different mutant K-ras gene in pancreatic cancer Bxpc-3 cells and its effects on chemotherapy sensitivity.
Topics: Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, ras; Green Fluorescent Proteins; Humans; Mutation; Pancreas; Pancreatic Neoplasms; Plasmids; Quinazolines; ras Proteins; Recombinant Proteins | 2014 |
Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Compassionate Use Trials; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2014 |
The role of BIM-EL and BCL2-α on the efficacy of erlotinib and gefitinib in lung cancer.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Membrane Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Real-Time Polymerase Chain Reaction; RNA, Messenger | 2015 |
Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment.
Topics: Administration, Inhalation; Benzamides; Erlotinib Hydrochloride; Gefitinib; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2014 |
Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Lymphocytes; Male; Neutrophils; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2017 |
Long-term survival of non-small-cell lung cancer patients with EGFR inhibitor treatment.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2014 |
New therapy targets resistant non-small-cell lung cancers.
Topics: Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Drug Combinations; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; National Cancer Institute (U.S.); Quinazolines; United States | 2014 |
A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.
Topics: Animals; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glioblastoma; Heterografts; Humans; Membrane Proteins; Mice; Mice, Nude; Proto-Oncogene Proteins; Quinazolines; Receptors, Urokinase Plasminogen Activator; Signal Transduction | 2015 |
Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; Binding Sites; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HT29 Cells; Humans; Molecular Docking Simulation; NADP; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Structure-Activity Relationship | 2014 |
Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M.
Topics: Apoptosis; Autophagy; Casein Kinase II; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Naphthyridines; Phagosomes; Phenazines; Protein Kinase Inhibitors; Quinazolines | 2014 |
A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HLA-A2 Antigen; Humans; Immunotherapy; Mutation; Peptides; Quinazolines | 2015 |
Can EGFR mutation status be reliably determined in pre-operative needle biopsies from adenocarcinomas of the lung?
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Preoperative Care; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Analysis, DNA | 2015 |
Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors.
Topics: Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Quinazolines; Signal Transduction; STAT5 Transcription Factor | 2015 |
A kinase-independent role for EGF receptor in autophagy initiation.
Topics: Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Proteins; Beclin-1; Cell Line, Tumor; Endosomes; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Oncogene Proteins; Protein Kinase Inhibitors; Quinazolines; Vesicular Transport Proteins | 2015 |
Gender-based impact of epidermal growth factor receptor mutation in patients with nonsmall cell lung cancer and previous tuberculosis.
Topics: Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sex Factors; Taiwan; Tuberculosis, Pulmonary | 2015 |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2015 |
Oncologists push beyond new lung cancer genomic testing guidelines.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Genomics; Humans; Lung Neoplasms; Medical Oncology; Molecular Targeted Therapy; Mutation; Practice Guidelines as Topic; Precision Medicine; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Societies, Medical; Sulfones; Translocation, Genetic | 2015 |
Metabolic glycoengineering sensitizes drug-resistant pancreatic cancer cells to tyrosine kinase inhibitors erlotinib and gefitinib.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glycosylation; Humans; Metabolic Engineering; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; STAT Transcription Factors | 2015 |
Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2015 |
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aniline Compounds; Antineoplastic Agents; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Recurrence; Retinoblastoma Protein; Signal Transduction; Small Cell Lung Carcinoma; Sulfonamides | 2015 |
AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells.
Topics: Animals; Axl Receptor Tyrosine Kinase; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Mice, SCID; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Receptor Protein-Tyrosine Kinases; Resorcinols; Xenograft Model Antitumor Assays | 2015 |
Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms.
Topics: Animals; Brain Neoplasms; Crizotinib; Cyclin-Dependent Kinase Inhibitor p16; Doxycycline; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Imidazoles; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Phosphorylation; Protein Processing, Post-Translational; PTEN Phosphohydrolase; Pyrazoles; Pyridines; Quinazolines; Quinolines; Tumor Cells, Cultured | 2015 |
Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Drug Substitution; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nephrosis, Lipoid; Protein Kinase Inhibitors; Quinazolines | 2015 |
Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Fetus; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Maternal-Fetal Exchange; Mutation; Perfusion; Placenta; Pregnancy; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution | 2015 |
10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2015 |
EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Databases, Protein; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Molecular Dynamics Simulation; Mutation; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Quinazolines | 2015 |
Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Pleural Effusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Tomography, X-Ray Computed | 2015 |
Combined effects of EGFR tyrosine kinase inhibitors and vATPase inhibitors in NSCLC cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lapatinib; Lung Neoplasms; Macrolides; Membrane Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; RNA Interference; Transfection; Vacuolar Proton-Translocating ATPases | 2015 |
Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments.
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Dynamics Simulation; Mutant Proteins; Mutation; Protein Binding; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-3; Regression Analysis; Signal Transduction; Structural Homology, Protein; Thermodynamics | 2015 |
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
Topics: Aged; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Polymorphism, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Retrospective Studies | 2015 |
Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion; Survival Rate | 2015 |
Modern Treatments in Advanced Non-Small-Cell Lung Cancer: Temporal Trends and Effect on Survival. A French Population-Based Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Follow-Up Studies; France; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Platinum Compounds; Population Groups; Quinazolines; Survival Analysis; Treatment Outcome | 2015 |
Decision to adopt medical technology under the National Health Insurance System in Taiwan: case study of new molecular targeted drugs among non-small cell lung cancer patients.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Databases, Factual; Decision Making; Drug Utilization; Erlotinib Hydrochloride; Female; Gefitinib; Hospital Administration; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; National Health Programs; Ownership; Quinazolines; Residence Characteristics; Taiwan | 2015 |
Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Sequence Deletion | 2015 |
Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Outcome Assessment, Health Care; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors | 2015 |
Bidirectional signaling between TM4SF5 and IGF1R promotes resistance to EGFR kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Membrane Proteins; Protein Kinase Inhibitors; Quinazolines; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Spheroids, Cellular | 2015 |
Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent.
Topics: Antineoplastic Agents; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Molecular Docking Simulation; Quinazolines; Receptor, ErbB-2; Retrospective Studies | 2015 |
Novel quinazoline derivatives exhibit antitumor activity by inhibiting JAK2/STAT3.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 2; Mice; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2015 |
Antitumoral activity of tyrosine kinase inhibitors in patients with non-small cell lung cancer harbouring rare epidermal growth factor receptor mutations.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Treatment Outcome | 2015 |
[Targeted therapy for solid tumors in the elderly].
Topics: Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Cetuximab; Colonic Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Trastuzumab | 2015 |
Gefitinib and Erlotinib Lead to Phosphorylation of Eukaryotic Initiation Factor 2 Alpha Independent of Epidermal Growth Factor Receptor in A549 Cells.
Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Cyclin D1; Endoplasmic Reticulum Stress; ErbB Receptors; Erlotinib Hydrochloride; Eukaryotic Initiation Factor-2; Gefitinib; Humans; Lung Diseases, Interstitial; Phosphorylation; Pulmonary Alveoli; Quinazolines; Signal Transduction; Taurochenodeoxycholic Acid | 2015 |
Gli1-Mediated Regulation of Sox2 Facilitates Self-Renewal of Stem-Like Cells and Confers Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hedgehog Proteins; Humans; Lung Neoplasms; Promoter Regions, Genetic; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; SOXB1 Transcription Factors; Spheroids, Cellular; Stem Cells; Transcription Factors; Tumor Cells, Cultured; Zinc Finger Protein GLI1 | 2015 |
Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Young Adult | 2015 |
Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diabetes Mellitus, Type 2; Disease-Free Survival; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Amino Acid Substitution; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Carcinoma, Non-Small-Cell Lung; Drug Monitoring; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis | 2015 |
Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxybutyrates; Lapatinib; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Purines; Quinazolines; Receptor, ErbB-2; Staurosporine | 2016 |
Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study.
Topics: Adult; Aged; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; DNA Mutational Analysis; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genes, erbB-1; Hospitals; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Smoking | 2015 |
Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Crystallography, X-Ray; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Binding; Protein Kinase Inhibitors; Quinazolines | 2015 |
Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer.
Topics: Afatinib; Calibration; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Erlotinib Hydrochloride; Gefitinib; Humans; Limit of Detection; Lung Neoplasms; Quinazolines; Tandem Mass Spectrometry | 2016 |
Health-related quality of life after first-line anti-cancer treatments for advanced non-small cell lung cancer in clinical practice.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum; Prospective Studies; Quality of Life; Quinazolines; Sickness Impact Profile; Surveys and Questionnaires; World Health Organization | 2016 |
Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Hospitals, University; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Retrospective Studies; Risk Factors; Salvage Therapy; Time Factors; Treatment Failure | 2015 |
[Gefitinib therapy in advanced non-small cell lung cancer in patients with EGFR mutations: cost-effectiveness analysis].
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quality of Life; Quinazolines; Retrospective Studies; Russia; Treatment Outcome | 2015 |
Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diphosphonates; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pamidronate; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2016 |
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
Topics: Aged; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Mutation; Proto-Oncogene Proteins; Quinazolines; RNA, Messenger; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Gemcitabine; Gene Deletion; Genetic Markers; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Pemetrexed; Prognosis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Taxoids | 2016 |
Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer.
Topics: Acneiform Eruptions; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Compassionate Use Trials; Cross-Sectional Studies; Drug Eruptions; Erlotinib Hydrochloride; Gefitinib; Humans; Ichthyosis; Lung Neoplasms; Paronychia; Pruritus; Quinazolines; Retrospective Studies | 2016 |
Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Real-Time Polymerase Chain Reaction; Retrospective Studies; Time Factors; Treatment Failure; Treatment Outcome | 2016 |
Inhibition of epidermal growth factor receptor induces tumor necrosis factor-α via activation of peroxisome proliferator-activated receptor-γ and nuclear factor-κB in sebocytes: A possible pathogenesis of papulopustular rash.
Topics: Cell Line; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; NF-kappa B; PPAR gamma; Protein Kinase Inhibitors; Quinazolines; Sebaceous Glands; Signal Transduction; Skin Diseases, Papulosquamous; Time Factors; Tumor Necrosis Factor-alpha; Up-Regulation | 2016 |
Prolyl isomerase Pin1 promotes survival in EGFR-mutant lung adenocarcinoma cells with an epithelial-mesenchymal transition phenotype.
Topics: Acrylamides; Adenocarcinoma; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Lung Neoplasms; Mutation; NIMA-Interacting Peptidylprolyl Isomerase; Peptidylprolyl Isomerase; Phenotype; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference | 2016 |
Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Afatinib; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Crizotinib; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Maintenance Chemotherapy; Pemetrexed; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Singapore; Taxoids; Translocation, Genetic | 2015 |
Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Tumor Burden; Young Adult | 2016 |
Oncogenic activation of the PI3K/Akt pathway promotes cellular glucose uptake by downregulating the expression of thioredoxin-interacting protein.
Topics: Animals; Carrier Proteins; Cell Line; Cell Line, Tumor; Down-Regulation; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation; Glucose; Glucose Transporter Type 1; Humans; Insulin; Intercellular Signaling Peptides and Proteins; Oncogene Proteins; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Response Elements; RNA, Messenger; Signal Transduction; TOR Serine-Threonine Kinases; Transcription, Genetic | 2016 |
Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts.
Topics: Acrylamides; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
Flipped script for gefitinib: A reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; United States; United States Food and Drug Administration | 2017 |
Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gastric Acid; Gefitinib; Histamine H2 Antagonists; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2016 |
Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; China; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Treatment Outcome | 2016 |
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2016 |
Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Mutation; Nutrition Assessment; Nutritional Status; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2016 |
Inequalities in lung cancer: a world of EGFR.
Topics: Afatinib; Crown Ethers; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Geography; Global Health; Health Care Costs; Health Equity; Health Services Accessibility; Healthcare Disparities; Humans; Lung Neoplasms; Medical Oncology; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Surveys and Questionnaires; United States | 2016 |
Safe and successful treatment with afatinib in three postoperative non-small cell lung cancer patients with recurrences following gefitinib/erlotinib-induced hepatotoxicity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2016 |
Modulation of membrane properties of lung cancer cells by azurin enhances the sensitivity to EGFR-targeted therapy and decreased β1 integrin-mediated adhesion.
Topics: A549 Cells; Antineoplastic Agents; Azurin; Bacterial Proteins; Cell Adhesion; Cell Membrane; Cell Movement; Cell Proliferation; Drug Synergism; Elastic Modulus; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Matrix; Gefitinib; Gene Expression; Humans; Integrin beta1; Microscopy, Atomic Force; Quinazolines; Surface Properties | 2016 |
EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chordoma; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mice; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib.
Topics: A549 Cells; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Interleukin-8; Lung Neoplasms; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; p38 Mitogen-Activated Protein Kinases; Phenotype; Quinazolines; Signal Transduction; Up-Regulation | 2016 |
Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Staging; Predictive Value of Tests; Quinazolines; Response Evaluation Criteria in Solid Tumors; ROC Curve; Survival Analysis; Time Factors; Treatment Outcome | 2016 |
Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Prognosis; Quinazolines; Radiation-Sensitizing Agents | 2016 |
A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Fibrin Fibrinogen Degradation Products; Gefitinib; Humans; Iatrogenic Disease; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2016 |
A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer.
Topics: Adenovirus E1A Proteins; Animals; Apoptosis; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Therapy; Humans; Kaplan-Meier Estimate; Lapatinib; Mice; Mice, SCID; Neoplasm Transplantation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases | 2016 |
Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib.
Topics: Algorithms; Animals; Antineoplastic Agents; Biomarkers; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mice; Models, Biological; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma.
Topics: Administration, Oral; Adult; Afatinib; Aged; Aged, 80 and over; Calibration; Carbamates; Chromatography, Liquid; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Reproducibility of Results; Sulfonamides; Tandem Mass Spectrometry | 2016 |
Developments for Personalized Medicine of Lung Cancer Subtypes: Mass Spectrometry-Based Clinical Proteogenomic Analysis of Oncogenic Mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Asian People; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; Lung Neoplasms; Mass Spectrometry; Molecular Targeted Therapy; Mutation; Oncogene Proteins, Fusion; Precision Medicine; Protein Interaction Mapping; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Quinazolines; Receptor, ErbB-2; White People | 2016 |
Plexin A1 signaling confers malignant phenotypes in lung cancer cells.
Topics: Animals; Apoptosis; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Proliferation; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glucose; Mice; Nerve Tissue Proteins; Protein Kinase Inhibitors; Quinazolines; Receptors, Cell Surface; RNA, Small Interfering; Semaphorin-3A; Signal Transduction | 2016 |
Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2016 |
Construction of a novel cell-based assay for the evaluation of anti-EGFR drug efficacy against EGFR mutation.
Topics: Afatinib; Antineoplastic Agents; Cell Culture Techniques; Cells, Cultured; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Protein Kinase Inhibitors; Quinazolines; Transfection | 2017 |
EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Databases, Factual; Disease Progression; Disease-Free Survival; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines; Retrospective Studies; Risk Assessment; Risk Factors; Singapore; Time Factors; Treatment Outcome | 2016 |
Computational and Experimental Characterization of Patient Derived Mutations Reveal an Unusual Mode of Regulatory Spine Assembly and Drug Sensitivity in EGFR Kinase.
Topics: Allosteric Regulation; Amino Acid Motifs; Animals; Catalytic Domain; CHO Cells; Cricetinae; Cricetulus; Drug Resistance; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hydrophobic and Hydrophilic Interactions; Immunoblotting; Lapatinib; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Protein Structure, Secondary; Quinazolines | 2017 |
Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs.
Topics: Anti-HIV Agents; Antineoplastic Agents; Computer Simulation; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; HIV Infections; Humans; Models, Biological; Quinazolines | 2017 |
The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2017 |
A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Crown Ethers; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Precision Medicine; Prognosis; Quinazolines; Reagent Kits, Diagnostic; Sensitivity and Specificity; Treatment Outcome | 2017 |
Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA, Long Noncoding | 2017 |
Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2017 |
Retrospective analysis of survival in patients with leptomeningeal carcinomatosis from lung adenocarcinoma treated with erlotinib and gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Meningeal Carcinomatosis; Middle Aged; Prognosis; Quinazolines; Retrospective Studies | 2017 |
Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Movement; Choline Kinase; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hep G2 Cells; Humans; Immunoblotting; Immunohistochemistry; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 2; Mice; Multiprotein Complexes; Neoplasm Invasiveness; Neoplasm Transplantation; Quinazolines; RNA, Messenger; TOR Serine-Threonine Kinases; Wound Healing; Xenograft Model Antitumor Assays | 2017 |
EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib.
Topics: Acrylamides; Adenocarcinoma; Afatinib; Alleles; Aniline Compounds; Animals; Antineoplastic Agents; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Middle Aged; NIH 3T3 Cells; Phosphorylation; Piperazines; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured | 2017 |
Distinct Benefit of Overall Survival between Patients with Non-Small-Cell Lung Cancer Harboring EGFR Exon 19 Deletion and Exon 21 L858R Substitution.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Odds Ratio; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion | 2017 |
Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Postoperative Period; Quinazolines; Retrospective Studies; Treatment Outcome | 2017 |
An unexpected response to second line EGFR inhibitor in relapsing leptomeningeal carcinomatosis from lung adenocarcinoma raises questions on differential mechanisms of action of these agents.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Quinazolines | 2017 |
Reply to C.-H. Chang et al.
Topics: Adenocarcinoma of Lung; Erlotinib Hydrochloride; Gefitinib; Humans | 2017 |
Gefitinib or Erlotinib for Previously Treated Lung Adenocarcinoma: Which Is Superior?
Topics: Adenocarcinoma of Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2017 |
[Precision treatment after resistance to first-generation EGFR-TKI in patients with non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Patient response to use of tyrosine kinase inhibitors in lung cancer: a retrospective audit during funding changes.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Financing, Government; Gefitinib; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Medical Audit; Middle Aged; New Zealand; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2017 |
Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Prednisolone; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Epidermal growth factor receptor (EGFR) structure-based bioactive pharmacophore models for identifying next-generation inhibitors against clinically relevant EGFR mutations.
Topics: Antineoplastic Agents; Computer-Aided Design; Databases, Pharmaceutical; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hydroxamic Acids; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors; Quantitative Structure-Activity Relationship; Quinazolines; Small Molecule Libraries | 2017 |
Clinical Response to Everolimus of EGFR-Mutation-Positive NSCLC With Primary Resistance to EGFR TKIs.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Gefitinib; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Prognosis; Quality of Life; Quinazolines | 2017 |
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Hedgehog Proteins; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing.
Topics: Amino Acid Substitution; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; CRISPR-Cas Systems; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Editing; Gene Expression; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash.
Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Biomarkers, Tumor; Calcifediol; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Survival Analysis | 2017 |
Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Filaggrin Proteins; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines | 2017 |
Impact of Small Molecules on β-Catenin and E-Cadherin Expression in HPV16-positive and -negative Squamous Cell Carcinomas.
Topics: Antigens, CD; Antineoplastic Agents; beta Catenin; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Dasatinib; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2017 |
Corneal edema with a systemic epidermal growth factor receptor inhibitor.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Corneal Edema; Dose-Response Relationship, Drug; Drug Substitution; Epithelium, Corneal; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines | 2017 |
Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2017 |
Droplet digital PCR improved the EGFR mutation diagnosis with pleural fluid samples in non-small-cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Particle Size; Pleural Effusion; Polymerase Chain Reaction; Quinazolines | 2017 |
Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Comorbidity; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Prognosis; Propensity Score; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Registries; Retreatment; Severity of Illness Index; Taiwan; Treatment Outcome | 2017 |
Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Treatment Outcome | 2017 |
Significance of neutrophil-to-lymphocyte ratio in Western advanced EGFR-mutated non-small cell lung cancer receiving a targeted therapy.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Neutrophils; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2017 |
Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Crown Ethers; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy | 2018 |
Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
Topics: ADAMTS Proteins; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Calcium-Binding Proteins; Calponins; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exome; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Humans; Lung Neoplasms; Male; Microfilament Proteins; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Suppressor Protein p53; Wnt Proteins | 2017 |
Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells.
Topics: Acetophenones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2017 |
Effects of an Alkaline Diet on EGFR-TKI Therapy in EGFR Mutation-positive NSCLC.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydrogen-Ion Concentration; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Quinazolines; Urine | 2017 |
Adverse Prognostic CT Findings for Patients With Advanced Lung Adenocarcinoma Receiving First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pleural Effusion; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Young Adult | 2018 |
A method of high-throughput functional evaluation of
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; HEK293 Cells; Humans; Mice; Mutation; Quinazolines | 2017 |
Up-regulation of YPEL1 and YPEL5 and down-regulation of ITGA2 in erlotinib-treated EGFR-mutant non-small cell lung cancer: A bioinformatic analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; China; Computational Biology; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Nuclear Proteins; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Transcriptional Activation; Up-Regulation | 2018 |
Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch Population.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Diagnostic Techniques; Netherlands; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2018 |
A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2018 |
EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer.
Topics: Acrylamides; Afatinib; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Databases, Factual; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Nivolumab; Prognosis | 2018 |
Investigation of the binding characteristics between ligands and epidermal growth factor receptor by cell membrane chromatography.
Topics: Afatinib; Cell Membrane; Chromatography; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HEK293 Cells; Humans; Ligands; Molecular Docking Simulation; Morpholines; Piperidines; Protein Binding; Protein Kinase Inhibitors; Quinazolines | 2018 |
Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression.
Topics: Aged; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis | 2018 |
Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Selection; Program Evaluation; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Failure | 2018 |
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Spain; Treatment Outcome | 2018 |
Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Mutation; Piperazines; Protein Kinase Inhibitors; Treatment Outcome | 2018 |
Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Computer Simulation; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Principal Component Analysis; Protein Kinase Inhibitors; Quinazolines | 2018 |
Comparative studies on the human serum albumin binding of the clinically approved EGFR inhibitors gefitinib, erlotinib, afatinib, osimertinib and the investigational inhibitor KP2187.
Topics: Acrylamides; Afatinib; Aniline Compounds; Binding Sites; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hydrogen Bonding; Molecular Docking Simulation; Piperazines; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Serum Albumin, Human; Solvents; Spectrometry, Fluorescence | 2018 |
Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
Topics: Acrylamides; Afatinib; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Mutation; Piperazines; Protein Kinase Inhibitors; Tumor Cells, Cultured | 2018 |
RASopathic comedone-like or cystic lesions induced by vemurafenib: a model of skin lesions similar but not identical to those induced by dioxins MADISH.
Topics: Antineoplastic Agents; Chloracne; Cytochrome P-450 CYP1A1; Dioxins; Drug Eruptions; Enzyme Activation; Epidermal Cyst; Erlotinib Hydrochloride; Female; Gefitinib; Hep G2 Cells; Humans; Male; Melanoma; Protein Kinase Inhibitors; Skin Neoplasms; Vemurafenib | 2018 |
Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Compassionate Use Trials; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Republic of Korea; Treatment Outcome; Young Adult | 2018 |
Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Calgranulin B; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Myeloid-Derived Suppressor Cells; Prognosis; Survival Rate | 2018 |
Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Treatment Outcome | 2018 |
Efficacy of thoracic radiotherapy in patients with stage IIIB-IV epidermal growth factor receptor-mutant lung adenocarcinomas who received and responded to tyrosine kinase inhibitor treatment.
Topics: Adenocarcinoma of Lung; Adult; Afatinib; Aged; Antineoplastic Agents; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors | 2018 |
MEF2C promotes gefitinib resistance in hepatic cancer cells through regulating MIG6 transcription.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MEF2 Transcription Factors; Mice; Mice, Nude; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines; Transcription, Genetic; Tumor Suppressor Proteins; Up-Regulation | 2018 |
Systematic bioinformatic approaches reveal novel gene expression signatures associated with acquired resistance to EGFR targeted therapy in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Computational Biology; Databases, Genetic; Drug Resistance, Neoplasm; ELAV-Like Protein 1; ErbB Receptors; Erlotinib Hydrochloride; Estrogen Receptor alpha; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines | 2018 |
Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2019 |
Relationship between Paronychia and Drug Concentrations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Topics: Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paronychia; Protein Kinase Inhibitors; Quinazolines | 2018 |
Afatinib restrains K-RAS-driven lung tumorigenesis.
Topics: Adenocarcinoma of Lung; Afatinib; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Proto-Oncogene Proteins p21(ras); Signal Transduction | 2018 |
[The efficacy of TKIs in treatment of human primary small cell lung cancer xenograft model in vivo].
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.
Topics: Adenocarcinoma of Lung; Afatinib; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2018 |
Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lithospermum; Lung Neoplasms; Mice, Nude; Naphthoquinones; Protein Kinase Inhibitors; Reactive Oxygen Species | 2018 |
Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis.
Topics: Aged; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Pneumatosis Cystoides Intestinalis; Protein Kinase Inhibitors; Quinazolines | 2018 |
Iatrogenic pneumopericardium in the setting of carcinomatous pericarditis.
Topics: Adenocarcinoma of Lung; Aged; Carcinoma; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Humans; Iatrogenic Disease; Lung Neoplasms; Pericarditis; Pneumopericardium; Protein Kinase Inhibitors; Punctures; Radiography; Ventilators, Negative-Pressure | 2018 |
Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Consolidation Chemotherapy; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Retrospective Studies; Survival Analysis | 2019 |
Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Survival Analysis | 2018 |
Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study.
Topics: Adenocarcinoma of Lung; Adult; Aged; Asian People; Brain Neoplasms; China; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Retrospective Studies; Survival Analysis | 2018 |
CD146-mediated acquisition of stemness phenotype enhances tumour invasion and metastasis after EGFR-TKI resistance in lung cancer.
Topics: beta Catenin; Carcinoma, Non-Small-Cell Lung; CD146 Antigen; Cell Movement; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Phenotype; Protein Kinase Inhibitors; Signal Transduction; Up-Regulation | 2019 |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Sex Factors; Taiwan; Time Factors | 2019 |
Insight into binding mechanisms of EGFR allosteric inhibitors using molecular dynamics simulations and free energy calculations.
Topics: Acrylamides; Allosteric Regulation; Aniline Compounds; Benzeneacetamides; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Molecular Dynamics Simulation; Mutation; Protein Binding; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2019 |
CT texture analysis as predictive factor in metastatic lung adenocarcinoma treated with tyrosine kinase inhibitors (TKIs).
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Protein-Tyrosine Kinases; Retrospective Studies; Tomography, X-Ray Computed | 2018 |
Nile Tilapia Derived TP4 Shows Broad Cytotoxicity Toward to Non-Small-Cell Lung Cancer Cells.
Topics: Animals; Antimicrobial Cationic Peptides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cichlids; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Fish Proteins; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors | 2018 |
Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; Mice; NF-kappa B; Oxazines; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2019 |
Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2019 |
Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Cost-Benefit Analysis; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Models, Econometric; Pemetrexed; Quality-Adjusted Life Years; Survival Analysis | 2019 |
Is EGFR really a therapeutic target in head and neck cancers?
Topics: Antineoplastic Agents, Immunological; Carcinoma, Squamous Cell; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Panitumumab; Protein Kinase Inhibitors; Radiotherapy, Adjuvant | 2019 |
Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Prognosis; Proportional Hazards Models; Radiotherapy; Retrospective Studies; Treatment Outcome | 2019 |
Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Copy Number Variations; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors | 2019 |
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Critical Pathways; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Guideline Adherence; Humans; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Mutation; Practice Guidelines as Topic; Progression-Free Survival; Prospective Studies; Protein Kinase Inhibitors; Time Factors; Treatment Failure | 2019 |
Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Cranial Irradiation; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Radiosurgery; Radiotherapy Dosage; Retrospective Studies; Treatment Outcome | 2019 |
Effects of removing reimbursement restrictions on targeted therapy accessibility for non-small cell lung cancer treatment in Taiwan: an interrupted time series study.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Costs; Drug Prescriptions; Erlotinib Hydrochloride; Gefitinib; Humans; Interrupted Time Series Analysis; Lung Neoplasms; National Health Programs; Reimbursement Mechanisms; Taiwan | 2019 |
Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Mutation Rate | 2019 |
Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Young Adult | 2019 |
Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins p21(ras); Signal Transduction; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2019 |
Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Survival Rate; Treatment Outcome | 2019 |
Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Survival Analysis | 2019 |
Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab.
Topics: Afatinib; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein Multimerization; Treatment Outcome | 2019 |
Tyrosine Kinase Inhibitors Imatinib and Erlotinib Increase Apoptosis of Antimitotic Drug-resistant KBV20C Cells Without Inhibiting P-gp.
Topics: Antimitotic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Protein Kinase Inhibitors; Vincristine | 2019 |
Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
Topics: Acrylamides; Adult; Afatinib; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Treatment Outcome | 2019 |
EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.
Topics: Acrylamides; Alkylating Agents; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cells, Cultured; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Ethylnitrosourea; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Middle Aged; Mutagenesis; Mutation; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2019 |
Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Topics: Afatinib; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2019 |
Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours.
Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2019 |
[Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population].
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Retrospective Studies | 2019 |
A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Smoking | 2019 |
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; France; Gefitinib; Humans; Liquid Biopsy; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Mutation | 2020 |
Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Sequence Deletion | 2019 |
The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Health Resources; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome; United States | 2019 |
Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell-Free Nucleic Acids; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Retrospective Studies; Survival Rate | 2020 |
Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Patient Reported Outcome Measures | 2020 |
Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in Taiwan.
Topics: Adult; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Retrospective Studies; Survival Analysis; Taiwan; Treatment Outcome; Young Adult | 2020 |
Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lysosomes; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met | 2020 |
Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population.
Topics: Adenocarcinoma of Lung; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Survival Rate; Young Adult | 2020 |
Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Mutation; Neutrophils; Prognosis; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2020 |
Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System.
Topics: Acrylamides; Adverse Drug Reaction Reporting Systems; Afatinib; Aniline Compounds; Data Mining; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Pharmacovigilance; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Safety; United States; United States Food and Drug Administration | 2020 |
Overexpression of AGR2 Is Associated With Drug Resistance in Mutant Non-small Cell Lung Cancers.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mucoproteins; Mutation; Neoplasm Invasiveness; Oncogene Proteins; Protein Kinase Inhibitors; Quinazolines | 2020 |
Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Life Expectancy; Lung Neoplasms; Male; Propensity Score; Protein Kinase Inhibitors; Quality of Life; Survival Rate; Taiwan; Tertiary Care Centers | 2020 |
A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Young Adult | 2020 |
In Vitro Inhibition of Human Aldehyde Oxidase Activity by Clinically Relevant Concentrations of Gefitinib and Erlotinib: Comparison with Select Metabolites, Molecular Docking Analysis, and Impact on Hepatic Metabolism of Zaleplon and Methotrexate.
Topics: Acetamides; Aldehyde Oxidase; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Liver; Methotrexate; Molecular Docking Simulation; Protein Conformation; Pyrimidines | 2020 |
Effects of tyrosine kinase inhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer: An observational study.
Topics: Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Correlation of Data; Cross-Sectional Studies; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Skin; Surveys and Questionnaires; Taiwan | 2020 |
Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non-small cell lung cancer (NSCLC) with brain metastases.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Tandem Mass Spectrometry | 2020 |
Tyrosine Kinase Inhibitors and Everolimus Reduce IGF1R Expression in HPV16-positive and -negative Squamous Cell Carcinoma.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dasatinib; Erlotinib Hydrochloride; Everolimus; Gefitinib; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Papillomavirus Infections; Protein Kinase Inhibitors; Pyrimidines; Receptor, IGF Type 1; Squamous Cell Carcinoma of Head and Neck | 2020 |
Nationwide Real-world Cohort Study of First-line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer.
Topics: Adolescent; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Netherlands; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Survival Rate; Young Adult | 2020 |
Propensity score analysis of overall survival between first- and second-generation EGFR-TKIs using real-world data.
Topics: Acrylamides; Adult; Afatinib; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Male; Middle Aged; Mutation; Protein Kinase Inhibitors | 2020 |
Long-Term Effect of Erlotinib Therapy in the Third Line of Anticancer Treatment in a Patient with Non-Small-Cell Lung Cancer - a Case Report.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Bevacizumab; Carboplatin; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Paclitaxel; Salvage Therapy | 2020 |
NRF2-GPX4/SOD2 axis imparts resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer cells.
Topics: Carbolines; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; NF-E2-Related Factor 2; Phospholipid Hydroperoxide Glutathione Peroxidase; Protein Kinase Inhibitors; RNA, Small Interfering; Superoxide Dismutase; Up-Regulation | 2021 |
Endothelin-1-Mediated Drug Resistance in
Topics: Animals; Antineoplastic Agents; Biological Availability; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Endothelin-1; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Vascular Endothelial Growth Factor A; Vasoconstriction; Xenograft Model Antitumor Assays | 2020 |
Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations.
Topics: Adult; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies | 2020 |
The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer.
Topics: Afatinib; Aged; Aged, 80 and over; Antacids; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung Neoplasms; Male; Metformin; Neoplasm Proteins; Neoplasm Staging; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Steroids; Treatment Failure | 2020 |
Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms.
Topics: Aged; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gain of Function Mutation; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolinones; Retrospective Studies; Sequence Deletion | 2020 |
EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cell Line, Tumor; Cohort Studies; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; RNA, Small Interfering; Signal Transduction; Urinary Bladder; Urinary Bladder Neoplasms | 2020 |
FGF Expression in HPV16-positive and -negative SCC After Treatment With Small-molecule Tyrosine Kinase Inhibitors and Everolimus.
Topics: Cell Line, Tumor; Dasatinib; Erlotinib Hydrochloride; Everolimus; Fibroblast Growth Factors; Gefitinib; Human papillomavirus 16; Humans; Papillomaviridae; Protein Kinase Inhibitors; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases | 2020 |
Loss of p120ctn causes EGFR-targeted therapy resistance and failure.
Topics: Antibodies, Monoclonal; Apoptosis; Catenins; Cell Line, Tumor; Cetuximab; Delta Catenin; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Esophagus; Gefitinib; Humans; Keratinocytes; Molecular Targeted Therapy; NF-kappa B; Protein Kinase Inhibitors; Treatment Outcome | 2020 |
EGFR tyrosine kinase inhibitors in non-small cell lung cancer: treatment paradigm, current evidence, and challenges.
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolinones | 2021 |
Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pneumonectomy; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Survival Rate; Treatment Outcome | 2020 |
Does metformin improve the efficacy of standard epidermal growth factor receptor-tyrosine kinase inhibitor treatment for patients with advanced non-small-cell lung cancer?
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Gefitinib; Humans; Male; Metformin; Middle Aged; Mutation; Protein Kinase Inhibitors | 2021 |
Pharmacokinetics of edoxaban in EGFR-mutated non-small cell lung cancer patients with venous thromboembolism.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Factor Xa Inhibitors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Pyridines; Thiazoles; Venous Thromboembolism | 2021 |
Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Survival Rate | 2021 |
The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs.
Topics: Cell Line, Tumor; Cetuximab; Cyclin-Dependent Kinase 8; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Inhibitory Concentration 50; Molecular Targeted Therapy; Protein Kinase Inhibitors | 2021 |
Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Circulating Tumor DNA; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Treatment Outcome | 2021 |
Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.
Topics: Acrylamides; Angiogenesis Inhibitors; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; China; Clinical Trials as Topic; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Markov Chains; Mutation; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolinones | 2021 |
EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Hong Kong; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Mutation; Retrospective Studies | 2021 |
Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Ontario; Protein Kinase Inhibitors | 2021 |
Design and Synthesis of Non-Covalent Imidazo[1,2-
Topics: A549 Cells; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Inhibitory Concentration 50; Lung Neoplasms; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors; Quinoxalines; Structure-Activity Relationship | 2021 |
Efficacy and dose of afatinib in patients with non-small cell lung cancer after failure of prior gefitinib or erlotinib treatment.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors | 2021 |
An Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Afatinib, Alectinib, Ceritinib, Crizotinib, Dacomitinib, Erlotinib, Gefitinib, and Osimertinib in Human Serum.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carbazoles; Chromatography, Liquid; Crizotinib; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Quinazolinones; Sulfones; Tandem Mass Spectrometry | 2021 |
Tyrosine Kinase Inhibitors for Acute Respiratory Failure Because of Non-small-Cell Lung Cancer Involvement in the ICU.
Topics: Acrylamides; Adenocarcinoma of Lung; Adult; Aged; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Intensive Care Units; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Noninvasive Ventilation; Oxygen Inhalation Therapy; Protein Kinase Inhibitors; Respiration, Artificial; Respiratory Insufficiency; Retrospective Studies; Survival Rate | 2022 |
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma.
Topics: Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer.
Topics: Afatinib; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
Comparing survival and treatment response of patients with acquired T790M mutation second-line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real-world study.
Topics: Acrylamides; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Aniline Compounds; Drug Therapy; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies | 2021 |
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study.
Topics: Acrylamides; Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm, Residual; Protein Kinase Inhibitors; Retrospective Studies; Time Factors; Treatment Failure | 2021 |
RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs).
Topics: Alternative Splicing; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Protein Kinase Inhibitors; Receptor Activator of Nuclear Factor-kappa B; Receptors, Estrogen | 2021 |
A Rare Presentation of a Non-Asian Female With Metastatic Non-small-cell Lung Cancer Harboring
Topics: Carcinoma, Non-Small-Cell Lung; Epigenesis, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Middle Aged; Mutation; Protein Kinase Inhibitors; Quality of Life | 2022 |
Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Crown Ethers; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Tandem Mass Spectrometry | 2022 |
Uncovering Molecular Mechanisms of Drug Resistance via Network-Constrained Common Structure Identification.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell-Penetrating Peptides; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Peptides; Protein Kinase Inhibitors; Receptors, Progesterone | 2022 |
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2023 |
Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib.
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Histamine H2 Antagonists; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines | 2022 |
Antioxidant activity of erlotinib and gefitinib: theoretical and experimental insights.
Topics: Antioxidants; Erlotinib Hydrochloride; Gefitinib; Molecular Docking Simulation; Protons; Thermodynamics | 2022 |
Sensitivity analysis of EGFR L861Q mutation to six tyrosine kinase inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Retrospective Studies | 2022 |
Effects of miRNA-149-5p and Platelet-Activating Factor-Receptor Signaling on the Growth and Targeted Therapy Response on Lung Cancer Cells.
Topics: Biological Phenomena; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs | 2022 |
Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R/T790M, and L858R/T790M/C797S forms of EGFR.
Topics: Afatinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cytotoxins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Triple Negative Breast Neoplasms | 2022 |
Bioinformatics algorithm for lung adenocarcinoma based on macropinocytosis-related long noncoding RNAs as a reliable indicator for predicting survival outcomes and selecting suitable anti-tumor drugs.
Topics: Adenocarcinoma of Lung; Algorithms; Antineoplastic Agents; Computational Biology; CTLA-4 Antigen; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Prognosis; RNA, Long Noncoding | 2022 |
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac Glycosides; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; MCF-7 Cells; Ouabain; Precision Medicine; Sodium-Potassium-Exchanging ATPase; Tamoxifen | 2022 |
Resistor: An algorithm for predicting resistance mutations via Pareto optimization over multistate protein design and mutational signatures.
Topics: Algorithms; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Ligands; Lung Neoplasms; Mutation; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Retrospective Studies | 2022 |
Identifying a lactic acid metabolism-related gene signature contributes to predicting prognosis, immunotherapy efficacy, and tumor microenvironment of lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Erlotinib Hydrochloride; Etoposide; Gefitinib; Humans; Immunologic Factors; Immunotherapy; Lactic Acid; Lung Neoplasms; Prognosis; Reproducibility of Results; Tumor Microenvironment | 2022 |
Identification of an Oxidative Stress-Related LncRNA Signature for Predicting Prognosis and Chemotherapy in Patients With Hepatocellular Carcinoma.
Topics: Biomarkers, Tumor; Carcinoma, Hepatocellular; Dasatinib; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Liver Neoplasms; Oxidative Stress; Prognosis; RNA, Long Noncoding; Sorafenib | 2022 |
Ocellatuperoxides A-F, Uncommon Anti-Tumoral
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Circular Dichroism; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Structure; Mollusca; Peroxides; Pyrones; RNA | 2022 |
Prevalence, Treatment Patterns, and Outcomes of Individuals with
Topics: Afatinib; Alberta; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Platinum; Prevalence | 2022 |
Advanced Lung Cancer Patients' Use of EGFR Tyrosine Kinase Inhibitors and Overall Survival: Real-World Evidence from Quebec, Canada.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quebec | 2022 |
Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Retrospective Studies; Taiwan; Tyrosine Kinase Inhibitors | 2023 |
Targeting EGFR in Combination with Nutritional Supplements on Antitumor Efficacy in a Lung Cancer Mouse Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Dietary Supplements; ErbB Receptors; Erlotinib Hydrochloride; Fish Oils; Gefitinib; Glycogen Synthase Kinase 3 beta; Mice; Protein Kinase Inhibitors; Selenium | 2022 |
Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Topics: Afatinib; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Retrospective Studies | 2023 |
Clinical impact of tetracyclines and/or proton pump inhibitors on the efficacy of epidermal growth factor receptor inhibitors in non-small cell lung cancer: a retrospective cohort study.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines; Retrospective Studies; Tetracyclines | 2023 |
Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Prospective Studies; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors | 2023 |
Determining plasma and cerebrospinal fluid concentrations of EGFR-TKI in lung cancer patients.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Tandem Mass Spectrometry | 2023 |
Inequalities in survival and care across social determinants of health in a cohort of advanced lung cancer patients in Quebec (Canada): A high-resolution population-level analysis.
Topics: Canada; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quebec; Social Determinants of Health | 2023 |
The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Tyrosine Kinase Inhibitors | 2023 |
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC.
Topics: Afatinib; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Treatment Outcome | 2023 |